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Abstract
Protein–protein interactions dictate biological functions, including ones essential to living
organisms such as immune response or transcriptional regulation. To fundamentally under-
stand these biological processes, we must understand the underlying interactions at the
atomic scale. However interactions are overly abundant and traditional structure deter-
mination methods cannot manage a comprehensive study. Alternatively, computational
methods can provide structural models with high-throughput overcoming the challenge
provided by the sheer breadth of interactions, albeit at the cost of accuracy. Thus, it is
necessary to improve modeling techniques if these approaches will be used to rigorously
study protein–protein interactions.
In this dissertation, I describe my advances to protein–protein interaction modeling
(docking) methods in Rosetta. My advances are based on challenges encountered in a blind
docking competition, including: modeling camelid antibodies, modeling flexible protein
regions, and modeling solvated interfaces. First, I detail improvements to RosettaAntibody
and Rosetta SnugDock, including making the underlying code more robust and easy to use,
enabling new loop modeling methods, developing an automatically updating database, and
implementing scientific benchmarks. These improvements permitted me to conduct the
largest-to-date study of antibody CDR-H3 loop flexibility, which showed that traditional,
small-scale studies missed emergent properties.
Then, I pivot from antibodies to focus on the modeling of disordered protein regions.
I contributed advances to the FloppyTail protocol, including enabling the modeling of
multiple disordered regions within a single protein and pioneering an ensemble-based
ii
analysis of resultant models. I modeled Hfq proteins across six species of bacteria and
demonstrated experimentally-validated prediction of interactions between disordered and
ordered protein regions. My simulations provided a hypothetical mechanism for Hfq
function.
Finally, I designed crystallographic protein–protein interactions, with the goal of improv-
ing protein crystal resolution. To approach this exceptional challenge, I first demonstrated
that, under homogenous conditions, Rosetta scores can correlate with crystal resolution.
Next, I computationally designed and experimentally characterized sixteen variants of a
model protein. Only five crystallized, with one providing an improvement in resolution,
showing that improvement through computational design is challenging, but possible.
In sum, my work advanced our understanding and our ability to model and design
several challenging protein–protein interactions.
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Molecules orchestrate the processes of life: complex, diverse molecules with
focused functional capabilities. Like the machines of the modern world, these
molecules are built to perform specific functions efficiently, accurately, and
consistently.
David S. Goodsell, The Machinery of Life
1.1 Proteins are integral to biological functions
Essential to life are proteins: unbranched polymers of variable length composed of amino
acid building blocks. After water, amino acids are the second largest contributor to cell
mass1. The sequence of amino acids determines a protein’s three-dimensional structure and
function. There are twenty “canonical” amino acids, with chemically diverse properties
(varying in size, charge, hydrophobicity, and hydrogen bonding character). In water, a
protein will “fold” to bury the hydrophobic amino acids and expose the hydrophilic amino
acids, and form hydrogen bonding and electrostatic interactions across amino acids. The
structure of a “folded” protein will determine its function: a protein with enzymatic activity
might have binding pockets for reactants that coax the molecules into a geometry favorable
for the forward reaction, a structural protein might expose two patches of complementary
charge that lead to the formation of long polymers by end-to-end stacking of multiple
molecules, or a protein involved in homeostasis might use a hydrophobic patch to recognize
and sequester an unfolded protein.
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As these examples imply, proteins do not exist in isolation, and protein–protein interac-
tions are exceptionally prevalent. In humans for example, it is estimated that approximately
250,498 protein–protein interactions exist among 10,531 studied proteins2. The actual num-
ber of interactions is likely much higher as there are approximately 20,000 protein-coding
genes3 and that study did not consider interaction between human and non-human pro-
teins. In light of their breadth, the study of protein–protein interactions may seem futile.
However, interactions can be grouped, categorized, and classified, and studies can prioritize
interactions of significant biological importance. In this dissertation, I focus on a subset of
interactions that are challenging to study with current methods.
1.1.1 Protein structure is determined through experimental methods
Traditionally, to better understand the role of proteins and their interactions in fundamental
biological processes, scientists have turn to experimental structure determination4–10. X-ray
crystallography is the premier methodi for acquiring atomic-resolution protein structures.
However, it requires an extremely pure sample of protein that has been coaxed to form a
crystalline state, such that all molecules of the protein adopt identical conformations in a
symmetrically repeating fashionii. Producing such a sample can require significant time
and resource investment and does not always guarantee successful structure determination.
In my PhD, I sought to develop computational methods to supplement experimental
structure determination methods. For example, the significant cost in time means that
protein targets must be specifically selected and cannot be studied in a high-throughput
fashion. This shortcoming prevents the effective study of systems where numerous proteins
differ slightly in sequence but greatly in structure and function. I developed and applied
computational modeling approaches to study two such systems: the millions of unique
antibodies in the adaptive immune system and Hfq proteins, which are ubiquitous across
iTwo alternative approaches are nuclear magnetic resonance (NMR) and (cryo-) electron microscopy (cryo-
EM or EM).
iiNMR and cryo-EM have their own shortcomings: NMR struggles with large proteins, whereas cryo-EM
struggles with small proteins and cannot reliably acquire high-resolution data
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many bacterial species. Computational modeling provides an attractive alternative for
studying these systems, due to its time and cost efficiency. Additionally, as the quality of
the protein crystal is a key factor that determines the resolution of the data, I sought to
computationally design high-resolution protein crystals.
1.1.2 Antibodies protect vertebrates from foreign pathogens
Antibodies are proteins produced by the vertebrate adaptive immune system in specific
response to pathogenic molecules (antigens). Their function is to target an antigen (by
specific binding) for destruction (by activating the complement system or signaling for
phagocytosis/degranulation)11. Antibody diversity mediates the specific binding of nu-
merous antigens and arises from genetic mechanisms. Briefly, the prototypiciii antibody
is a pair of pairs of proteins, where a heavy and light chain pair with another, identical
heavy and light chain pair (Figure 1.1). The N-terminal domains of the chains are highly
variable. In the case of the human heavy chain, one combination is produced from 56 V, 23
D, and 6 J genes, in a process known as VDJ recombination. For the light chain this process
is similar, except there is no D gene and there are two sets of V/J genes (referred to as λ
and κ, with 205 and 165 combinations, respectively). The heavy VDJ-recombined gene is
paired with one of nine constant domain genes (which vary in length), whereas the light
VJ-recombined gene is paired with one of five constant domain genes (which do not vary in
length). When expressed, heavy and light chains are paired with each other to produce a
naïve antibody (one that is not specific to an antigen). Such antibodies are displayed on
B cells and when they begin to bind antigen (in the presence of antigen-specific helper T
cells), a process known as somatic hypermutation occurs, which introduces point mutations
in the variable region. Simultaneously, there is a selection pressure for antibodies that bind
antigen specifically and with high affinity.
The diversity at the genetic level gives rise to a structural diversity. A single antibody
iiiIgG isotype
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23 D genes 6 J genes 9 C genes
CDR-H3
Loop
Figure 1.1: Antibody proteins are generated by the recombination of V, D, and J genes for the heavy
chain and V and J genes for the light chain (not shown), followed by somatic hypermutation of the
genes under a selective pressure for antigen binding. The antibody isotype is determined by the
constant domain gene. Gene counts are from IGMT queries12 for functional Homo sapiens genes in
IMGT groups: IGHV, IGHD, IGHJ, and IGHC . The dashed box shows a crystal structure (PDB ID
3BDY) of the an antibody Fab fragment (variable region and the first constant domain) bound to an
antigen (vascular endothelial growth factor, VEGF).
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chain contains multiple immunoglobulin domains. A single immunoglobulin domain is
approximately 130 residues in length and contains two anti-parallel β-sheets sandwiched
against one another, with a single cross-sheet disulfide bond. The strands that make up the
sheets are connected by flexible loops. The subset of these loops that is solvent exposed
and oriented away from the first constant regions is the source of structural diversity in the
variable region13. In particular, there are three key loops, referred to as complementarity
determining regions (CDRs) for their role in antigen recognition. In most antibodies, the
CDRs are the regions making contacting with the antigen (i.e. the CDRs are the paratope)14.
Not all CDRs contribute equally to antigen interactions. The third loop on the heavy
chain often contributes the majority of antigen-binding energy15. Unsurprisingly, the CDR-
H3 loop is the center of VDJ recombination, containing the entirety of the D gene and parts
of the V and J genes. Diversity at the genetic level gives rise to structural plasticity: 30% of
CDR-H3 loops have unique structures when compared to a set of non-redundant protein
loops whereas that number is only 3% for all other loops16. While the variation across
antibody structures and sequences is essential to their function, it precludes comprehensive
study. Uncovering the relationship between antibody sequence and structure, and how it
contributes to antigen binding, would enable more efficient development of vaccines and
therapeutics.
1.1.3 Hfq facilitates RNA–RNA interactions
Hfq (Host factor for RNA phage Qβ replication) is an RNA-binding protein present in most
sequenced bacteria17. Its role is to regulate the expression of metabolic, stress-response,
and virulence genes18 by facilitating interactions between small non-coding RNAs (sRNAs)
and their cognate mRNA. Hfq must rapidly anneal RNAs and dissociate the product in an
efficient manner, as there are many cellular nucleic acids19. The RNA-binding sites in the
core, folded portion of Hfq are well studied20–22, but less is known about the functional
importance of its disordered termini.
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In the context of proteins, disorder implies the lack of ordered structure (in the absence
of external perturbation). Instead, disordered proteins or protein regions occupy an en-
semble of conformational states. Despite seemingly breaking the paradigm that structure
determines function, disordered proteins and protein regions are functional, and estimates
for the disorder content of a given proteome vary from 10–40%23. Furthermore, disordered
proteins have significant biological relevance as they are the causative agents of many forms
of neurodegenerative disease24.
In Hfq, a recent study revealed that the disordered C-terminal domain (CTD) can
displace RNA from the Hfq protein25, but did not identify the molecular mechanism. As
the termini are conserved across bacterial species26, but vary in their sequence and length
(as is common for disordered peptides), it is appealing to suggest that the CTD behaves
according a random polymer model and randomly, or non-specifically, displaces Hfq-
bound RNA. The alternative hypothesis is that there are specific interactions guiding the
CTD to the RNA-binding sites and that RNA displacement is not random. Developing
a method to distinguish the two possibilities would be potentially useful for predicting
the sequence–function relationship of disordered domains in other partially disordered
proteins.
1.1.4 Protein crystals form through repetitive, identical protein–protein con-
tacts
In order to determine a protein structure through X-ray crystallography, one needs a protein
crystal. First, a pure sample of the target protein must be produced at a medium-to-high
concentration, typically 15–20 mg/ml. Next, one of several approaches could be taken
to grow a protein crystal. In the vapor diffusion method, the purified protein is mixed
with a precipitant and a small volume (drop) of the mixed solution is placed in a sealed
container with a reservoir solution containing a higher precipitant concentration. Through
diffusion, the drop and reservoir come into equilibrium. This action increases the precipitant
concentration in the drop, forcing the protein to supersaturate. The supersaturated state
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is not stable, so the protein that is in excess of its solubility limit solidifies, either by
aggregating in an unstructured fashion or nucleating a crystal27. Following nucleation,
the protein crystal grows until the on-rate for molecules diffusing to and encountering
the crystal in the correct orientation matches the off-rate for molecules detaching from the
crystal, which is related to the strength of the protein–protein interaction in the crystal
lattice and the protein concentration in solution. The crystal is then harvested, frozen, and
diffraction data is collected.
The resolution of the structure determined from the diffraction data depends on multiple
variables: the flux of the X-ray beam, the detector size and pixel count, and the quality of
the crystal. If a protein crystal is conformationally heterogeneous (i.e. the repeating units
are not truly identical) or if it is anisotropic (i.e. grows asymmetrically along an axis), then
diffraction data will be of lower quality than for a well-ordered, isotropic crystal. As both
of these properties depend on the protein–protein interactions in the latticeiv, it should be
possible to develop computational design strategy to strengthen crystal contacts (when they
are known) and improve crystal resolution.
1.2 The Rosetta software suite
Rosetta is a software suite for biomolecular structure prediction and design. Initially, Rosetta
was developed to predict protein structure, given protein sequence29. Then, it was applied
to protein design (i.e. the reverse process: given protein structure, predict the optimal
sequence)30. As Rosetta demonstrated success in both of these domains, it was applied to
more challenging and diverse problems, including the prediction31 and design32 of protein
complexes. Nowadays, the structural modeling or design of exotic molecules such as
carbohydrates33 or RNAs34 is possible.
At its core Rosetta has two primary functions: (1) sampling relevant conformational
ivConformational heterogeneity can also arise from internal protein flexibility, in which case other engineering
approaches such as surface entropy reduction can be taken28.
7
space, e.g. the native or folded state, and (2) distinguishing this native conformation from the
many possible conformations sampled during modeling. Rosetta samples conformational
space in a Monte-Carlo-plus-Minimization fashion. The protein, complex, sugar, RNA, etc.
degrees of freedom are perturbed, the system degrees of freedom are energy-minimized,
and changes are accepted or rejected according to the Metropolis criterion: accept if A ≥
U(0, 1) where U(0, 1) is a uniform random number between zero and one, inclusive, and
A = min(1, e−∆E/kT), with ∆E being the change in energy between the initial and final
conformations. The energy of a biomolecular conformation is computed by a hybrid physics-
and statistics-based scoring function in Rosetta35.
1.2.1 Rosetta samples in internal coordinate spate
Rosetta is constructed in a object-oriented fashion. At the heart of Rosetta lie “mover”
objects which make conformational changes to “pose” objects (collections of molecules).
For the sake of efficiency, Rosetta uses internal coordinates (ϕ, ψ, ω and χ angles for each
residue) to store protein conformations, instead of traditional Cartesian coordinates (x, y,
and z for each atom). Thus, the primary degrees of freedom sampled during a simulation are
dihedral angles and rigid-body transformations (if multiple proteins are present). The bond
lengths and angles could be sampled but are typically held fixed.
1.2.2 Rosetta scores with a hybrid statistical/physical potential
Rosetta combines a milieu of physical and statistical terms to approximate the energy of a
biomolecular conformation35. The total energy is computed as a sum over the terms, which
are a function of the degrees of freedom of the system (D) and the chemical identities (aa):
Etotal = ∑ wiEi(D, aa), where physical terms are weighted at 1.0 and statistical terms are
optimized to reproduce small-molecule thermodynamics36 and features of high-resolution
protein crystal structures37. The standard Rosetta scoring function (talaris2014 for studies
prior to 2016 and REF2015 afterward) includes the following:
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• a Lennard-Jones potential,
• a Gaussian exclusion implicit solvation potential (with orientation-dependent solva-
tion of polar atoms added in REF2015),
• a Coulombic electrostatic potential,
• an orientation-dependent hydrogen bonding potential,
• disulfide-bond potential,
• a statistical potential for the amino acid identity (given the backbone dihedral angles),
• a statistical potential for the backbone dihedral angles (given the amino acid identity),
• a statistical potential for the side-chain rotamer (given the backbone dihedral angles),
• a term penalizing deviation from a planar peptide bond (ω = 0 °or ω = 180°),
• a term penalizing the opening of proline ring: a term penalizing a non-planar tyrosine
χ3 dihedral angle, and
• a set of unfolded-state reference energies for each amino acid identity.
1.2.3 Rosetta modeling is assessed on known structures.
In a standard Rosetta modeling protocol, thousands of models are produced and scored.
The set of lowest-scoring models is assumed to be representative of the native structure.
This is not speculation. As Rosetta protocols are developed, their performance is validated
against proteins with known structures such that the root-mean-squared-deviation (RMSD)
between model and structure coordinates can be computed. The RMSD is plotted against
the score for the entire set of models (as in Figure 1.2). For successful simulations, low-
RMSD (native) models are also low-scoring models whereas high-RMSD (non-native) do
not score well. This gives the figure a funnel-like shape and RMSD vs. score plots are

















Figure 1.2: A sample funnel plot of the antibody-bound tissue factor extracellular domain (PDB ID
1AHW). The interface energy (y-axis, score of the complex minus score of the individual partners) is
plotted against the Cα RMSD (x-axis). Ten “native” models, starting from the crystal structure and
refined in the Rosetta score function, are shown for reference in red. One thousand models from a
docking simulation are shown in black.
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1.3 Dissertation outline
In the present thesis, Chapter 1 provides an introduction to the general themes of my
research. Next (Chapter 2), I highlight interesting and challenging targets from my par-
ticipation in the Critical Assessment of PRotein Interactions (CAPRI) competition over
the last six years. A set of challenges was associated with robustness and assumptions
underlying the modeling of antibodies and antibody–antigen interactions in Rosetta. In
Chapter 3, I describe the technical advances made to simplify the use of RosettaAntibody
and Rosetta SnugDock from the user perspective and to expand the classes of antibodies to
which these tools can be applied. In Chapter 4, I apply RosettaAntibody and graph theory
to assess the effects of affinity maturation on CDR-H3 loop flexibility. The analysis of a
large set of antibodies permitted me to observe new, emergent properties, which were not
evident in previous, small-scale studies. In Chapter 5, I continue to apply Rosetta to model
structural properties at a larger scale than is possible with experiment, this time studying
the Hfq family of proteins. I identify key atomic interactions between Hfq’s ordered core
and disordered termini that span multiple bacterial species and can be tied directly to its
function. In Chapter 6, I expand on my structural modeling expertise by attempting to
design crystallographic protein–protein interactions. I demonstrate that point mutations
can substantially alter protein crystal resolution, although there is not yet a way to reliably
predict the exact effect of each mutation. Finally, I map my contributions to the field and
detail directions for future explorers in Chapter 7.
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of U6 small nuclear RNA. Nature 506, 116–120 (2014).
22. Mikulecky, P. J. et al. Escherichia coli Hfq has distinct interaction surfaces for DsrA,
rpoS and poly(A) RNAs. Nature Structural & Molecular Biology 11, 1206–1214 (2004).
23. Oates, M. E. et al. D2P2: database of disordered protein predictions. Nucleic Acids
Research 41, D508–D516 (2012).
24. Uversky, V. N., Oldfield, C. J. & Dunker, A. K. Intrinsically Disordered Proteins in
Human Diseases: Introducing the D 2 Concept. Annual Review of Biophysics 37, 215–246
(2008).
25. Santiago-Frangos, A., Kavita, K., Schu, D. J., Gottesman, S. & Woodson, S. A. C-terminal
domain of the RNA chaperone Hfq drives sRNA competition and release of target
RNA. Proceedings of the National Academy of Sciences of the United States of America 113,
E6089–E6096 (2016).
26. Zheng, A., Panja, S. & Woodson, S. A. Arginine Patch Predicts the RNA Annealing
Activity of Hfq from Gram-Negative and Gram-Positive Bacteria. Journal of Molecular
Biology 428, 2259–2264 (2016).
27. McPherson, A. et al. Introduction to protein crystallization. Acta Crystallographica
Section F Structural Biology Communications 70, 2–20 (2014).
28. Cooper, D. R. et al. Protein crystallization by surface entropy reduction: optimization
of the SER strategy. Acta crystallographica. Section D, Biological crystallography 63, 636–45
(2007).
29. Simons, K. T., Kooperberg, C., Huang, E. & Baker, D. Assembly of protein tertiary
structures from fragments with similar local sequences using simulated annealing and
bayesian scoring functions. Journal of Molecular Biology 268, 209–225 (1997).
30. Kuhlman, B. et al. Design of a Novel Globular Protein Fold with Atomic-Level Accuracy.
en. Science 302, 1364–1368 (2003).
13
31. Gray, J. J. et al. Protein–Protein Docking with Simultaneous Optimization of Rigid-body
Displacement and Side-chain Conformations. Journal of Molecular Biology 331, 281–299
(2003).
32. Kortemme, T. et al. Computational redesign of protein-protein interaction specificity.
Nature structural & molecular biology 11, 371–379 (2004).
33. Labonte, J. W., Adolf-Bryfogle, J., Schief, W. R. & Gray, J. J. Residue-centric model-
ing and design of saccharide and glycoconjugate structures. Journal of Computational
Chemistry 38, 276–287 (2017).
34. Das, R. Atomic-Accuracy Prediction of Protein Loop Structures through an RNA-
Inspired Ansatz. PLoS ONE 8, e74830 (2013).
35. Alford, R. F. et al. The Rosetta All-Atom Energy Function for Macromolecular Modeling
and Design. Journal of Chemical Theory and Computation 13, 3031–3048 (2017).
36. Park, H. et al. Simultaneous Optimization of Biomolecular Energy Functions on Fea-
tures from Small Molecules and Macromolecules. Journal of Chemical Theory and Com-
putation 12, 6201–6212 (2016).
37. Leaver-Fay, A. et al. Scientific benchmarks for guiding macromolecular energy function
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and Gray JJ, “Modeling oblong proteins and water-mediated interfaces with
RosettaDock in CAPRI rounds 28–35.” Proteins 85(3), 479–486 (2017), with
permission from the publisher. *Equal-contribution authors
2.1 Overview
The Critical Assessment of PRotein Interactions (CAPRI) is a continuous, community-
wide evaluation of the performance of computational methods predicting the structure
of protein complexes. I was a member of the Gray lab CAPRI team from 2014–2019,
participating rounds 28–47. During my tenure, I observed a trend in CAPRI targets. From
my perspective as a developer of modeling methods, targets could be categorized as either
“easy”, i.e., targets that were typically useful for determining the accuracy of preexisting
tools, or “challenging”, which constitute targets that often necessitated the development
of novel approaches. In this chapter I highlight several rounds featuring challenging
targets that led to the development of new computational methods. Particularly, Targets
123, 124, and 160 featured camelid antibodies, which gave rise to the development of
new homology modeling and docking methods; Targets 98–101 (among others) featured
potentially disordered termini and protein regions, which led to an investigation of how
best to model such regions; and Targets 104 and 105 (among others) featured highly solvated
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interfaces, which inspired analysis, and later design, of crystallographic protein–protein
interfaces.
2.2 Introduction
Proteins play important roles in cellular structure, metabolic activity, biochemical signaling,
and multitudes of other biological functions. A protein’s function is determined by its
three-dimensional structure, particularly how this structure interacts with other proteins
or other biological molecules to form complexes. Consequently, if the structure of protein
complexes can be predicted, the nature of their function can likewise be elucidated. Though
experimental methods exist to determine protein structure (X-ray crystallography, NMR
spectroscopy, and cryo-electron microscopy among others), these are costly, time consuming,
and low-throughput. Computational structure prediction is an alternative that can quickly
and cheaply generate a structural model of a protein complex.
The CAPRI competition offers an opportunity to evaluate the performance of state-of-
the-art computational protein–protein docking methods1. A set of experimentally deter-
mined protein complex structures are withheld before publication, and protein docking
groups are invited to submit their computational predictions of these structures. These
predictions are assessed for accuracy by comparison with the experimentally determined
structures. Thus, CAPRI serves as an important benchmark to evaluate the state of the
field of computational protein docking, and to reveal remaining challenges. Our group
has participated in CAPRI since its inception to evaluate the development of our docking
method, RosettaDock2. RosettaDock is, at its core, a Monte-Carlo based rigid-backbone
docking method with side chain optimization. RosettaDock is extensible, and several ancil-
lary protocols have proven effective in previous CAPRI rounds3. The conformer-selection
protocol EnsembleDock4 and the flexible-loop induced fit protocol SnugDock5 are among
the most broadly useful.
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2.3 Camelid targets have difficult-to-model H3 loops
Targets 123, 124 (both April 2017), and 160 (March 2019) each featured at least one camelid
(single-chain) antibody6. Target 123 is the complex structure of a camelid-derived chaperone
nanobody (called nb02) and the PorM N-terminal domain; PorM is an inner membrane
protein involved in the Type IX secretion system (T9SS or PorSS)7. Akin to Target 123, Target
124 is the complex structure of another nanobody (called nb130) and the dimeric form of the
PorM C-terminal domain. Finally, Target 160 is the assembly domain of a bacterial surface
layer protein, with six distinct structural sub-domains, in complex with two chaperone
nanobodies.
To model the nanobodies, I adapted the latest RosettaAntibody approach8. The nanobody
sequences were deconstructed into four structurally conserved regions using regular expres-
sion to identify sequence motifs. These regions were the heavy-chain framework, capturing
the conserved β-sandwich structure on which the loops rest, and the three complementarity
determining regions (CDRs), comprising two loops with canonical structure (termed the
CDR H1 and H2)9 and one highly variable loop (termed the CDR H3)10. The sequence for
each structural region was aligned against a database of sequences with known structure
using BLAST+, and the homologous structures were grafted together following threading
of the target sequence. Finally, to account for the highly variable nature of the CDR-H3
loop, I generated 1,000 models using de novo loop modeling methods11.
Wei utilized two approaches to modeling the nanobody partners. Structures were
unavailable for the PorM N-terminal and C-terminal domains, so we used both homology
and de novo modeling through the Robetta server12, and de novo modeling with the ab initio
protocol within Rosetta13, combined with constraints derived from sequence co-evolution
analysis14. The ab initio models of the PorM C-terminus had to be additionally docked
symmetrically15,16, as the structure was reported to be a dimer. For the surface layer
iDr. Shourya Sonkar Roy Burman assisted in the modeling of the PorM termini.
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Figure 2.1: PorM N-terminal domain models (five homology models and five de novo models)
aligned to the crystal structure (pink) of the PorM N-terminal domain in complex with nb01 reveal
accurate modeling of four α-helical bundle domain (models in white). The model backbone RMSDs
range from 2.7 Å to 4.5 Å, with most variability occurring in the helix-loop-helix motif (residues
159–189). Note that this comparison is not for the CAPRI Target 123 structure, but rather a related
complex containing the same PorM N-terminal domain, but a different nanobody.
protein, the six sub-domain structures were given, but not the relative orientations. Thus,
weii separately considered the problems of identifying nanobody-domain interactions and
assembling the domains.
For all targets, the best scoring individual models were globally docked with their
partner using ClusPro17–20. Top-scoring models from ClusPro were further refined by
SnugDock, a variant of RosettaDock which intercalates refinement of the CDR-H2 and -H3
loops with the standard approach.
For Target 160, the structures were not released as of this publication and thus could not
be analyzed. For Target 123, only a structure of the PorM N-terminal domain in complex
with a different nanobody was released as PDB ID 6EY07. The structure (Figure 2.1) revealed
that we had accurately modeled most of the N-terminal domain, particularly the region
binding nb01 antibody. Most of our PorM N-terminal domain models missed some element
iiDr. Sai Pooja Mahajan, Dr. Sudhanshu Shanker, and Ameya Harmalkar aided in the modeling of surface
layer protein.
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A: PorM CTD D4














Figure 2.2: A comparison of PorM CTD sub-domains and their models, and nb130 and its models.
The Porm CTD structure is decomposed into two sub-domains (D4 & D3, shown above in A &
B respectively) as no accurate models were produced for the CTD dimer. Modeling the dimer
was exceptionally challenging as it involved a β-strand swap between neighboring D3 domains.
Additionally, modeling the linker between the D3 and D4 domains proved to be a challenge. The
individual domains were modeled with reasonable accuracy (both at 4.9 Å backbone RMSD to
native). The lowest-RMSD model for the D4 domain (A) missed the orientation of a mid-domain β-
hairpin, whereas the lowest-RMSD model of the D3 domain (B) missed the β-strand that is swapped
in the dimer. The ten lowest-scoring nanobody models range in backbone RMSD from 4.7–2.8 Å,
with most of the difference occurring in the CDR-H3 loop (C). The native loop has two α-helical
segments, which were challenging to model, that gave rise to a compact conformation. All but one
model failed to capture both α-helical segments and be comparably compact.
of an internal helix-loop-helix motif (residues 159–189), with the lowest backbone RMSD
model (at 2.7 Å) accurately capturing the helices, but not the linking loop.
Target 124, the nanobody-bound PorM C-terminal domain dimer complex, was released
as PDB ID 6EY67. The structure revealed that the PorM C-terminal domain consisted
of two sub-domains (termed D3 and D4) and formed a homodimer with neighboring
D3 sub-domains swapping β-strands across their β-sheets and a nanobody bound at the
homodimeric interface. Despite modeling the D3 and D4 sub-domains to ∼5 Å backbone
RMSD (Figure 2.2A, 2.2B), PorM C-terminal domain modeling failed. We were unable to
correctly predict the D3–D4 orientation because we treated the two as a single domain
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during our approach and did not accurately model the linker, resulting in significant
lever-arm effects and poor input models for symmetric docking. Not to mention that we
did not capture the strand swap. The nanobody was challenging to model due to its 21-
residue CDR-H3 loop, which is well beyond the limits of accurate loop modeling21. Figure
2.2C shows that none of the modeled CDR-H3 loops were as compact as the crystallized
nanobody, nor did they feature as many helical residues. In conjunction, the aggregate
inaccuracies in modeling the PorM C-terminal domain dimer and the lengthy CDR-H3 loop
contributed to our failure to model the complex correctly.
2.4 Flexible targets provide a sampling challenge
Targets 98–101 (December 2014) provided a combinatorial docking challenge which asked
us to dock deubiquitinating enzyme UCH-L5, with or without its conjugate ubiquitin (Ub),
to either of two inhibitors, RPN13 or INO80G. Unbound structures of UCH-L5, RPN13,
and Ub were available (3IHR, 2KQZ, and 1UBQ, respectively). We homology modeled
INO80G by threading from PDB structure 2KQZ, loop-building, and refining in Rosetta.
Additionally, we built a homology UCH-L5–Ub complex by aligning the two proteins to
PDB structure 4IG7. Using the FloppyTail protocol22, we modeled the tails of RPN13, which
are unresolved in 2KQZ, and the homologous regions of INO80G. We found no biochemical
data or homology complexes that clearly identified a binding site, necessitating a global
docking search. Due to the uncertainty in the monomer structures, we ran EnsembleDock
with 30-member ensembles (generated by relaxing our top homology models). 20,000
decoys were generated for each target.
The assessment reveal that these targets were quite difficult: across all four targets, no
CAPRI group submitted a model of acceptable-quality or better. Comparison of the complex
binding mode to the unbound structures revealed that RPN13 undergoes a significant
conformational shift upon binding, in which a helical bundle hinges open to bind around a
helical element from UCH-L5, which itself undergoes a substantial kinking upon binding
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Figure 2.3: The bound UCH-L5–RPN13 complex (grey and pink), with the unbound RPN13 super-
imposed on top (blue). Upon binding, the RPN13 helical bundle hinges open to accommodate the
UCH-L5 C-terminal helix.
(Fig. 2.3). Though INO80G has no unbound structure to compare with its bound forms,
the inhibitor is similarly entwined with the UCH-L5 helix. This binding mode is doubly
difficult to predict. Firstly, predicting conformational change upon binding has been
observed to be difficult in previous CAPRI challenges3, particularly when the change is so
large. Secondly, the degree of structural entwinement between the two partners requires
a hybrid folding/docking algorithm to predict correctly: the bound forms of RPN13 and
INO80G would have high energies in solution due to their open hydrophobic pocket, and
even if these forms could be predicted, due to the high degree of entwinement they would
be almost impossible to dock by rigid-body methods.
2.5 Rosetta can position waters accurately at solvated interfaces
Targets 104 and 105 (March 2015) presented a dual challenge: first, to predict the complex
structure of a DNase (PyoAP41 or PyoS2) with its cognate immunity protein (ImAP41
or ImS2), then to predict the mediating waters and side chains at the protein interface.
While the DNase proteins had crystal structures available in the PDB, we had to generate
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homology models for ImAP41 and ImS2. The available homologous structure was colicin
Im2 (chain A in PDB ID 3U43), a previous CAPRI Target (47) with 50% identity to ImAP41
and 59% identity to ImS2. The starting complexes were then generated by aligning the
homology models (ImAP41 or ImS2) and structures (PyoAP41 or PyoS2) to their homolog’s
position in PDB 3U43. For Target 104, we then used structural ensembles of PyoAP41 to
account for a flexible loop at the interface and ran an local EnsembleDock to optimize
the complex (50,000 decoys). For Target 105, we ran a local RosettaDock to optimize the
complex (20,000 decoys). We used a new method for interface water predictions: HBNet
with Bridging Waters (HBNetBW).
We expanded HBNet, a method for designing hydrogen bond networks23, to include a
statistical potential to capture water molecules that form bridging hydrogen bonds between
side chains. The two-term potential utilizes the distance between the two protein atoms that
hydrogen bond to the water molecule (acceptor or donor polar hydrogen) and the dihedral
angle between those two atoms and their base atoms (e.g. the base atom for a carbonyl
oxygen acceptor would be the carbon it is double bonded to, and the base atom of the polar
hydrogen would the heavy-atom donor that it is covalently bonded to). We calibrated the
potential using interface waters from the Top 8000 dataset24 and bicubic spline interpolation;
the two-dimensional function that defines the bridging water score is:
score(a1, a2, a3, a4) = f (distance(a2, a3), dihedral(a1, a2, a3, a4))
where a2 and a3 are the protein atoms hydrogen bonded to the bridging water, a1 is the
base atom of a2, and a4 is the base atom of a2. To identify water positions during HBNet
search, if two rotamers have a bridging water score below a specified threshold, they are
connected as part of a potential hydrogen bond network and an explicit water molecule is
placed at ideal geometry relative to the hydrogen-bonding atoms. We ran HBNetBW on
each docked backbone, sampling rotamers of the interface residues to identify the most
22
Figure 2.4: Our best medium-quality model for Target 105, superimposed with the crystal structure.
Our model is colored in red/purple shades, while the crystal structure is colored in blue shades.
satisfied networks. There is a substantial energetic penalty associated with burying polar
atoms that do not participate in hydrogen bonds (either to solvent or other protein atoms);
thus, we hypothesized that using this criterion would be advantageous for discriminating
between docked complexes.
For Target 104, all of our models were incorrect. An ex post facto analysis revealed
that our homology model had the correct complex orientation, and that our docking
simulation moved the complex away from that conformation. For Target 105, all four of
our submitted models were of medium quality, the best having an interface RMSD of 1.757
Å and recovering 48.1% of native interface contacts. Similar to Target 104, however, the
unrefined homology model had a more native-like orientation than our docked model. One
of our models from Target 105 had a fair-quality water prediction (Figure 2.4), recovering
11.8% of native interactions with waters, indicating that HBNet can be useful even without
a perfectly-aligned interface.
After the CAPRI blind challenge, we ran HBNetBW on the revealed crystal structures for
Targets 104 and 105 and the closest homology model to each. We removed water molecules
from the structures. We then relaxed (cycles of minimization and side-chain repacking)
the structures using Rosetta. Next, we ran HBNetBW using identical parameters to those
during analysis of submitted docked complexes. In regions of the interface where the
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backbone was close to that of the crystal structure, the native side-chain hydrogen-bond
networks were largely recapitulated, and a couple of the bridging water molecules were
placed in agreement with interface waters in the crystal structure; for example, running
HBNetBW on the Target 105 homology model generated a network with a bridging water
molecule between Tyr640, Tyr55, and His34 that is in close agreement to the experimental
crystal structure. However, many false-positive networks and water placements were also
generated – multiple networks are identified for each fixed-backbone decoy, making it
challenging to choose which networks and water placements to keep and which to discard.
Ranking networks according to satisfaction and connectivity led to success in designed
protein-only networks23; however, as used here, these metrics are only as reliable as the
bridging water identification and placement, and our results suggest that there is significant
room for improvement to both.
2.6 Discussion
Over the years, challenges presented by CAPRI targets have led to the development of
fully-fledged modeling protocols. For example, following the task of modeling a lysozyme–
inhibitor complex (which is relevant in a low pH) target, dynamic residue protonation
was introduced to RosettaDock25. In another example, antibody–complex targets led to
the development of SnugDock, which introduced refinement of loops during docking3.
The targets highlighted in the chapter identified future research directions in modeling
camelid antibodies, flexible regions, and solvated interfaces, guiding the direction of my
PhD research.
In the process of modeling the three camelid antibody targets, I identified shortcomings
in our methodology. First, the grafting step of the RosettaAntibody protocol lacked the
capacity to assemble a heavy-chain only antibody, due to the assumed presence of a light
chain. Second, the database for grafting lacked templates sourced from camelid antibody
structures and, owing to its manual curation, had not been updated in years. Third, as with
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Figure 2.5: A comparison of the bound and unbound crystal structures of nanobody 06 exemplifies
the large motions associated with flexible loop regions. The CDR-H3 loop (salmon [PDB ID 5E7B] or
dark red [PDB ID 5E7F]) partially unfolds a helix and shifts from interacting with the framework
β-sheets to the interacting with the other CDRs.
grafting, Rosetta SnugDock could not natively dock a single-chain antibody to an antigen.
Finally, the CDR-H3 loop accuracy of models tended to be low due to its inherent flexibility.
Alleviating these deficiencies (among others) is the basis of Chapter 3.
The difficulty of accurately modeling flexible regions was observed with Targets 98–101,
in addition to the CDR-H3 loops. Modeling these regions was particularly challenging due
to the size of the possible conformation space and, often, the large structural re-arrangement
between between the initial and final conformation (as showcased in Figures 2.3 and 2.5).
From these observations arises the need to more thoroughly characterize the motions of
flexible regions and the biological consequences of flexibility. In Chapter 5, I systematically
investigated the large conformational freedom and energy landscape accessible to the
disordered termini of the Hfq protein across several bacterial species and its effects on Hfq’s
RNA annealing function. In Chapter 4, I assessed the differences in CDR-H3 loop flexibility
between naïve and antigen-experienced antibodies by combining Rosetta loop modeling
methods and a graph-theoretical approach for estimating atomic rigidity.
Finally, we observed unexpected success in modeling water positions at a highly sol-
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vated interface, even when the interface itself was not accurately modeled. This was
surprising because Rosetta was developed to model ab initio folding and optimized in many
aspects for this task, including the sampling strategies and scoring potentials – that is to say
hydrophobic interactions tend to be more emphasized and better modeled than electrostatic
interactions – and Rosetta, by default, uses an implicit solvent model. In this context, the
accurate placement of water molecules at an interface was a significant achievement. This
modeling success inspired me, in partiii, to pursue the ambitious design of highly solvated
protein–protein interactions at crystallographic interfaces, detailed in Chapter 6.
iiiAdditional motivation was provided by the broad potential impact of a reliable crystal design tool.
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As demonstrated in Chapter 2 and other prior work1, the most scientifically challenging
aspects of antibody modeling and antibody–antigen docking with RosettaAntibody and
Rosetta SnugDock are (1) modeling the CDR H3 loop, (2) modeling camelid antibodies,
and (3) identifying templates for exotic antibodiesi. Additionally, non-scientific issues
arise for both end users and developers of the software. End users are burdened by
an unwieldy options system and unclear default settings, whereas developers at times
must interact with poorly structured code. In this chapter, I report advances I have made
towards addressing these challenges. I contributed several direct changes to address the
scientific questions: (1) I implemented an updated loop modeling implementation in Rosetta
Antibody and SnugDock that simplified the code structure and permitted for the use of
new loop modeling techniques such as loop hash or fragment insertion; (2) I enabled the
modeling of camelid antibodies throughout both methods by relaxing assumptions about
the presence/absences of chains in the antibody and implementing a novel FoldTree in
SnugDock; (3) I developed a program to automatically update the template database for
RosettaAntibody. To rigorously test the effects of my changes, I contributed scientific
iFor example, antibodies that have atypical CDR lengths or sequences, or come from species other than
mouse or human.
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benchmarks. Then, I simplified the command-line options and set reasonable defaults to
make our software more easily accessible to end users. Finally, with othersii, I re-factored
the grafting step of RosettaAntibody to be more sustainable and developer friendly.
3.2 Introduction
RosettaAntibody is a hybrid modeling tool, utilizing both homology and de novo modeling to
predict the structures of antibodies from sequence. The approach is inspired by observations
of variance in antibody crystal structures and can be divided into two stages. The first stage,
referred to as “grafting”, selects templates based on homology for conserved structural
regions of the antibody (the CDR loops, the framework regions [FR], and the relative
orientation) and assembles a single model from the multiple sourced templates (Figure
3.1). The second stage, referred to as “refinement”, de novo models the CDR-H3 loop
by random perturbation and kinematic closure2 and refines the heavy-chain–light-chain
(VH–VL) relative orientation by a generic local docking approach3. In a typical simulation,
the user, with a FASTA file as the only input, will first generate ten grafted models, each
differing only in the VH–VL relative orientation, then further generate 1,000 refined models
for the most likely orientation and 200 models for the remaining orientations, resulting in
2,800 models of which (usually) the ten lowest scoring are selected as those most likely to
approximate the native structure.
While RosettaAntibody has proven itself to be a useful tool, antibodies are often not
modeled in isolation. Rather, the key biological interest lies in how a given antibody might
interact with its cognate antigen. This question is addressed by Rosetta SnugDock. Given a
plausible initial conformation of an antibody–antigen complex, SnugDock simulates the
antibody–antigen interaction by simultaneously optimizing the antibody–antigen interface,
the VH–VL interface, and the six CDR loops, with refinement of the CDR-H3 and -H2
loops. In a typical simulation, the user will provide a starting conformation along with
iiSergey Lyskov and Dr. Brian D. Weitzner.
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Figure 3.1: Schematic of the RosettaAntibody grafting step.
31
an ensemble of antibody models (or structures) and an ensemble of antigen models (or
structures) to SnugDock, generate 1,000 docked models, and select the 10 lowest-scoring
models as the ones most representative of the native structure.
In recent years, most usage of these modeling tools has been coupled. A frequent
modeling task for users has been to first model a set of antibody sequences (known to
bind a target antigen), and then dock the antibody models to the antigen (for which the
structure may be known or modeled). In one such example, these antibody sequences were
acquired from sequencing following phage display against a target implicated in Celiac
disease pathology4. There are many possible sources of antibody sequences, including
high-throughput sequencing studies that can produce on the order of 105 paired VH–VL
sequences5. It is not unreasonable that antibody sequence-determination methods will
continue to improve and generate more data in the near future, thus it is expected that
the need for accurate computational modeling will similarly rise6. In anticipation of these
trends, I have contributed multiple improvements to the RosettaAntibody and SnugDock
protocols that enable sustainable future development.
3.3 Making antibody grafting object-oriented
Before expanding the functionality of Rosetta Antibody, Dr. Brian D. Weitzner, Sergey
Lyskov, and I improved the stability of the grafting stage. We refactored the old ap-
proach, contained entirely by the Python script graft.py, into object-oriented, C++ code
that comprised multiple objects and classes, united in a single grafting application called
antibody.cc. The re-factored application split the tasking of antibody grafting into three
sub-tasks: (1) identifying structural regions for grafting, (2) identifying templates for the
regions, and (3) assembling the templates into a single model. Unified modeling language
(UML) diagrams of the classes central to the re-factored grafting approach are included as
Supplemental Figures 3.A.1–3.A.3.
In antibody.cc, an input sequence is used to construct an AntibodySequence object,
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Table 3.1: Antibody structural regions used in RosettaAntibody and corresponding numbering
under the Chothia convention. These definitions are hybrid Chothia/Kabat. FRH/L do not com-
plement CDR sequences as there are additional (non-CDR) loops that should be excluded when
selecting a template. *What exactly contributes to VH–VL orientation is unclear, so the combined





















which is a struct containing a std::string for each structural component of the antibody.
We define eight structural components: the six CDRs (three from each chain) and the
two frameworks (one from each chain). Our definitions are compared to the canonical
Chothia numbering scheme in Table 3.1. Detection of these regions is done either by regular
expressions (with the Regex_based_CDR_Detector class) or by external specification through
a JSON-formatted file (with the Json_based_CDR_Detector class). The AntibodySequence
object is written such that any class can pass structural definitions to it.
Next, a “structural component selector” (SCS) is instantiated and configured. Currently,
we use SCS_BlastPlus which identifies templates by a BLAST+7 comparison against a
pre-constructed database. The code is structured such that one could use any method for
selection, as long as it inherits from the correct base class: SCS_LoopOverSCs. For example,
Dr. Brian D. Weitzner has implemented a selector using custom substitution matrices rather
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than the default ones (e.g. PAM32) supplied by BLASTiii. Following the identification of
possible templates, the most favorable ones must somehow be selected. This is done by a






• outlier (read from external list),
• template B-factor,
• OCDiv, and
• template PDB ID.
Finally, the SCS results are sorted by bit score and resolution. This could be altered in the
future by replacing or altering the SCS_BlastComparator_BitScore_Resolution class.
After sorting, the final stage of grafting is assembling the individual structural com-
ponents into a single model. This is handled by the graft_cdr_loops function, which
assembles antibodies in the following order. First, the templates for the heavy and light
frameworks are loaded. Next, the framework query sequences are threaded on to the corre-
sponding templates and the threaded frameworks are aligned to the template orientation.
Finally, this is followed by sequential grafting and threading of each CDR on the assembled
frameworks. Grafting is done by the AntibodyCDRGrafter class developed by Jared-Adolf
Bryfogle for antibody design and detailed elsewhere9. This final stage can be repeated
multiple times, with multiple ranked sequence alignments producing a set of models. In
a standard antibody homology modeling problem, one should produce models with ten
iiiHowever, this and any future selector would have to be called in antibody.cc, which is not currently the
case.
ivOrientation Coordinate Distance is a measure of VH–VL relative orientation, originally defined by my
colleague Dr. Nick A. Marze8.
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different orientations to hedge against the challenge of correctly predicting the relative
VH–VL orientation8.
3.4 Automating the template database
A homology modeling method is only as good as the structural database it relies on. A
method relying on a database with few structures is unlikely to produce good models. The
CAPRI assessment (Chapter 2) revealed the outdated and rigid nature of the RosettaAnti-
body template database: when tasked with modeling camelid antibodies, we had struggled
to find good templates. Despite the knowledge of hundreds of camelid antibody structures
at the time, none had permeated the database. Why? Prior to improvements reported below,
the template database was constructed manually.
As I never participated in the manual construction of the original database10, I cannot
neither speculate on the rationale and reasoning behind it nor its evolution throughout the
years. At the onset of my tenure, the following files were essential to the antibody database:
• Chothia-numbered PDB structures,
• BLAST databasev, categorized by region and length (if the region is a loop),
• a file containing B-factorsvi,
• a file containing the OCD between all antibodies in the database,
• a file containing outliers, and
• a summary file with CDR and FR sequences for all antibodies, “antibody.info”.
Based on the presence of these files, I wrote a script to automatically update each. The
PDBs are now downloaded directly from SAbDab11 in Chothia-numbered format. The
only requirement is that the PDB crystal structures have higher resolution than 3.0 Å. The
PDBs are then subject to quality checks. Using PyRosetta12, I check for missing residues or
vIntermediate “info” files were used to store the CDR sequences used for BLAST database construction, e.g.
“cdr.info”.
viActually, this file contained boolean values representing whether or not the structure met some criterion,
but it is not clear exactly what the criterion was.
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Table 3.2: Comparison between the last iteration of the manual database and the first iteration of
the automatic database (February 15th, 2019). Template counts for each region are shown.
Old Count New Count Overlap
All CDRs 1,902 2,611 1,560
FRH 1,785 2,390 1,427
FRL 1,577 2,832 1,111
Orientation 1,003 1,721 749
unrealistic peptide bond lengths in the regions crucial to modeling (i.e. CDRs and conserved
framework residues), excluding any region if it does not pass the check. During the quality
checks, sequences are extracted for each region and written to temporary “info” files. Then
these files are read in, grouped by region and length, and output in FASTA format. The
BLAST databases are then constructed as:
makeblastdb -in fasta -dbtype prot -title database.cdr.length -out
database.cdr.length
Finally, the relative orientations coordinates for each antibody, the relative orientations for
each pair, and the B-factors are extracted and written to files (to be used for filtering during
the grafting step).
In addition to automating database updating, I have also written comparison scripts
to assess the changes in the database from update to update and developed a scientific
benchmark to evaluate any changes in grafting accuracy. Table 3.2 summarizes the changes
following the shift from the manual to the automatic database. Shifting resulted in an
increase in templates for all regions. PDBs shared by both databases were used as a
comparison to test whether or not the auto-update script is producing reasonable output.
Table 3.3 highlights the differences at the sequence level following the shift. In general,
these differences are minimal (on the order of ∼1%). The differences arise for a variety
of reasons. In cases when multiple antibodies are present in the same PDB asymmetric
unit, different antibodies are selected from the multiple possibilities. In other cases, PDBs
are omitted in the new database due to geometry issues (missing atoms or non-ideal C–N
distances) in critical regions. Finally, the most prevelant case for FRH or CDR-H2 loop
36
Table 3.3: Comparison of sequences extracted for identical regions for identical PDBs. There are (in
terms of percent) very few mismatches.
Mismatch Count Mismatch Percent
CDR H1 30 1.1%
CDR H2 60 2.2%
CDR H3 33 1.3%
FRH 27 1.1%
CDR L1 11 0.4%
CDR L2 15 0.6%
CDR L3 8 0.3%
FRL 2 <0.1%
Orientation 10 1.3%
Figure 3.2: By importing Chothia-numbered PDBs, testing for the presence of all backbone atoms,
and testing for good C–N bond geometry, the new database properly processes and retains the entire
CDR-H3 loop for 4YDJ. The same PDB in the old database was (inexplicably) missing a large portion
of CDR-H3 loop atoms.
mismatches is when the numbering schemes are not identical between database. It is
unclear why the old database has some incorrectly numbered loops. It is possible that
the old database may have used regular expression, for which failures would have been
difficult to detect. In the new database, sequences are derived from Chothia-numbered
PDB files, from a validated server with an error rate close to 0%11,13. Figure 3.2 shows the
consequences of errant numbering: for this antibody (4YDJ), the CDR-H3 loop is missing
atoms in the old database.
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3.5 Modeling camelid antibodies with Rosetta
Exposure to the challenge of modeling camelid antibodies in Chapter 2, not only triggered a
re-think about the database, but also revealed an inability to model camelid antibodies with
RosettaAntibody and SnugDock. Interestingly, camelid antibody structure prediction was
possible at one point14, but that ability was lost due to underlying changes in the Rosetta
code base15. While re-enabling camelid antibody modeling with RosettaAntibody was
trivial, requiring only minor modifications to the grafting step, camelid antibody docking
necessitated more substantial changes.
Enabling the docking of single-chain antibodies in SnugDock was challenging. In the
course of a SnugDock simulation, both the relative orientation between the heavy and
light chain and the orientation between the antibody and antigen are refined. This case
constitutes a multi-body docking problem. Rosetta does not natively support multi-body
docking. Thus, the SnugDock protocol had to make certain assumptions and alterations
to the kinematic information stored during the simulation. The object storing this data is
known as the FoldTree16.
Briefly, the FoldTree is an object within Rosetta that dictates in what order residue/pro-
tein positions should be updated. In its implementation, the FoldTree is an acyclic graft
comprising directed edges connected by directed jumps. Edges represent physically con-
nected objects such as a single polypeptide chains. This representation is efficient and
the position for a given residue can be determined if the dihedral angles of the preceding
residues in the FoldTree are known17. Jumps represent virtually connected objects, such as
two proteins. Again, this representation is efficient as the position of the second protein
can be specified by a rotation matrix and a translation vector relative to the first protein.
However, in this implementation only a single jump can be updated at time, making it
impossible to dock multiple proteins relative to one another. If three protein chains (A, B,


























Figure 3.3: (A) An implemented example of a simple FoldTree for multiple body docking, here with
four proteins. Proteins are shown as blobs and labeled A, B, C, and D. In this setup, A can dock to
BCD, AB can dock to CD, and ABC can dock to D, but B could not move independently. (B) An
implemented example of a Hierarchical FoldTree, as currently implemented in Rosetta SnugDock,
here virtual atoms, placed at corresponding centers of mass, are shown as points and labeled.
Relevant jumps are shown as dotted lines and labeled. Jumps connecting center of mass virtual
atoms (VA, VB, VC, and VD) and the N-termini of corresponding polypeptide chains are omitted.
In this configuration any protein within a complex can be docked to its neighbors and complexes
can be docked to each other. For example, by docking across J1, the AB complex can be docked to
the CD complex, or by docking across J5, protein C can be docked to protein D. Another equally
valid approach would be to connect individual proteins to the complex center of mass (i.e. J5 would
connect VD to VCD and not VC).
given FoldTree (Figure 3.3A). For example, if one wanted to dock AB to C, and then dock
AC to B, one would have to construct two separate FoldTree objects (one in which A jumps
to B jumps to C, so C can move relative to the AB complex, and another where A jumps
to C jumps to B, so B can move relative to the AC complex). The three proteins could not
move simultaneously because storing the translations and rotations for all three proteins in
the FoldTree would break the acyclic property.
SnugDock avoids this issue by separating the antibody–antigen docking simulation into
a collection of smaller simulations, each with its own FoldTree18. However, assumptions
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are necessarily made when handing off the collection of atoms from one simulation to the
next (e.g. the first polypeptide is the heavy chain, the second is the light, and the third is
the antigen), as the FoldTree object does not have any knowledge of the collection of atoms
to which it is attachedvii. Prior to my changes, it was impossible to input a single chain
antibody to a SnugDock simulation because of the assumed presence of a light chain.
To correct this issue, I introduced what is known as a “Hierarchical FoldTree”, originally
proposed by Dr. Nick A. Marze in his PhD dissertation as a “Universal FoldTree”19, to
Rosetta SnugDock. This FoldTree places what are known as “virtual” residues at protein and
complex centers of mass and then connects the polypeptide chains in a hierarchical fashion,
such that complexes of interest are grouped togetherviii (e.g. the two antibody chains or any
number of antigen chains). By using virtual atoms at the centers of mass, transformations
and rotations between most potential docking partners are known. Thus, complexes can
dock to other complexes and neighboring polypeptide chains within complexes chains can
dock to each other (Figure 3.3B). An additional benefit of using virtual residues, rather
real ones, is that each polypeptide chain can have its own internal FoldTree, which is then
connected to the Hierarchical FoldTree. This permits FoldTree-dependent modifications
within in each chain (such as loop modeling) to take place, without necessitating a new
FoldTree. As a result, the updated SnugDock protocol uses a single FoldTree throughout
the simulation.
3.6 Introducing new loop modeling approaches
Having the ability to model and dock camelid antibodies does not necessarily result in the
ability to produce high-accuracy models. As was shown in Chapter 2, camelid antibody
models suffer from significant inaccuracies in the CDR-H3 loop. In fact the CDR-H3 loop
is the most challenging region to model for most antibodies1. CD3-H3 loop prediction is
viiCollections of atoms (typically proteins) are stored in Pose objects in Rosetta. It would be silly and inefficient
to store the same information twice by replicating Pose data in the FoldTree.
viiiIn general, the design choice to connect neighboring chains is purely stylistic and an equally valid alternative
is to connect the chains to the complex center of mass, so one can dock each chain against the complex.
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a substantial challenge in the field20. The challenge arises from the immense diversity of
the CDR-H3 loop, which occurs both at a sequence21 and structural level22. One possible
approach to improving loop modeling accuracy is to introduce and apply novel loop
modeling methods. Since CDR-H3 loops are more diverse than standard protein loops, why
should we use standard loop modeling approaches?
To that end, I have collaborated with Prof. Tanja Kortemme’s lab at the University of
California, San Francisco to implement new loop modeling methods in RosettaAntibody
and Rosetta SnugDock. Her group’s recent advances in loop modeling build on their
development of kinematic loop closure (KIC)2,23 by introducing the use of fragments to
either perturb loop structure before closure (termed “fragment KIC”) or to assist closure
of a perturbed loop (termed “loop hash KIC”). Fragment KIC has been benchmarked on a
diverse set of protein loops and shown to improve loop modeling performance (Xingjie Pan,
unpublished). On the other hand, Loop hash KIC is still under development and testing on
regular protein loops. Thus while both methods are implemented for antibody modeling
and docking, I only assessed the performance of fragment KIC on the more challenging
problem of antibody loops.
Figure 3.4 compares the distribution of minimum CDR-H3 loop RMSDs produced for
a set of 49 antibodies. How the antibodies were selected and the simulations conducted
is detailed in the following section, with sample command lines given in the Appendix.
Fragments were selected using the Robetta server, which implements the fragment picker24.
Briefly, the fragment picker protocol takes as input a protein sequence and breaks it into all
overlapping windows of a particular length (three and nine in this case). For each window,
secondary structure propensities are calculated from the sequence, and 200 fragments are
selected from a pre-constructed databaseix by comparing sequences and secondary structure
propensities. To give an example, a 50 residue protein has 50 − 3 = 47 windows and, for
each, 200 fragments will be selected.

















Figure 3.4: The distributions of the minimum CDR-H3 loop RMSDs observed for all antibodies in
the benchmark, for two loop modeling methods, do not significantly differ according to Student’s
t-test (p-value = 0.67).
From Figure 3.4, it is clear that including fragments does not improve overall CDR-H3
loop prediction accuracy, as the minimum RMSD distributions are identical. This result
is not surprising considering it has recently been reported that 30% of CDR-H3 loops
do not have matching (< 1Å RMSD) four-residue fragments in the PDB22. However, as
the fragments used in my study were of length three or nine, I decided to quantify the
structurally similarity of fragments and loops in both my antibody set and Xingjie’s protein
set.
To evaluate structural similarity, I compared every fragment to its overlapping loop seg-
ment. For overlapping residues, I calculated the difference between the fragment and loop
backbone dihedral angles. I then expressed this difference as a chord distance: D2(θ1, θ2) =
2 − 2 cos(θ2 − θ1) and summed over the overlapping residues: ⟨D⟩ = 1n ∑n(D2ϕ + D2ψ)/2.
Thus, ⟨D⟩ has a minimum of 0, if a fragment matches a loop exactly, and a maximum of 4,
if a fragment differs by 180 degrees at every dihedral from a loop.
The structural comparison of Rosetta-derived fragments and protein or antibody loops
is shown in Figure 3.5 for three-residue fragments and Figure 3.6 for nine-residue fragments.



















Comparison of Three-Residue Fragments
Protein Loops
Antibody CDR-H3 Loop
Figure 3.5: Three-residue fragments from the PDB are more structurally similar to protein loops
than to the antibody CDR-H3 loop. The cumulative distribution function yields the probability



















Comparison of Nine-Residue Fragments
Protein Loops
Figure 3.6: Nine-residue fragments from the PDB are more structurally similar to protein loops than
to the antibody CDR-H3 loop. The cumulative distribution function yields the probability (y-axis)
that a fragment is within a certain chord distance (x-axis) of a loop.
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each ⟨D⟩ value along the x-axis, the y-axis represents the fraction of fragments with similar
or smaller ⟨D⟩. Even at a quick glance, these figures confirm the earlier findings that
CDR-H3 loops are structurally distinct, as over nearly all values of ⟨D⟩ protein loops have
more matches in their respective fragment set.
3.7 Scientific tests
When developing software, it is important to track how changes to the underlying code
affect software functionality. In the worst case, a developer would want to catch changes
that break the software before releasing an unusable product to the public. In less severe
cases, a developer would want to know if their changes improve or worsen the software
in terms of some performance metric (e.g. speed or for scientific software accuracy). In
Rosetta, changes in code functionality are tracked through a series of tests, each operating
on a different scale.
At the smallest scale of object-oriented code, unit tests assess the individual classes and
functions, by evaluating how the code processes pre-determined queries. For example, a test
for an addition function might ask what “2+2” evaluates to (4) or if the function can process
“ab + cd” as input (it should not unless there is expected behavior for adding strings). These
tests report on a pass/fail level, which makes results simple to interpret. However useful,
these tests cannot capture interactions between objects. This is the role of integration tests,
which in Rosetta are implemented as subsequent comparisons of simulation output for very
brief simulations. These tests report whether or not a change is detected, so a developer
can track the effects of their code modifications. The tests are short so they can be run
every time code is edited. As a consequence, integration tests cannot inform on large scale
effects of changes. For example, after updating the RosettaAntibody code, the integration
test of homology modeling PDB 1ZTX might change, but that would not give information
about RosettaAntibody’s performance on antibody modeling in general. To understand
how changes affect large-scale performance, the Rosetta community relies on scientific tests.
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Table 3.4: Summary of antibody-related scientific benchmarks.
Test Executable Metrics Set
Antibody Grafting antibody OCD, and RMSD of H1, H2, 49 antibodies
H3, FRH, L1, L2, L3, FRL
Antibody CDR-H3 antibody_H3 CDR-H3 Loop RMSD, Kink 49 grafted models
Loop Modeling
Antibody–Antigen Docking snugdock Interface Score, RMSD 15 complexes
Scientific tests typically amount to recreating published results, as they aim to evaluate
the performance of a particular modeling protocol (e.g. RosettaAntibody) on a comprehen-
sive set of targets (e.g. 49 antibodies). For this reason, scientific tests are computationally
expensive, but also the best indicator for modeling accuracy. Automated interpretation of
scientific results is challenging as one has to quantify what a “good” test outcome might
constitute. In the process of making the fundamental alterations to antibody modeling and
docking code I described in this chapter, I have also assessed the updated codes’ perfor-
mance on scientific tests, and I am working with Dr. Julia Koehler Leman (of the Flatiron
Institute) to standardize these tests within the Rosetta software suite and to setup the tests
on the testing servers. The tests are summarized in Table 3.4.
The test for RosettaAntibody consists of 49 antibodies, the selection of which is fully
detailed in the methods of two prior papers8,25. Briefly, the antibodies were selected for
unique CDR-H3 loop sequences and high resolution (better than 2.5 Å) in addition to other
quality criteria. The test comprises two stages: grafting and H3 modeling. As of the writing
of this thesis, PDB IDs 3NPS and 3MLR are omitted. 3NPS is missing key residues in heavy
framework and 3MLR has an extra long CDR-L3 loop with no other possible templates, so
an realistic estimation of its grafting accuracy is not feasible.
For the grafting stage, the FASTA sequence of each antibody is used as input and a
single homology model is generated, while excluding the input PDB ID as a possible
grafting source (see the Appendix). Each model is then compared to the crystal structure.
The following structural metrics are compared: the orientation coordinates, calculated as
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previously described8, and RMSDs for structural regions on the light and heavy chain, which
are extracted following alignment on conserved framework positions for the respective
chainsx.
A sample outcome for the scientific benchmark of grafting is shown in Figure 3.7, which
compares the results for grafting before and after the automation of the antibody database.
In the case of Figure 3.7, the benchmark was run twice (once with each database) and
the RMSDs are compared. When implemented as a server-based, stand-alone test, the
benchmark will not be able to compare against itself. Instead, quantifiable metrics, such as
the fraction sub-Ångström models for each region will report a pass or fail status based on
a threshold. For each of the framework regions, I would set a threshold at one model with
RMSD greater than 1 Å. I would exclude the CDR-H3 loop from this analysis as the goal of
grafting is not to yield an accurate CDR-H3 loop model. For the remaining CDRs, I would
anticipate no more than 5 of the models (for each CDR) to have RMSD higher than 1 Å.
Grafted models are used as input for the H3 modeling test (because the ultimate chal-
lenge for RosettaAntibody is to produce an accurate model from sequence alone, it is
nonsensical to test H3 modeling on a crystal structure). For each input model, 1000 CDR-H3
loop models are generated with RosettaAntibody’s default H3 modeling approach (the com-
mand line titled “Antibody H3 Kink Constraints“ in the Appendix). Following modeling,
CDR-H3 loop RMSDs are calculated by aligning the heavy chain of the model to the crystal
structure and comparing the positions of the heavy atoms.
The result for the CDR-H3 loop modeling benchmark were shown earlier in this chapter
in Figure 3.4. Here, the benchmark was run twice. First, with the standard next-generation
KIC method for loop closure, then with the new fragment-based method. In Figure 3.4, I
compared the minimum RMSD observed across all models for each antibody target, as I
sought to answer whether or not fragments improved CDR-H3 Loop modeling (they did
not). When implemented on the testing servers, the benchmark will not run as a comparison.
xTo ensure accurate comparison, the light and heavy are not aligned simultaneously, but rather indepen-
dently.
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CDR L1 (Å) CDR L2 (Å) CDR L3 (Å)
CDR H1 (Å) CDR H2 (Å) CDR H3 (Å)
OCD FRH (Å) FRL (Å)
0.3 0.6 0.9 1.2 0.5 1.0 1.5 2.0 1 2
0.5 1.0 1.5 2.0 1 2 3 0 1 2 3










































Figure 3.7: Values for structural metrics with respect to native following the grafting step with either
the old (manual, x-axis) or new (automatic, y-axis) database are plotted. The new database slightly
improves the performance of the grafting step of RosettaAntibody, with 55% of CDR loops and
53.5% of FRs having lower RMSDs.
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Instead, the minimum CDR-H3 loop RMSD values for each targets will be binned and
the number of sub-X Ångström models will be compared to a standard. For example, I
expect between zero and one loops to have an RMSD of > 3.0 Å, between five and ten
loops to have an RMSD of 3.0 ≤ X > 2.0 Å, between 15 and 20 loops to have an RMSD of
2.0 ≤ X > 1.0 Å, and between 10 and 15 loops to have an RMSD of 1.0 ≤ X > 0.0 Å. As the
CDR-H3 loop modeling is stochastic in nature, these values are estimates and will need to
be calibrated over time.
The test for Rosetta SnugDock consists of 15 antibody–antigen complexesxi, for some of
which unbound structures are available, established in the original SnugDock paper18. The
input for the SnugDock scientific test is the ten antibody homology models produced by
the default RosettaAntibody protocol26, while excluding the native PDB from grafting, and
a backbone-constrained relaxed27 (unbound when possible) antigen structure. The input
structures are prepacked3 in preparation for docking, using the docking_prepack_protocol
application (sample commands are shown in the Appendix). Finally, SnugDock is run,
when possible using Motif Dock Score to improve low-resolution sampling28. Afterwards,
models are aligned to crystal structures and the interface RMSD is computed, along with
the interface score.
A sample result for the SnugDock scientific benchmark is shown in Figure 3.8. This
figure exemplifies the challenges of assessing scientific benchmarking results (an issue that
exists for the CDR-H3 loop modeling benchmark as well, but was not discussed). By eye,
the user can see good performance (low-scoring, low-RMSD models with few/no false
positives [low-scoring, but high-RMSD models]) of the docking algorithm for 5 targets
(1ahw, 1jps, 1mlc, 1ynt, and 1ztx), with decent performance for a further 5 targets (1bql,
2aep, 2b2x, 2bdn, and 2jel), and poor performance for the remaining 5 targets (1jhl, 1k4c,
1nca, 1wej, and 1vfb). However, there is no single quantifiable metric that can capture
comprehensively capture these observations.








































f5(T10) = 1.0 f5(T10) = 0.5 f5(T10) = 0.2
f5(T10) = 1.0 f5(T10) = 0.3 f5(T10) = 0.7
f5(T10) = 0.1 f5(T10) = 0.5 f5(T10) = 0.1
f5(T10) = 0.8 f5(T10) = 0.9 f5(T10) = 0.5
f5(T10) = 0.2 f5(T10) = 0.4 f5(T10) = 0.5
Figure 3.8: “Funnel plots” show interface RMSD versus interface score for models produced by
docking simulations (here 15 antibody–antigen complexes, with PDB IDs specified for each sub-plot).
If the modeling protocol is properly calibrated, low score will trend with low RMSD and hence
points will “funnel” towards the bottom left of each sub-plot. Native structures are scored as well
(red points), with minor refinement, as a control. “Funnel plots” address two questions about
docking: (1) does the simulation sample native-like (low-RMSD) conformations, for example 2bdn
does not, and (2) does the simulation score these points accurately, for example 1wej does not. The
value in the bottom right is the fraction of top 10 lowest-scoring models with an interface RMSD less
than 5 Å.
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As with the CDR-H3 benchmark, one could use minimum-RMSD values as a proxy
for sampling, answering whether or not the simulations are exploring near-native confor-
mations. But such an approach would not be comprehensive. It contains no information
about performance in blind cases, ones where the user would select low-scoring models,
assuming these models were representative of the native structures. Therefore, an alterna-
tive approach is to quantify the number of models below a certain RMSD from the top X
lowest-scoring, then set a threshold for success. Based on the CAPRI criteria for a “medium”
quality complex models, I propose the following definition of success: 50% of the top 10
lowest-scoring models have an interface RMSD of less than 5 Ångströms (this value is
shown in the bottom of each sub-plot of Figure 3.8).
3.8 Summary
In this chapter, I reported the recent technical advances I have contributed to RosettaAn-
tibody and Rosetta SnugDock. To encourage future development, I made the code more
stable by converting old Python scripts to object-oriented C++ classes, I expanded the ho-
mology database and enabled its automatic updating, and I curated scientific benchmarks.
To tackle new classes of antibodies (such as those with only a single heavy chain), I made
RosettaAntibody and Rosetta SnugDock more robust, implemented new loop modeling
methods, and developed a Hierarchical FoldTree. Finally, I eased the use of future users by
simplifying the user interface. Collectively, these changes enabled multiple future studies4,
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Figure 3.A.1: UML diagram of the SCS_Functor and associated classes for filtering antibody tem-
plates. In a UML diagram, classes are represented by boxes. Data methods (of the form attribute:
type) and members (of the form function(args): return) follow in subsequent boxes. The first
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+ h2: SCS_ResultOP 
+ h3: SCS_ResultOP 
+ frh: SCS_ResultOP 
+ l1: SCS_ResultOP 
+ l2: SCS_ResultOP 
+ l3: SCS_ResultOP 
+ frl: SCS_ResultOP 
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SCS_ResultSet
Figure 3.A.2: UML diagram of the SCS_ResultSet and associated classes for storing potential
template data. In a UML diagram, classes are represented by boxes. Data methods (of the form
attribute : type) and members (of the form function(args): return) follow in subsequent
boxes. The first character indicates the visibility (“+”: public). Open triangle connections indicate











































































































































































































































































































































































































































































































































Figure 3.A.3: UML diagram of the Reporter-derived classes. The CDR_Detector identifies CDRs
from sequences based on rules defined by the inheriting subclass. The SCS_Base class defines
the necessary virtual function for selecting structural templates. In a UML diagram, classes are
represented by boxes. Data methods (of the form attribute : type) and members (of the form
function(args): return) follow in subsequent boxes. The first character indicates the visibility
(“+”: public, “-”: private, “#”:protected). Open triangle connections indicate inheritance.
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3.A.2 Sample Commands to Run RosettaAntibody and SnugDock
These commands are valid for the git branch: lqtza/enable_fkic_in_antibody_H3 (9f10be3).
Once merged with this branch is merged with the master branch, the commands will be
valid for the public release of Rosetta. Note that these commands do not include the Q–Q
constraint because it has to be manually specified via a constraint file. The Q–Q constraint
should be automated in the future.
Antibody Grafting
antibody.linuxgccrelease -fasta my.fasta
Antibody Grafting Exclude PDB
antibody.linuxgccrelease -fasta my.fasta -antibody:exclude_pdb PDBID
Antibody H3 Minimal
antibody_H3.linuxgccrelease -s model.relaxed.pdb -nstruct 1000




























-loops:frag_sizes 9 3 1






















































































3.A.4 Antibody Modeling Benchmark List
1dlf ,1fns ,1gig ,1jfq ,1jpt ,1mfa ,1mlb ,1mqk ,1nlb ,1oaq ,1seq ,1x9q ,2adf ,
2d7t ,2e27 ,2fb4 ,2fbj ,2r8s ,2v17 ,2vxv ,2w60 ,2xwt ,2ypv ,3e8u ,3eo9 ,3g5y ,
3giz ,3gnm ,3go1 ,3hc4 ,3hnt ,3i9g ,3ifl ,3liz ,3lmj ,3m8o ,3mlr ,3mxw ,3nps ,
3oz9 ,3p0y ,3t65 ,3umt ,3v0w ,4f57 ,4h0h ,4h20 ,4hpy ,4nzu
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Large-Scale Antibody CDR-H3 Loop
Flexibility Assessment
This chapter includes published material, which is free to reuse under the Creative
Commons Attribution license, from Jeliazkov JR, Sljoka A, Kuroda D, Tsuchimura
N, Katoh N, Tsumoto K, and Gray JJ, “Repertoire analysis of antibody CDR-H3
loops suggests affinity maturation does not typically result in rigidification.”
Fronteirs in Immunology 9, 413 (2018)
4.1 Overview
Antibodies can rapidly evolve in specific response to antigens. Affinity maturation drives
this evolution through cycles of mutation and selection leading to enhanced antibody
specificity and affinity. Elucidating the biophysical mechanisms that underlie affinity matu-
ration is fundamental to understanding B-cell immunity. An emergent hypothesis is that
affinity maturation reduces the conformational flexibility of the antibody’s antigen-binding
paratope to minimize entropic losses incurred upon binding. In recent years, computational
and experimental approaches have tested this hypothesis on a small number of antibodies,
often observing a decrease in the flexibility of the Complementarity Determining Region
(CDR) loops that typically comprise the paratope and in particular the CDR-H3 loop, which
contributes a plurality of antigen contacts. However, there were a few exceptions, and
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previous studies were limited to a small handful of cases. Ii determined the structural
flexibility of the CDR-H3 loop for thousands of recently-determined homology models of
the human peripheral blood cell antibody repertoire using rigidity theory. I found no clear
delineation in the flexibility of naïve and antigen-experienced antibodies. To account for
possible sources of error, I additionally analyzed hundreds of human and mouse antibodies
in the Protein Data Bank through both rigidity theory and B-factor analysis. By both metrics,
I observed only a slight decrease in the CDR-H3 loop flexibility when comparing affinity-
matured antibodies o naïve antibodies, and the decrease was not as drastic as previously
reported. Further analysis, incorporating molecular dynamics (MD) simulations, revealed a
spectrum of changes in flexibility. My results suggest that rigidification may be just one of
many biophysical mechanisms for increasing affinity.
4.2 Introduction
Antibodies are proteins produced by the B cells of jawed vertebrates that play a central role
in the adaptive immune system. They recognize a variety of pathogens and induce further
immune response to protect the organism from external perturbation. Molecules that are
bound by antibodies are referred to as antigen and are recognized by the antibody variable
domain (Fv), which is comprised of a variable heavy (VH) and light (VL) domain. To
overcome the challenge of recognizing a vast array of targets — the number of antigens being
far greater than the number of antibody germline genes — antibodies rely on combinatoric
and genetic mechanisms that increase sequence diversity1–3. Starting from a limited array
of germline genes, a naïve antibody is generated by productive pairing of a randomly
recombined VH, assembled from V-, D-, and J-genes on the heavy locus, and randomly
recombined VL, assembled from V- and J-genes on the kappa and lambda loci1. Next, in
a process known as affinity maturation, iterations of somatic hypermutation are followed
by selection to evolve the antibody in specific response to a particular antigen. This
iWhile I guided the research in general, worked on antibody modeling, and analyzed results, Adnan Sljoka
developed the graph theoretical approach, and Daisuke Kuroda ran the molecular dynamics simulations.
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evolution results in the gradual accumulation of mutations across the entire antibody, with
higher mutation rates in the six complementarity determining regions (CDRs) than in
the framework regions (FRs)4,5. The CDRs are hypervariable loops comprising a binding
interface on the Fv domain beta-sandwich framework, with three loops contributed by
each chain; the light chain CDRs are denoted as L1, L2, and L3 and the heavy chain
CDRs are H1, H2, and H3. The five non-H3 CDRs can be readily classified into a discrete
amount of canonical structures6–10 because they possess limited diversity in both sequence
and structure. The CDR-H3 on the other hand is the focal point of V(D)J recombination,
resulting in exceptional diversity of both structure and sequence. While all CDRs contribute
to antigen binding, the diverse CDR-H3 is often the most important CDR for antigen
recognition11–14. Thus, to understand the role of B cells in adaptive immunity and how they
evolve antibodies capable of binding specific antigens, we must first understand the effects
of affinity maturation on the CDRs, and in particular on the CDR-H3.
Over the last 20 years, the effects of affinity maturation have been studied with an as-
sortment of experimental and computational methods. X-ray crystallography has been used
to compare antigen-inexperienced (naïve) and antigen-experienced (mature) antibodies
with both antigen present and absent. Analysis of the catalytic antibodies 48G7, AZ-28,
28B4, and 7G12 showed a 1.2 Å average increase in Cα RMSD of the CDR-H3 upon antigen
binding in the naïve over that of the mature antibody, whereas motion in the other CDRs
varied15–19. Beyond structural studies, surface plasmon resonance (SPR) has been used
to assess the energetics and association/dissociation rate constants of antibody–antigen
binding. Manivel et al. studied a panel of 14 primary (naïve) and 11 secondary (mature)
response anti-peptide antibodies, observing that affinity maturation resulted in increases in
the association rate and corresponding changes in the entropy of binding20. Schmidt et al.
saw the opposite when studying a broadly neutralizing influenza virus antibody, observing
that affinity maturation resulted primarily in a decrease in the dissociation rate, with little
effect on the association rate21. Isothermal calorimetry (ITC) has also been used to determine
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antigen-binding energetics including the enthalpic and entropic contributions. For nine
anti-fluorescein antibodies, including 4-4-20 and eight anti-MPTS antibodies, ITC results
revealed diverse effects of affinity maturation: 14 of 17 mature antibodies bound antigen
in an enthalpically favorable and entropically unfavorable manner, yet 3 of 17 showed the
opposite, with entropically favorable and enthalpically unfavorable binding energetics22,23.
Three-pulse photon echo peak shift (3PEPS) spectroscopy has been used to quantify dynam-
ics of chromophore-bound antibodies on short timescales of femto- to nanoseconds. 3PEPS
spectroscopy results from a panel of 18 antibodies showed that mature antibodies can
possess a range of motions from small rearrangements such as side-chain motions to large
rearrangements such as loop motions22–24. In a specific comparison of naïve vs. mature, for
the 4-4-20 antibody, the mature antibody was found to have smaller motions, i.e. to be more
rigid, than naïve22–27. Antibody dynamics have also been studied by hydrogen–deuterium
exchange mass spectroscopy (HDX-MS), which in contrast to 3PEPS probes timescales of
seconds to hours. Comparison of three naïve and mature anti-HIV antibodies showed
changes in CDR-L2/H2, but not in CDR-H3 dynamics28. Finally, MD simulations have
been used to study antibody dynamics on intermediate timescales of nano- to microsec-
onds. MD simulations showed rigidification and reduction of CDR-H3 loop motion upon
maturation for seven studied naïve/mature antibodies, with two exceptions, depending
on the specific study21,27,29–33 (22, 28, 30-34). In an orthogonal protein design approach to
examine the CDR-H3 loop flexibility, Babor et al. and Willis et al. found that naïve antibody
structures are more optimal for their sequences, when considering multiple CDR-H3 loop
conformations34,35. In sum, past studies focusing on the effects of affinity maturation on
CDRs have found evidence suggesting that mature antibodies have more structural rigidity
and less conformational diversity than their naïve counterparts15,17,18,22–26.
With recent growth in the number of antibody structures deposited in the Protein Data
Bank (PDB) and development of homology models from high-throughput sequencing of
paired VH–VL genes in B cells, we now have the datasets necessary to test the rigidity
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hypothesis on a large scale. Prior studies, usually focused on a few antibodies at time,
generally support the hypothesis that affinity maturation rigidifies the CDR-H3 loop. Thus,
I hypothesized that this effect should be observable in a repertoire-scale study of thousands
of antibodies. I first analyzed thousands of recently-determined RosettaAntibody homology
models of the most common antibody sequences found in the human peripheral blood
cell repertoire36. I estimated the structural flexibility of the CDR-H3 loop by applying
graph theoretical techniques based on mathematical rigidity theory, namely the Floppy
Inclusions and Rigid Substructure Topography (FIRST) and extensions of the Pebble Game
(PG) algorithms to determine backbone degrees of freedom (DOFs). Surprisingly, I found
no difference in the CDR-H3 loop flexibility of the naïve and mature antibody repertoires.
I considered alternative explanations for my results, which were incongruent with past
studies, by expanding my analysis to a large set of antibody crystal structures, including
several previously characterized antibodies, and extending my methods to include other
measures of flexibility such as B-factors and MD simulations. By all analysis methods,
I found mixed results: some antibodies’ CDR-H3 loops were more flexible after affinity
maturation whereas others’ became less flexible. In summary, I find that while affinity mat-
uration can modulate antibody binding activity by reducing CDR-H3 structural flexibility,
it does not necessarily have to do so.
4.3 Methods
4.3.1 Immunomic repertoire modeling
Briefly, RosettaAntibody is an antibody modeling approach that assembles homologous
structural regions into a rough model and then refines the model through gradient-based
energy minimization, side-chain repacking, rigid-body docking, and de novo loop modeling
of the CDR-H3. The approach is fully detailed in other publications37,38. In a typical
simulation, 1,000 models are generated and the ten lowest-energy models are retained.
The immunomic repertoire I analyzed is from DeKosky and Lungu, et al.36. In that study,
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models were generated for each of the 1,000 most frequently occurring naïve and mature
antibody sequences from two donors (a total of 20,000 models representing the 2,000 most
frequent antibodies).
4.3.2 Structural rigidity determination
The flexibility or rigidity of the CDR-H3 loop backbone was determined by using several
extensions of the Pebble Game (PG) algorithm39–42 and method FIRST43; I refer to here as
FIRST-PG. This approach can determine flexible and rigid regions in a protein and quantify
the internal conformational degrees of freedom from a single protein conformational snap-
shot. FIRST generates a molecular constraint network (i.e. a graph) consisting of vertices
(nodes) representing atoms and edges (interactions representing covalent bonds, hydrogen
bonds, hydrophobic interactions, etc.). Each potential hydrogen bond is assigned an energy
in kcal/mol which is dependent on donor-hydrogen–acceptor geometry. FIRST is run with
a selected hydrogen-bonding energy cutoff, where all bonds weaker than this cutoff are
ignored in the network. On the resulting network, the well-developed mathematical and
structural engineering concepts44 of flexibility and rigidity of molecular frameworks and the
PG algorithm are then used to identify rigid clusters, flexible regions, and overall available
conformational DOFs. For a given antibody structure, DOFs for the protein backbone of
the CDR-H3 loop were calculated at every hydrogen-bonding energy cutoff value between
0 to −7 kcal/mol in increment steps of 0.01 kcal/mol. This calculation was repeated for
every member of that antibody ensemble (i.e. ten lowest energy models of the ensemble)
and finally, at each energy cutoff, the DOF count was averaged over the entire ensemble.
For a given energy cutoff and a given member of the ensemble, the DOF count for the
CDR-H3 loop (residues 95–102) was obtained using a special PG operation which calculates
the maximum number of pebbles that can be gathered on the backbone atoms (Cα, C, N)
of the CDR-H3 loop39. The PG algorithm starts with the constrained molecular graph and
generates a directed multigraph, where available free pebbles are absorbed one by one by
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independent edges (constraints). Each pebble represents one of 6 DOF associated with an
atom. After PG completion, the remaining free pebbles that can be collected on the CDR-H3
backbone (i.e. a subgraph in the constrained network) represent its conformational DOF
count.
4.3.3 Degree of freedom scaling
To compare flexibility across CDR-H3 loops of different lengths, the DOF metric computed
above is scaled by a theoretical maximum DOF. I define sDOF = DOF
(2L+6) , where, 2L (the
loop length in residues) represents the backbone degrees of freedom (torsion angles: ϕ,ψ),
and 6 represents the trivial but ever-present rigid-body DOFs (i.e. combination of rotations
and translations in 3D).
4.3.4 Area under the curve calculation
The area under the curve (AUC) is approximated by simple numerical integral (akin to
trapezoidal integration), where the first term defines a rectangle and the second term defines
a triangle:
AUC = ∑(xi − xi−1) · yi−1 +
1
2
(xi − xi−1)(yi − yi−1)
4.3.5 Crystallographic dataset
On June 27th, 2017, a summary file was generated from the Structural Antibody Database
(SAbDab)45, using the “non-redundant search” option to search for antibodies with maxi-
mum 99% sequence identity, paired heavy and light chains, and a resolution cutoff of 3.0
Å. The summary file, containing 1021 antibodies, was used as input to a SAbDab down-
load script which yielded corresponding sequences, Chothia-numbered PDBs, and IMGT
data (on occasion this had to be updated to match the reported germline in the IMGT
3Dstructure-DB)46. The structures were further pruned: structures were omitted if there
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were unresolved CDR-H3 residues, as this would preclude flexibility calculations, or if
the antibody was neither human nor mouse, as this would prevent alignment to germline.
Prior to analysis, structures were truncated to the Fv region (removing all residues but
light chain residues numbered 1–108 and heavy chain residues numbered 1–112, in Chothia
numbering) and duplicate and non-antibody (for example, bound antigen) chains were
removed. A total of 922 antibody crystal structures were analyzed. The following CDR
definitions were used throughout this paper, in conjunction with the Chothia numbering
scheme: L1 spans light chain residue numbers 24–34, L2 spans 50–56, L3 spans 89–97, H1
spans heavy chain residue numbers 26–35, H2 spans 50–56, and H3 spans 95–102.
4.3.6 Alignment to germline
The germline of each antibody was determined by IMGT lookup46. Then, BLASTP (version
2.2.29+) with the BLOSUM50 scoring matrix was used to align the antibody variable region
heavy and light sequences to corresponding germline sequences (IGHV, IGKV, and IGLV
loci only, downloaded from IMGT). The number of mismatches according to BLAST were
considered as the number of amino acid mutations from germline. Supplementary Table 1
in the original publication47 details the PDB ID, CDR-H3 length, number of heavy chain
mutations, number of light chain mutations, heavy germline gene, and light germline gene
data for each structure in the dataset.
4.3.7 B-factor Z-score calculation
Temperature factors (B-factors) were extracted for all Cα atoms in the variable region of the
antibody heavy chain (VH, Chothia numbering 1–112). The arithmetic mean and sample
standard deviation values were calculated for the B-factors. For each Cα atom in the CDR-
H3 region, residue numbers spanning 95–102 under the Chothia numbering convention11,
the z-score was calculated as (x − µ)/σ, where x is the B-factor of the current Cα atom
and µ and σ are the mean and standard deviation of B-factors for all Cα atoms in the VH,
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respectively. PDB IDs 2NR6 and 3HAE were excluded from B-factor analysis because all
reported B-factors were identical and so the z-scores were zero by definition.
To test whether two observed B-factor distributions arose from the same underlying
distribution, I turned to randomization testing. First, I computed the difference of the
observed distribution means. Next, I pooled the data from the two distributions (e.g.
CDR-H3 loop B-factor z-scores) and randomly sampled the pooled data to create two
simulated distributions (e.g. randomly assigning z-scores to either the naïve or mature
category). Finally, I computed the simulated difference of the randomized distribution
means. This process was repeated 10,000 times, so that I could identify the fraction of
random distributions with differences greater than the observed. Since this process is
stochastic and does not exhaustively sample all permutations of the data, it was further
repeated 10 times to acquire a standard deviation.
4.3.8 Rosetta relaxation and ensemble generation
Antibody structural ensembles with 10 members were generated using either the Rosetta
FastRelax48 or Rosetta KIC protocol49, and Rosetta version 2017.26-dev59567 was used for
all simulations (corresponding to weekly release version 2017.26). The Rosetta FastRelax
protocol consists of five cycles of side-chain repacking and gradient-based energy minimiza-
tion in the REF2015 version of the Rosetta energy function50. Thus, FastRelax ensembles
explore the local energy minimum of the crystal structure. KIC ensembles are more diverse
and representative of RosettaAntibody homology models: each ensemble member was
generated by running the CDR-H3 refinement step of the RosettaAntibody protocol, con-
sisting of VH–VL docking, CDR-H3 loop remodeling, and all-CDR loop minimization37,38.
Sample command lines are given in the Supplementary Material. The structural ensembles
produced by both FastRelax and KIC were used for rigidity analysis. For technical reasons,
six targets could not be analyzed from the FastRelax ensemble, and 177 targets from the
KIC ensemble were omitted due to non-trivial incompatibilities between the input structure
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numbering and Rosetta’s internal antibody numbering scheme and a computing cluster
time limitation. The excluded targets were randomly distributed and likely would not affect
the conclusions.
4.3.9 Molecular dynamics simulations
The Fv regions were retrieved from the original PDB files. The MD simulations were
performed using the NAMD 2.12 package51 with the CHARMM36m force field and the
CMAP backbone energy correction52. The truncated Fv structures were solvated with TIP3P
water in a rectangular box such that the minimum distance to the edge of the box was 12 Å
under periodic boundary conditions. Na or Cl ions were added to neutralize the protein
charge, then further ions were added corresponding to a salt solution of concentration
0.14 M. The time step was set to 2 fs throughout the simulations. A cutoff distance of 10
Å for Coulomb and van der Waals interactions was used. Long-range electrostatics were
evaluated through the Particle Mesh Ewald method53.
The initial structures were energy-minimized by the conjugate gradient method (10,000
steps), and heated from 50K to 300K during 100 ps, and the simulations were continued by
1 ns with NVT ensemble, where protein atoms were initially held fixed whereas non-protein
atoms freely moved, gradually releasing the whole system to facilitate a stable simulation
over the 1 ns. Further simulations were performed with NPT ensemble at 300K for 200
ns without any restraints other than the SHAKE algorithm to constrain bonds involving
hydrogen atoms. The last 180 ns of each trajectory was used for the subsequent clustering
analyses. Similar to a previous work54, a total of 2000 evenly spaced frames from each
trajectory were clustered based on root-mean-square deviation (RMSD) of the Cα and Cβ
atoms using the K-means clustering algorithm implemented in the KCLUST module in
the MMTSB tool set55. The cluster radius was adjusted to maintain 20 clusters in each
trajectory. The structure closest to the center of each cluster was chosen as a representative
structure of each cluster. The 10 representative structures were chosen from the top 10
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largest clusters and these representative structures were energy-minimized by the conjugate
gradient method (10,000 steps) in a rectangular water box. The minimized antibody Fv
structures were used as the inputs for the rigidity analysis.
Root-mean-square quantities of the MD trajectories were calculated based on the last
180 ns trajectories. After superposing Cα atoms of the FR of the heavy chain (FRH) of each
snapshot onto Cα atoms of FRH of the reference structures (i.e. crystal structures), Cα-RMSD
of the CDR-H3 loop was calculated as the time average. Similarly, after superposing Cα
atoms of entire Fv domains of each snapshot onto those of the reference structures, the




where xi is the distance between the Cα atom of the snapshots at a given time and the Cα
atom of the ith residue of the reference structures56.
4.4 Results
4.4.1 Immunomic repertoire reveals no difference in flexibility between naïve
and mature CDR-H3 loops
I initially asked whether CDR-H3 loop rigidification, having been observed in many past
studies, was present in a large set of antibodies derived from human peripheral blood
cells. Previously, DeKosky and Lungu et al. used RosettaAntibody to model the structures
of 1,911 common antibodies found in the peripheral blood cells of two human donors36.
Paired VH–VL sequences were derived from either CD3−CD19+CD20+CD27− naïve B
cells or CD3−CD19+CD20+CD27+ antigen experienced B cells (mature) isolated from
peripheral mononuclear cells. RosettaAntibody structural models were created by identi-
fying homologous templates for the CDRs, VH–VL orientation, and FRs; assembling the
templates into one model; de novo modeling the CDR-H3 loop; rigid-body docking the
VH–VL interface; side-chain packing; and minimizing in the Rosetta energy function37.
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Since de novo modeling of long loops is challenging, DeKosky and Lungu et al. limited their
antibody set to the more tractable subset of antibodies with CDR-H3 loop lengths under 16
residues. They compared their models for seven human germline antibodies with solved
crystal structures and found models had under 1.4 Å backbone RMSD for the FR and under
2.4 Å backbone RMSD for the CDR-H3 loop.
I used the FIRST-PG method39,43 to estimate flexibility from the RosettaAntibody ho-
mology models, determining the number of backbone DOFs for the CDR-H3 loop as each
hydrogen bond is broken in order from weakest to strongest. FIRST models the antibody as
a molecular graph where nodes represent atoms and edges represent atomic interactions.
An extension of the PG algorithm uses this molecular graph to compute the DOFs of the
CDR-H3 loop. To mitigate the effects of homology modeling inaccuracies on the FIRST-PG
analysis, I used an ensemble of ten lowest-energy RosettaAntibody models. FIRST-PG anal-
ysis on structural ensembles has been shown to predict hydrogen–deuterium exchange and
protein flexibility40. To account for varying CDR-H3 loop lengths, I scaled the calculated
DOFs by a theoretical maximum value (Methods). Figure 4.1A shows a curve of the scaled
DOFs averaged over all naïve or mature antibodies as a function of the hydrogen-bonding
energy cutoff used in the FIRST-PG analysis. At a cutoff of 0 kcal/mol, all hydrogen bonds
are intact and the average CDR-H3 loop scaled DOFs are about 20% of the theoretical
maximum. Moving from right to left on the plot increases the minimum energy cutoff for
including interactions in the FIRST graph; effectively hydrogen bonds of increasing strength
are “broken” and the available DOFs rise from 20% to over 90% of the maximum theoretical
flexibility while the loop becomes unstructured (unfolded) in FIRST.
I compared the DOFs distributions for naïve and mature antibodies at every hydrogen-
bonding energy cutoff by two-sample Kolmogorov–Smirnov (KS) testing, with null hypoth-
esis being that the two distributions are identical (Figure 4.1A). There is no difference in the
average, scaled DOFs. To further quantify this comparison, I computed the average AUC
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Figure 4.1: CDR-H3 loop flexibility analysis of the immunomic antibody set reveals that no difference
in naïve (blue) and mature (red) antibodies. FIRST-PG was used to determine the degrees of freedoms
(DOFs) as a function of hydrogen-bonding energy cutoff in RosettaAntibody models of the 1,911
most frequent public antibodies. Results were split, depending on whether the antibody was naïve
or mature, as determined by B-cell surface receptors, and the mean DOFs were calculated along
with the SD, shown in a lighter shade of the respective color. Subplots, below each main plot, show
the p-value computed by a two-sample Kolmogorov–Smirnov (KS) test comparison of the naïve and
mature DOFs distributions for each hydrogen-bonding energy cutoff, with null hypothesis being that
the distributions are the same. A dashed line indicates a p-value of 0.05. (A) To permit comparison
across loops of multiple lengths, the DOFs were scaled to a theoretical maximum for each length (a
value of 1 indicates all DOFs are available, whereas a value of 0 indicates no DOFs are available). I
found the scaled DOFs to be similar for both naïve and mature antibodies, quantified by the KS test
p-values and area under the curve (AUC) ± SD: −5.21 ± 0.44 and −5.23 ± 0.44, respectively. (B) To
exclude length effects on flexibility calculations, I compared DOFs for the most popular length (12
residues). I found the naïve AUC ± SD at 158.15 ± 11.98 and mature AUC ± SD at −156.97 ± 11.56
to be similar. The distributions appear similar at cutoffs between 0 and −5.0 kcal/mol, according to
the KS test p-values.
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are identical for the naïve (−5.21 ± 0.44) and mature antibody repertoires (−5.23 ± 0.44).
This lack of difference persists (AUC −158.15 ± 11.98 [naïe] vs. −156.97 ± 11.56 [mature])
when accounting for CDR-H3 loop length, by comparing loops of only length 12, the most
popular length (Figure 4.1B), and so the observed similarity of DOFs in naïve and mature
antibodies is not due to averaging over loops of different lengths. Thus, on the immunomic
repertoire scale, I do not observe the difference in flexibility between naïve and mature
antibodies predicted by the paratope rigidification hypothesis.
Before amending the rigidification hypothesis in light of these results, I considered
several alternative explanations for my observations. First, I addressed whether the use
of homology models for flexibility analysis introduced inaccuracies by analyzing a large
set of antibody crystal structures and Rosetta-generated models from that set with varying
quality, ranging from models with sub-angstrom backbone RSMD to models that may be
several angstroms off (and more representative of an average homology model). Next, I
addressed whether backbone DOFs, as calculated by FIRST-PG, were a good measure of
flexibility, by assessing flexibility through two alternative measures: B-factors and MD
simulations. Additionally, I addressed whether averaging flexibilities and comparing
across many germlines affected results, by detailed flexibility analysis of previously studied
naïve–mature antibody pairs and RosettaAntibody-modeled pairs.
4.4.2 Only small flexibility differences are observed between naïve and mature
antibodies in the crystallographic set
4.4.2.1 Preparation of an antibody crystal structure dataset
Of course, the strongest critique of the immunomic antibody set is that these models are
only approximating the actual antibody structure. Thus, I applied FIRST-PG analysis to
a large set of antibody crystal structures. I curated the set of all non-redundant mouse
and human antibody crystal structures from SAbDab45. To be consistent with the models
produced by RosettaAntibody, I truncated the structure of each antibody to only the Fv
domain, excluding other antibody regions or antigen. Then, I used IMGT/3Dstructure-DB46
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to identify the variable domain genes and determined the number of somatic mutations by
aligning the sequence derived from the crystal structure to the IMGT-determined V-gene.
I defined mature antibodies as those possessing at least one somatic mutation in either
V-gene. The full dataset has 922 antibodies of which 23 are naïve.
4.4.2.2 FIRST-PG analysis of crystal structures
From the crystal structures, I created two sets of structural ensembles and assessed flexi-
bility by FIRST-PG. Flexibility analysis has previously been shown to be more accurate on
ensembles in comparison to analysis using single (snapshot) conformers40,57. Ensembles
of ten representative structures were generated from the initial crystal structure by using
either Rosetta FastRelax48 or the refinement step of RosettaAntibody37,38, which I term
KIC ensembles after the loop modeling algorithm used in refinement49. Rosetta FastRelax
samples structures around the crystallographic, local energy-minimum, with typically <
1 Å backbone RMSD, whereas the refinement step of RosettaAntibody samples a more
diverse set of low-energy CDR-H3 loop conformations and VH–VL orientations. Thus,
FastRelax ensembles are representative of the crystal structures, whereas KIC ensembles
are representative of RosettAntibody homology models. By comparative FIRST-PG analysis
of the two sets, I can assess the effects of modeling inaccuracies on flexibility analysis.
The scaled DOFs as calculated by FIRST-PG for FastRelax ensembles of antibody crystal
structures are shown in Figure 4.2A. There are only minor differences between the naïve and
mature flexibility curves, two-sample KS testing reveals insignificant p-values (≫ 0.05) for
all hydrogen-bonding energy cutoffs, and the AUC is similar for both sets (4.70± 0.46 [naïve]
vs. 4.70 ± 0.48 [mature]). Again, I considered the possibility that different distributions
of loop lengths in the two sets obscures the affinity maturation contributions to flexibility.
Therefore, I analyzed loops of length 10 (Figure 4.2B), the single most common length in the
crystallographic set. When loops of a single length were compared, there was a separation
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Figure 4.2: When accounting for length, CDR-H3 loop flexibility analysis of the crystallographic
antibody set reveals naïve (blue) antibodies to be slightly more flexible than mature (red). FIRST-
PG was used to determine the DOFs as a function of hydrogen-bonding energy cutoffs in crystal
structure ensembles created by Rosetta FastRelax. Results were split, depending on whether the
antibody was naïve or mature, as determined by BLAST alignment to its germline V-genes, and
the mean DOFs were calculated along with the standard deviation, shown in a lighter shade of
the respective color. Subplots, below each main plot, show the p-value computed by a KS-test
comparison of the naïve and mature DOF distributions for each hydrogen-bonding energy cutoff,
with null hypothesis being that the distributions are the same. A dashed line indicates a p-value
of 0.05. (A) To permit comparison across loops of multiple lengths, the DOFs were scaled to a
theoretical maximum for each length (a value of one indicates all DOFs are available whereas a
value of zero indicates not DOFs are available). I found the scaled DOFs to be similar for both
naïve and mature antibodies, quantified by KS-test p-values and the AUCs ± SD: −4.70 ± 0.46
and −4.70 ± 0.48, respectively. (B) To exclude length effects on flexibility calculations, I compared
DOFs for the most popular length (10 residues). I found the naïve AUC ± SD at −128.82 ± 8.99
was greater than the mature AUC ± SD at −121.85 ± 10.09, but still within a standard deviation.
The distributions appear similar at cutoffs between 0 and −6.0 kcal/mol, according to the KS-test
p-values.
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consistently greater than the mature set, but not significantly so, except for some energy
cutoffs below −5 kcal/mol, according to KS testing. As expected, the AUC values differ, but
are within a standard deviation (128.2 ± 9.0 [naïve] vs. 121.9 ± 10.1 [mature]). I repeated
FIRST-PG analysis for KIC ensembles of antibody crystal structures and observed similar
results (Supplementary Figure 4.A.1): for scaled DOFs, the AUC was 5.91 ± 0.20 (naïve) vs.
−5.81 ± 0.26 (mature) and, for loops of length 10 only, the AUC was −154.10 ± 4.80 (naïve)
vs. −150.44 ± 7.73 (mature). Thus, there does not appear to be a large, consistent CDR-H3
loop flexibility difference across all antibody crystal structures analyzed.
4.4.2.3 B-factor analysis of crystal structures
However, I have not accounted for the possibility that backbone DOFs as calculated by
FIRST-PG may not capture the effects of affinity maturation on CDR-H3 loop flexibility.
Thus, I assessed loop flexibility as determined by atomic temperature factors or B-factors.
In protein crystal structures, B-factors measure the heterogeneity of atoms in the crystal
lattice. Thus, rigid regions have lower B-factors as they are more homogeneous throughout
the crystal whereas flexible regions have higher B-factors as they are less homogeneous
throughout the crystal. B-factors are also affected by crystal resolution, so I cannot compare
raw values across structures of varying resolution. Instead, I computed a normalized
B-factor z-score, which has zero mean and unit standard deviation for each antibody chain.
Finally, to account for different CDR-H3 loop lengths, I averaged the B-factor z-scores for
the CDR-H3 loop residues.
Figure 4.3A shows the distributions of B-factor z-scores averaged over the CDR-H3
loop residues of naïve and mature antibodies. Both distributions span a similar range
and overlap significantly, with the naïve curve peak shifted toward higher values than the
mature. The majority of the naïve CDR-H3 loop B-factor z-score averages were positive
(65%), whereas the majority of the mature CDR-H3 loop B-factor z-score averages were
negative (64%). To address the question whether these distributions arose from the same
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Figure 4.3: Comparison of the distribution of average CDR-H3 loop B-factor Z-scores in antibody
crystal structures suggests that naïve are more flexible than mature. (A) Distributions of average
CDR-H3 loop B-factors for the crystallographic set of antibodies are distinct for the mature (orange)
and naïve (blue) sets. The mature antibody CDR-H3 loops have lower B-factors than the naïve,
corresponding to more rigidity. Bars show binned counts in intervals of 0.25. Both the bars and
smoothed densities are normalized so the maximum value is 1. A two-sample KS test confirms
different underlying distributions with a p-value of 0.006 and maximum vertical deviation, D, of
0.36. (B) The observed difference in distribution means is difficult to replicate by random chance,
occurring only 6.6 ± 2.6 times out of 10,000 simulations. Compare the observed difference in means
(red line, dashed) to simulated differences (white bars) acquired by randomly assigning B-factor
values from the original distributions to either a naïve or mature set, in the observed numbers
(Nmature = 897 and Nnaive = 23), before computing the difference in means.
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Figure 4.4: When considering only antigen-free crystal structures (to control for rigidification upon
antigen biding), the difference between naïve and mature average CDR-H3 loop B-factor z-score
distributions is small. (A) The distributions of CDR-H3 loop average B-factors are less distinct
between the mature (orange) and naïve (blue) sets. Bars show binned counts in intervals of 0.25.
Both the bars and smoothed densities are normalized so the maximum value is 1. A two-sample KS
test results in a p-value of 0.15 and D of 0.27, indicating that the null hypothesis of indistinguishable
underlying distributions cannot be discarded. (B) The observed difference in distribution means
(red line, dashed) is occasionally replicated in random resampling (white bars). When average
CDR-H3 loop B-factor z-scores are pooled and randomly assigned to either a naïve or mature set, in
the observed numbers (Nmature = 355 and Nnaive = 18), the observed difference in means is matched
or surpassed in 340 ± 20 out of 10,000 simulated differences.
underlying distribution I turned to randomization testing, as described in the Methods.
The observed difference in distribution means is matched by only 0.066 ± 0.026% of
simulated differences (Figure 4.3B), indicating that naïve and mature distributions are likely
distinct. Furthermore, a two-sample KS test confirms the distributions to be distinct, with a
maximum vertical deviation, D, of 0.36 and a p-value of 0.006.
However, I was concerned that the mixing of bound and unbound crystal structures
would influence results, as I previously observed bound structures to have lower average
B-factors58. Furthermore, in the PDB-derived dataset, naïve antibodies were mostly crystal-
lized in the unbound state (19 of 23), whereas mature antibodies were mostly co-crystallized
with their cognate antigen (544 of 899). In conjunction, these two observations suggested
that the high number of antigen-bound mature antibody crystal structures was the primary
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Figure 4.5: Antigen-bound and antigen-free distributions of B-factor z-scores are distinct. (A) Distri-
butions of CDR-H3 loop average B-factors for the crystallographic set of antibodies are distinct for
the antigen-bound (red) and antigen-free (purple) sets. Bound antibody CDR-H3 loops have lower
B-factors than unbound, corresponding to more rigidity. Bars show binned counts in intervals of
0.25. Both the bars and smoothed densities are normalized so the maximum value is 1. Distributions
appear distinct according to a two-sample KS test with a p-value of 2.2E-16 and D of 0.31. (B) The
observed difference in distribution means (red line, dashed) is never replicated in 10,000 attempts
at random resampling (white bars). Simulated differences were acquired by randomly assigning
values from both sets to either a naïve or mature set, in the observed numbers (Nbound = 546 and
Nnaive = 374), before computing the difference means.
driver of the difference between naïve and mature B-factor z-scores. Thus, I compared the
B-factor averages of unbound structures only and found that while the distributions appear
to be distinct (Figure 4.4A), when the difference in distribution means is compared to a
randomized set, 3.4 ± 0.2% of random differences are greater than or equal to the observed
differences, and the distributions fail a two-sample KS test (D = 0.27, p = 0.15). Thus,
the difference between naïve and mature antigen-free crystal structures does not appear
significant.
As I conjectured, a significant difference was found between the bound and unbound
distributions (Figure 4.5), with a two-sample KS test confirming the difference between
the distributions (D = 0.31, p < 2.16E − 16) and randomized testing never showing a
difference in means as large as the observed difference. Additionally, I considered other
possible origins of difference between the naïve and mature distributions that are not related
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to affinity maturation, including comparison across species, crystal structure resolutions,
CDR-H3 loop lengths, and if the CDR-H3 loop was at a crystal contact or not. I found none
of these to have as clear of an effect on the distribution of B-factor averages as whether
or not antigen was bound (Supplementary Figures 4.A.2 and 4.A.3). In summary, the
distributions of B-factor z-score averages (Figures 4.3, 4.4, 4.5) suggest that both the naïve
and mature antibody sets possess CDR-H3 loops of varying flexibility and that neither set
is significantly more flexible or rigid than the other.
4.4.3 Comparison of mature to naïve-reverted models reveals varying rigidifi-
cation across matched pairs
Having not observed consistent rigidification of the CDR-H3 loop in two large sets of
antibodies, I postulated that rigidification was not a repertoire-wide phenomenon (i.e. all
mature antibodies are not more rigid than all naïve antibodies), but it could still be plausible
that matched pairs of naïve and mature antibodies would reveal rigidification.
To investigate this hypothesis, I selected ten mature antibodies from the SAbDab set
with CDR-H3 loops of length 10, a length for which loop modeling performs well49,59. I
identified antibodies that had at least 5 ( 97% sequence identity), but no more than 25
( 85% sequence identity), mutations when compared to the germline V-genes. To control
for species, half of the selected antibodies were human and half were mouse. I reverted
the mature antibody sequences to naïve using the germline sequences from the aligned
V-genes, as described in the methods, and using germline J-genes from sequence alignments
from IMGT/DomainGapAlign46. The reverted sequences are reported in the Supplemental
Material. I then used RosettaAntibody to generate homology models for the naïve-reverted
sequences. I analyzed the ensembles of the ten lowest-energy homology models using FIRST-
PG. To ensure fair comparison, I also used FIRST-PG to analyze homology model ensembles
of the mature sequences. To provide an estimate for the accuracy of RosettaAntibody
homology models, I computed RMSDs for the mature models using the known crystal
structures and found all had sub-2-Å CDR-H3 loop backbone RMSD, calculated after
80
1RZ7 1BLN 1A4J 1IGF 1RUR










































−6 −4 −2 0 −6 −4 −2 0 −6 −4 −2 0 −6 −4 −2 0 −6 −4 −2 0
−6 −4 −2 0 −6 −4 −2 0 −6 −4 −2 0 −6 −4 −2 0 −6 −4 −2 0
Hydrogen-Bonding Energy Cutoff (kcal/mol)
−11.94±16.34 −7.33±11.56 3.06±10.48−3.21±14.92 −0.36±9.23
4.14±13.35 6.87±11.13 11.39±9.47 11.98±8.97 12.60±12.29
Figure 4.6: FIRST-PG analysis of ten RosettaAntibody-modeled mature/naïve-reverted antibody
pairs (CDR-H3 loop length of 10 residues) shows that affinity maturation does not always result
in CDR-H3 loop rigidification. Naïve values are colored blue, while mature values are color red.
The difference between mature and naïve AUCs is reported in the bottom left of each sub-figure,
with a positive value indicate a more flexible naïve antibody. Four out of the ten cases have mature
antibodies with AUC greater than their naïve counterparts. Subplots, below each main plot, show
the p-value computed by a KS-test comparison of the naïve and mature DOF distributions for each
hydrogen-bonding energy cutoff, with null hypothesis being that the distributions are the same and
a dashed line indicating a p-value of 0.05.
alignment of the heavy chain FR, with 7 of 10 antibodies having sub-Å RMSD.
Of the ten naïve/mature antibody pairs I analyzed, six showed a decrease in flexibility
and four showed an increase in flexibility upon affinity maturation (Figure 4.6). These ten
antibodies demonstrate the breadth of possible affinity maturation effects, from an expected
flexibility decrease in antibody 2AGJ, with AUC decreasing by 9.34%, to the unexpected
flexibility increase in antibody 1RZ7, with AUC increasing by 10.65%.
4.4.4 Analysis of 48G7 antibody
Having analyzed 1911 models, 922 crystal structures, and 10 paired-reverted models, I had
yet to observe a consistent difference in CDR-H3 loop flexibility between naïve and mature
antibodies, as previously reported in literature. Thus, I turned to three previously-studied
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antibodies with known crystal structures and measured CDR-H3 loop flexibility. These are
(1) the esterolytic antibody 48G715,31,32,34, (2) the anti-fluorescein antibody 4-4-2022,25–27,30,32,
and (3) a broadly neutralizing influenza virus antibody21. For all three antibodies, the
effects of affinity maturation on CDR-H3 loop flexibility have been previously studied
by both experiment and simulation, allowing comparison with my results. For brevity, I
presently discuss the 48G7 antibody here, and full results for all antibodies are available in
the Supplementary Material.
The 48G7 antibody was first studied through crystallography, with structures capturing
the bound (holo) and unbound (apo) states of both the naïve and mature antibody15.
Comparison between the naïve and mature CDR loop motions from the free to the bound
state revealed minor changes, with the mature CDR-H3 loop being slightly more rigid and
moving an Ångström less than the naïve upon antigen binding (Supplementary Figures
4.A.4). For each of the four crystal structures, I extracted B-factors and computed B-factor
z-scores for the CDR-H3 loop, measuring the distance from the B-factor mean in standard
deviations. B-factor z-scores for the CDR-H3 loop of apo-48G7 are shown in Figure 4.7A.
The mature antibody has lower B-factors than the naïve antibody throughout the entire
CDR-H3 loop. This observation also holds for the holo-48G7 antibody structures as well
(Supplementary Figure 4.A.5). Supplementary Table 4.A.1 summarizes B-factors averaged
over the whole CDR-H3 loop. These B-factor results agree with the prior crystallographic
observations.
Follow-up studies on 48G7 used MD simulations to assess flexibility. Briefly, 500
ps short MD simulations of the naïve and mature antibodies in the presence of antigen
with an explicit solvent model (TIP3P) found the CDR-H3 loop to be more flexible in the
naïve than in the mature antibody by comparison of RMSFs29, but 15 ns MD simulations
of the naïve and mature antibodies in the absence of antigen with an implicit solvent
model (GB/SA) found no difference between the two, again by comparison of RMSFs31.
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Figure 4.7: Analysis of catalytic antibody 48G7 by CDR-H3 loop B-factors and RMSFs shows
conflicting results. (A) Comparison of normalized B-factor values for the CDR-H3 loop of the 48G7
antibody in crystal structures of the unbound naïve (dark blue) and mature (dark orange) antibodies
reveals a more rigidity in the mature antibody. The dashed line indicates the average value and is
outlined by a box defined by the average plus-or-minus the standard deviation. (B) Comparison of
CDR-H3 loop RMSFs for the MD simulations of the naïve and mature 48G7 antibodies shows the
opposite.
antigen, the fluctuations of the naïve and mature 48G7 were similar, but their binding
mechanisms could differ depending on response to antigen binding; the naïve antibody
shows a discrete conformational change induced by antigen whereas the mature antibody
shows lock-and-key binding60. Due to the contentious nature of these results, 200 ns MD
simulations were run for the 48G7 naïve and mature antibodies in the absence of antigen
with an explicit solvent model (TIP3P). I measured both RMSDs and RMSFs for the CÎś
atoms along the CDR-H3 loop and computed the difference between the naïve and mature
antibodies (Supplementary Table 4.A.1). Figure 4.7B shows that the CDR-H3 loop RMSFs
are consistently greater for the mature than the naïve 48G7 antibody.
Finally, as I have done through this study, I used FIRST-PG to measure CDR-H3 loop
flexibility. To limit the effects of crystal structure artifacts on FIRST-PG analysis, I used
an ensemble of ten representative structures, derived by clustering trajectory frames and
selecting ten structurally distinct cluster medians from the MD simulations, similar to a
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previous flexibility study for this antibody32. The CDR-H3 loop flexibility of apo-48G7, as
determined by FIRST-PG analysis of MD ensembles is shown in Figure 4.8. The FIRST-PG
analysis showed no significant difference between the mature and naïve antibodies.
In addition to using MD simulations to generate ensembles, I used ensembles generated
by RosettaAntibody and Rosetta FastRelax, permitting direct comparison. The CDR-H3
loop flexibility of apo-48G7, determined by FIRST-PG analysis of FastRelax and RosettaAn-
tibody ensembles, is shown in Figure 8. The curves from FastRelax and the MD simulation
are similar for low-energy cutoffs (e.g. in the range of 0.0 to −3.0 kcal/mol), with the naïve
and mature DOFs being the same. These curves diverge at higher-energy cutoffs where
the FastRelax curve shows a more flexible naïve antibody and the MD curve does not. The
curve from RosettaAntibody ensembles differs from the two and shows a more flexible
mature antibody at low-energy cutoffs and a more flexible naïve at high-energy cutoffs. For
less visual and more quantitative comparisons, I computed the AUC of the DOF versus
hydrogen-bonding energy cutoff plots (Supplementary Table 4.A.1). I find the AUC is only
slightly greater for naïve than mature antibodies in the FastRelax and RosettaAntibody
ensembles, with the naïve AUC reducing by only 3.9% and 0.2%, respectively, upon matu-
ration. MD ensembles show the opposite outcome, with the mature antibody having 1.3%
greater AUC than the naïve.
Further validation was carried out on two other previously studied antibodies and
reported in the Supplementary Table 4.A.1 and Supplementary Figures 4.A.5 and 4.A.6.
For the 4-4-20 antibody, antigen-bound structures were compared and the average mature
B-factors were within a standard deviation of the naïve. For the influenza antibody, average
B-factors were compared between an unbound naïve and a bound mature crystal structure,
showing significant rigidification. However, results are conflated due to the lack of unbound
crystal structures, as in bound structures antibody–antigen contacts artificially increase
rigidity of the CDR-H3 loop. In contrast to B-factor analyses, FIRST-PG analyses yielded










































Figure 4.8: FIRST-PG analysis of naïve (dark blue) and mature (dark orange) 48G7 antibodies using
either Rosetta FastRelax-, RosettaAntibody-, or MD-generated 10-member ensembles does not show
a difference between the naïve and mature antibodies. FIRST-PG analysis calculates the DOFs of
CDR-H3 loop as a function of hydrogen-bonding energy cutoff. Subplots, below each main plot,
show the p-value computed by a KS-test comparison of the naïve and mature DOF distributions
for each hydrogen-bonding energy cutoff, with null hypothesis being that the distributions are
the same and a dashed line indicating a p-value of 0.05. While the FastRelax ensembles appear
distinct in the range of −6 to −3 kcal/mol, the naïve and mature are indistinguishable for both the
RosettaAntibody and MD ensembles.
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flexible upon maturation by FIRST-PG analysis of all but Rosetta KIC ensembles. The
influenza antibody was found to become more rigid upon mature by FIRST-PG analysis
of all but Rosetta FastRelax ensembles. Finally, I analyzed RMSDs and RMSFs from MD
simulations and found that the mature 4-4-20 antibody has higher CDR-H3 loop RMSD, but
lower RMSF, values than the naïve while the mature influenza antibody was found to have
lower values for both (Supplementary Table 4.A.1). As with the repertoire analysis, I do not
see consistent rigidification in previously studied antibodies. I consider the significance of
this result and compare my analysis in detail to past analyses of flexibility in the Discussion
section.
4.5 Discussion
4.5.1 The varying effects of affinity maturation on CDR-H3 flexibility
Affinity maturation, through a series of somatic hypermutation events and selection pro-
cesses, can evolve a low-affinity, naïve antibody to bind an antigen with both high affinity
and specificity. Elucidating the affinity maturation process is desirable to understand molec-
ular evolution, develop antibody engineering methods, and guide vaccine development61.
Past studies have suggested that, with few exceptions28, naïve antibodies are highly flexible
and maturation leads to improved affinity and specificity through the optimization and
rigidification of the antibody paratope, and in particular the CDR-H3 loop21,26,30–32. How-
ever, these studies have been limited, often focusing on a single antibody and assessing flex-
ibility indirectly. I sought to test the generalizability of the rigidification-upon-maturation
hypothesis. I was enabled by the large number of antibody structures in the PDB, homology
models generated from high-throughput repertoire sequencing data, and the FIRST-PG
method for rapid structural flexibility calculation to ask whether affinity maturation leads
to CDR-H3 loop rigidification.
Unexpectedly, in a comparison of flexibility of repertoires, the data show little difference
between naïve and mature antibodies: FIRST-PG calculations showed no difference for
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RosettaAntibody homology model ensembles of the most common naïve and mature
antibodies in human peripheral blood cells. The same calculations showed no difference in
CDR-H3 loop DOFs of crystal structures under two different refinement schemes (FastRelax
and KIC). After accounting for the presence/absence of antigen, CDR-H3 loop B-factor
distributions were similar for both mature and naïve antibody crystal structures. These
results indicate that rigidification of the CDR-H3 loop does not always occur upon affinity
maturation.
Since these observations did not indicate clear rigidification over two sets of antibodies,
I considered the following possibilities: (1) comparison of different length CDR-H3 loops
was unfair because longer loops are inherently more flexible, (2) comparison of different
antibodies was unfair because different combinations of gene segments and VH–VL pairs
will result in different flexibilities, (3) mutations within CDR-H3 loop, which I could
not identify for the PDB set because of the difficulty in D/J-gene alignments, may have
modulated flexibilities of CDR-H3, (4) inaccuracies in the computational methods could
preclude observation of rigidification, and (5) FIRST-PG-measured backbone DOFs are not
a good measure of flexibility. To address the first concern, I analyzed loops of consistent
length via B-factor and FIRST-PG (Figures 4.1B & 4.2B, Supplementary Figures 4.A.1 &
4.A.2). I found that, according to KS testing and when accounting for the presence/absence
of antigen, B-factor distributions were not distinct for naïve and mature sets of antibodies
with same length CDR-H3 loops (length 10 for the crystallographic set and 12 for the
repertoire model set). I also found that FIRST-PG DOFs AUC values of the naïve and
mature sets of antibodies with the same length CDR-H3 loops were within a standard
deviation for RosettaAntibody, FastRelax, and KIC ensembles. So, even when accounting
for length, mature antibodies are not significantly more rigid than naïve ones.
To address the concern that comparison of sets of antibodies originating from different
VH and VL genes is unfair, I analyzed mature/naïve antibody pairs that had been pre-
viously studied and mature/naïve-reverted pairs that I generated with RosettaAntibody
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and analyzed by FIRST-PG (Figures 4.6, 4.7, 4.8, Supplementary Table 4.A.1). I found that
CDR-H3 loop B-factors did not always indicate rigidification upon maturation and for the
7G12 antibody I observed the reverse effect (Supplementary Figure 4.A.7). I also found that
mature antibodies did not always become more flexible upon naïve reversion, but instead
displayed a breadth of behaviors (Figure 4.6). So, when analyzing matched naïve/mature
pairs, I do not see consistent rigidification upon maturation.
My analysis of previously studied naïve/mature antibody pairs coupled with the earlier
repertoire analysis should alleviate concerns that the flexibility results for the PDB set were
strongly affected by the inability to align D/J-gene segments and thus consider mutations
in the CDR-H3 loop. The previously studied pairs included CDR-H3 mutations and the
repertoire set had antibody sequences determined by Illumina MiSeq sequencing with
naïve/mature status assigned by the absence/presence of the CD27 cell-surface receptor. In
both cases, the naïve and mature sequences were determined through the entire Fv, and
flexibility analysis still revealed mixed results.
Finally, to address the concern that RosettaAntibody models may not be accurate enough
to be useful for FIRST-PG calculations, I tested FIRST-PG on a range of structural ensembles
with varying deviation from the crystal structure. I found no difference in the naïve vs.
mature antibody CDR-H3 loop AUC of the FIRST-PG results, regardless of the ensemble
generation method used (compare Figure 4.2 and Supplementary Figure 4.A.1). I also
determined flexibility through alternative measures such as crystal structure B-factors and
RMSFs in MD simulations. For both, affinity maturation was not found to have a consistent,
rigidifying effect. Thus, even if model inaccuracies confound analysis, other data support
the same hypothesis.
4.5.2 Comparison with prior results
My analysis included several antibodies that have been the subject of previous flexibil-
ity studies, permitting a direct comparison. One of the most studied antibodies is the
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anti-fluorescein antibody, 4-4-20. Spectroscopic experiments measuring the response of
a fluorescent probe (fluorescein) and MD simulations measuring CÎś atom fluctuations
suggested that somatic mutations restrict conformational fluctuations in the mature anti-
body25,27,30. My analysis of 4-4-20 was not as clear: I observed no significant difference in
naïve vs. mature CDR-H3 loop crystallographic B-factors (Supplementary Figure 4.A.5)
and found the mature antibody to be more rigid in FIRST-PG calculations only in the
−2.0 −−0.0 kcal/mol range of hydrogen-bonding energy cutoffs (Supplemental Figure
4.A.6). Similar mixed results were observed by Li et al.32 who used a Distance Constraint
Model (DCM) to analyze flexibility in an ensemble of 4-4-20 conformations drawn from MD
simulations. They found increases in structural rigidity of the CDR-H3 loop, as determined
by the DCM, occurred upon affinity maturation, but these increases did not correspond
to decreases in dynamic conformational fluctuations, as determined by RMSFs from MD
simulations. Further studies artificially matured 4-4-20 by directed evolution, resulting
in a femtomolar-affinity antibody, 4M5.362, but the crystal structures of 4M5.3 and 4-4-
20 were almost identical (the reported backbone RMSD is 0.60 Å) and thermodynamic
measurements suggested that the affinity improvement was achieved primarily through
the enthalpic interactions with subtle conformational changes63. This observation was
contradicted by Fukunishi et al.64, who performed steered MD simulations to analyze the
effects of the mutations on the flexibility of 4-4-20 and 4M5.3. By applying external pulling
forces between the antibodies and the antigen along a reaction coordinate, they quantified
the interactions and showed that, during the simulations, fluctuations of the antibody,
especially the CDR-H3 loop, and of the antigen were indeed larger in 4-4-20 than in the
more matured antibody, 4M5.364. Thus, there is some variation not only in these results,
but also in the literature as to the effects of affinity maturation on 4-4-20.
Another set of well-studied antibodies are the four catalytic antibodies: 48G7, 7G12,
28B4, and AZ-28. In fact, the first crystallography studies to suggest rigidification of the
CDR-H3 loop as a consequence of affinity maturation were performed on 48G7. Wedemayer
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et al. observed larger structural rearrangements upon antigen binding in the CDR-H3
loop for the naïve antibody than the mature antibody (Supplementary Figure 4.A.4)15.
Crystallization of the naïve unbound, naïve bound, mature unbound, and mature bound
states for 7G12, 28B4, and AZ-28 revealed similar results17,18. Additionally, MD simulations
of the four catalytic antibodies in implicit solvent were used to calculate CDR Cα atom
B-factors31. Wong et al. showed a decrease in mature CDR-H3 loop B-factors in three cases
(7G12, 28B4, and AZ-28) whereas no significant difference was observed for 48G7 (see
Figure 2 in Wong et al.). Furthermore, for 48G7, Li et al. used MD simulation to generate
structural ensembles and DCM analysis to determine flexibility. They found that the mature
CDR-H3 loop is more rigid than the naïve, according to DCM, but used an unusual loop
definition that included five additional flanking residues (see Fig. 1 in Li et al.), making
comparison challenging (longer loops will be inherently more flexible), and they observed
increases in the mature CDR-H3 loop RMSFs (see Fig. 8 in Li et al.)32. My analysis of
CDR-H3 loop B-factors showed rigidification upon maturation for some of the 48G7 and
28B4 crystal structures (Figure 4.7 and Supplemental Figure 4.A.7), but not for 7G12 and
AZ-28 structures (Supplemental Figures 4.A.7 & 4.A.8). FIRST-PG analysis of FastRelax,
RosettaAntibody, and MD ensembles for 48G7 showed slight to no rigidification (Figure
4.8). Additionally, RMSFs from MD simulations for 48G7 showed higher values for the
mature loop, contrary to the expectation that it is more rigid. My mixed results for the
effects of affinity maturation on 48G7 are consistent with literature, but there is variation
between my results and the literature as to the effects of affinity maturation on the other
catalytic antibodies.
Finally, Schmidt et al. used X-ray crystallography, MD simulations, and thermodynamics
measurements to investigate how somatic mutations affected the binding mechanism of
anti-influenza antibodies21. They identified three mature antibodies, their unmutated com-
mon ancestor (UCA), and a common intermediate, all derived from a subject immunized
with an influenza vaccine. The affinities of the mature antibodies were about 200-fold better
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than the UCA. MD simulations of the UCA and the mature antibodies showed that CDR-H3
loop of the UCA could sample more diverse conformations than the mature antibodies,
whose CDR-H3 loop sampled only conformations optimal for antigen binding, supporting
the hypothesis that somatic mutations rigidify antibody structures. In another study by the
same group65, further MD simulations were performed on the same systems, showing that,
although many somatic mutations typically accumulate in broadly neutralizing antibod-
ies during maturation, only a handful of mutations substantially stabilize CDR-H3 loop
and hence enhance the affinity of the antibodies for antigen. In my study, all the results
(Supplemental Figures 4.A.5 and 4.A.6, Supplemental Table 4.A.1) for the anti-influenza
antibody, except FIRST-PG flexibility calculations for the Rosetta FastRelax ensemble, show
rigidification of the CDR-H3 loop as an effect of affinity maturation and agree with the
detailed analysis of Schmidt et al.
For the three antibody families I analyzed in detail, I observed mixed effects of affinity
maturation on two (catalytic antibodies and 4-4-20) and clear rigidification in one (anti-
influenza antibody). For the two with mixed results, I note that past work has also shown
conflicting results. I interpret these results as supportive of my repertoire-wide analysis
that affinity maturation does not always rigidify the CDR-H3 loop.
4.5.3 Biophysical properties underlying antibody binding
Why is antibody CDR-H3 loop rigidification not a consistent result of affinity maturation?
Consider the process of affinity maturation, which selects for antibody–antigen binding and
against interactions with self or damaged antibodies (i.e. when deleterious mutations are
introduced by activation-induced cytidine deaminase)66. Under these selection pressures,
what is the benefit of CDR-H3 loop rigidification? Loop rigidification can only decrease the
protein-entropy cost for antibody–antigen binding, having ostensibly no effect on enthalpy
and solvent entropy of binding, and self-interactions. If CDR-H3 loop rigidification is just
one of many biophysical mechanisms that can be selected for during affinity maturation,
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then I do not expect to observe it consistently, in line with my results.
What are the other possible mechanisms then? Collectively, studies have shown that
improved antibody affinity and specificity for antigen can be achieved by introducing
additional interfacial interactions including hydrogen bonds, salt bridges, and van der Waals
contacts15,67–69; increasing the buried surface area, either polar or apolar, depending on the
antigen19; and improving interface shape complementarity58, in addition to rigidification of
the paratope21. A detailed review on the structural basis of antibody affinity maturation
was recently published by Mishra and Mariuzza70.
An interesting example of the consequences of the biological antibody selection process
is the anti-hapten antibody, SPE771. For SPE7, mutations leading to multi-specificity or
promiscuity were beneficial–antibodies are multivalent, so an antibody capable of bind-
ing multiple antigens with intermediate affinity can gain an effective advantage through
cooperative binding over an antibody capable of binding only one antigen. Crystal struc-
tures of SPE7 with different antigens and in its apo-state demonstrated that SPE7 can
assume different conformations. Motivated by these observations, Wang et al. exploited
MD simulations to investigate the binding mechanisms of SPE772. The MD simulations
and subsequent analyses suggested that multi-specific antigen binding is mediated by a
combined mechanism of conformer selection and induced fit. Similar behavior, where the
mature antibody is more flexible than the naïve has been observed for an antibody that
recognizes the tumor-associated ganglioside GD273. Such antibodies could not have arisen
if CDR-H3 loop rigidification were a consistent result of affinity maturation.
4.6 Conclusions
I have conducted the largest-scale flexibility study of antibody CDR-H3 loops, analyzing
9,22 crystal structures and 1,911 homology models. I used B-factors and FIRST-PG to
assess flexibility. I sought to identify the effects of affinity maturation on CDR-H3 loop
flexibility, expecting the CDR-H3 loop to rigidify. I found that there were no differences in
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the CDR-H3 loop B-factor distributions or FIRST-PG DOFs for naïve vs. mature antibody
crystal structures and in the CDR-H3 FIRST-PG DOFs for homology models of repertoires
of naïve and mature antibodies. These findings suggest that there is no general difference
between naïve and mature antibody CDR-H3 loop flexibility in repertoires of naïve and
mature antibodies. However, I observed rigidification of the CDR-H3 loop for some, but
not all, antibodies when the mature antibodies were compared directly to their germline
predecessors. Thus, I conclude that increased rigidity occurs alongside other affinity-
increasing changes, such as improved interfacial interactions, increased buried surface area,
and improved shape complementarity.
Further work must be done to address the issues observed here, i.e. inconsistent results
across the different methods used to measure flexibility. One possible route is to explore
experimental methods that directly measure protein dynamics across several timescales,
and use them to study a relatively large (more than one or two antibodies) and diverse (e.g.
from different source organisms or capable of binding different antigens) set of antibodies.
For example, HDX-MS is capable of identifying protein regions with dynamics on timescales
from milliseconds to days, has been previously used to study antibody dynamics, and has
been correlated to FIRST-PG28,40.
Finally, I note the need for more rapid and accurate antibody modeling methods. With
the advent of high-throughput sequencing, there now exits a plethora of antibody sequence
data, but little structural data. Accurate modeling can overcome the lack of high-throughput
structure determination method and provide crucial structural data. These structures can




4.A.1 Rosetta modeling of crystals
Rosetta version 2017.26-dev59567 was used for all simulations. Antibody Fv regions were
relaxed with the following command and options:
relax.linuxgccrelease -l pdb.list -ex1 -ex2 -use_input_sc -beta -
nstruct 10
Antibody Fv regions had their CDR-H3 loop remodeled and relative VH–VL orientation
resampled with the command and options below.
antibody_H3.linuxgccrelease -l pdb.list -ex1 -ex2 -nstruct 10 @abH3.
flags
where, abH3.flags is a file containing the following additional options:
-antibody :: remodel perturb_kic
-antibody :: snugfit true
-antibody :: refine refine_kic
-antibody :: cter_insert false
-antibody :: flank_residue_min true
-antibody :: bad_nter false
-antibody :: h3_filter false










4.A.2 Rosetta modeling of sequences
Antibody Fv homology models were generate with RosettaAntibody in three steps: (1)
assembly of the homologous components, (2) FastRelax of the grafted model, (3) CDR-
H3 loop modeling and VH–VL docking. Homologous components were selected and
assembled with the following command and options:
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antibody.macosclangrelease -fasta pdb.fasta -antibody:
n_multi_templates 1 -antibody:no_relax
The resulting “model-0.pdb” was the relaxed with constraints by:
relax.macosclangrelease -s model -0.pdb -flip_HNQ -no_optH false -relax
:fast -relax:constrain_relax_to_start_coords -relax:
ramp_constraints false -use_input_sc -ex1 -ex2 -nstruct 1
Finally, CDR-H3 loop modeling and docking of VH–VL was done by:
antibody_H3.linuxgccrelease -s grafting/model -0_0001.pdb -nstruct 1000
@abH3.flags
with the following abH3.flags:
-antibody :: remodel perturb_kic
-antibody :: snugfit true
-antibody :: refine refine_kic
-antibody :: cter_insert false
-antibody :: flank_residue_min true
-antibody :: bad_nter false
-antibody :: h3_filter false














Mature sequences were aligned to germline V-genes as described in the methods. Ad-
ditionally, sequences were aligned to germline J-genes using IMGT/DomainGapAlign,
which yields germline alignments for both V- and J-genes. For example, the alignment
of the variable region of 1T2Q can be extracted from: http://www.imgt.org/3Dstructure-
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DB/cgi/details.cgi?pdbcode=1t2q. The germline sequence was used when possible. The



















































































































































4.A.4 Comparison of flexibility calculations across ensemble generation meth-
ods
In this work, I have considered multiple ensemble generation methods in conjunction
with FIRST-PG analysis to determine the flexibility of CDR-H3 loops. Of all methods
used in this paper to generate structural ensembles, only MD simulations have previously
been coupled with flexibility analysis. Rosetta FastRelax, KIC, and RosettaAntibody have
not been used previously for flexibility analysis. MD simulations permit for fluctuations
between low-energy states and variations in hydrogen bonding networks, effectively cap-
turing the “flickering” nature of hydrogen bonds. The Rosetta-based methods consider
hydrogen-bonding energy, but do not involve dynamic motion in the same way as MD
simulations. The Rosetta FastRelax protocol generates ensembles representative of the
local energy minimum through side-chain repacking and gradient-based energy minimiza-
tion, so flexibility analysis of these ensembles should be comparable to flexibility analysis
of crystal structures. Rosetta KIC on the other hand generates ensembles of low-energy
CDR-H3 loop conformations by de novo modeling of the CDR-H3 loop. RosettaAntibody
generates ensembles of low-energy antibody conformations, building on KIC motions
through additional VH–VL docking. I compared FIRST-PG calculations on Rosetta Fas-
tRelax, RosettaAntibody, and MD ensembles, for three well-studied antibodies, excluding
KIC ensembles from analysis because they are effectively superseded by RosettaAntibody
ensembles. Qualitatively, the FIRST-PG results agree for all methods for 48G7 and the
anti-fluorescein antibody. The Rosetta FastRelax results differ from the other methods
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for the anti-influenza, with the naïve showing significantly more rigidity. This is most
likely due to the difference in quality between the crystal structures. Quantitatively, the
∆AUC values for RosettaAntibody and MD ensembles for all three antibody pairs compare
well (Supplemental Table 4.A.1). Additionally, I compared only RosettaAntibody and MD
ensembles for three naïve-reverted/mature antibody pairs, where I found that the ∆AUC
values roughly agree for two out of three antibody pairs. Taken together, these results
indicate that flexibility analyses on RosettaAntibody homology model ensembles are similar
to analyses on MD ensembles.
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4.A.5 Supplemental tables
Table 4.A.1: Changes in the rigidity of the 48G7 antibody CDR-H3 loop according to several
methods. Unbound is denoted by (U) and bound is denoted by (B). A positive number indicates an
increase in rigidity upon affinity maturation. Changes for B-factors are calculated as the difference
in the average CDR-H3 loop B-factor between the naïve and mature crystal structure: ∆B =




mature. Changes in FIRST-PG are calculated as the percent change
between the AUC of the CDR-H3 melting curve for naïve and mature antibodies: ∆AUC = 100 ×
AUCmature−AUCnaive
AUCnaive
. Finally, changes in MD RMSD or RMSF are calculated as the difference in average
CDR-H3 loop RMSF or RMSD between the MD simulations of the naïve and mature antibodies:




mature. Only bound crystal structures were available for the 4-4-
20 antibody, but Relax, KIC, RA and MD simulations were run without antigen. Only an unbound
naïve and bound mature crystal structures were available for the anti-influenza antibody, but Relax,
KIC, RA and MD simulations were run without antigen.
Antibody ∆B- ∆Relax ∆KIC ∆RA ∆MD ∆MD ∆MD
Factor AUC AUC AUC RMSD RMSF AUC
48G7 (U) 2.14 ± 0.62 3.9 13.0 0.2 −1.04 ± 0.66 2.14 ± 0.62 −1.3
48G7 (B) 1.21 ± 0.89 −6.2 −8.9
4-4-20 (U) −6.2 0.85 ± 0.53 −0.35 ± 0.36 −4.1
4-4-20 (B) 0.46 ± 0.77 −8.4 2.8
Influenza (U) 6.1 2.25 ± 1.33 0.44 ± 1.14 9.1
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Naive AUC: −5.91±0.2 Naive AUC: −154.1±4.8
Mature AUC: −150.44±7.73
Figure 4.A.1: FIRST-PG analysis of KIC ensembles of the crystallographic antibody set, with naïve
antibody data shown in blue and mature antibody data shown in orange and standard error of
the mean shown in a lighter shade of the respective color. Subplots, below each main plot, show
the p-value computed by a KS comparison of the naïve and mature DOF distributions for each
hydrogen-bonding energy cutoff, with null hypothesis being that the distributions are the same
and a dashed line indicating a p-value of 0.05. (Left) When comparing DOFs scaled to a theoretical
maximum as a function of hydrogen-bonding energy cutoff for the entire set, the values are similar
for both naïve (AUC = −5.9 ± 0.2) and mature (AUC = −5.8 ± 0.3) antibodies. (Right) Comparison
of DOFs for a single length without scaling reveals naïve antibodies to possess a slightly higher
DOF value than mature antibodies at the same hydrogen-bonding energy cutoff. AUCs however are
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Distribution of Average CDR H3 B-Factors
Figure 4.A.2: Average CDR-H3 loop B-factor z-score for antibodies with loops of length 10 split by
number of mutations (left) and all antibodies split by heavy-chain species (right). Mature antibodies
have at least one mutation. Comparing the difference in mature versus naïve means for length 10
CDR-H3 loops only to a randomized test (as described in the methods) shows only 2.9% of random
permutations have an equal or greater difference. A two-sample KS test yields a p-value of 0.0135
and D of 0.4949, so these distributions appear to be on the threshold of significance. However,
that is obviated when bound structures are excluded from analysis, resulting in 4.8% of random
permutations having an equal or greater difference in means than the observed and a KS-test p-value
of 0.0989 (with D of 0.3989). It is difficult to quantify if there is a difference in the length 10 set due
to low counts (only 11 naïve antibodies), whereas there is no visible difference between the human
and mouse antibodies (21.3% of random permutations have an equal or greater difference and the



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Resolution vs. CDR H3 B-Factor
Figure 4.A.3: Average CDR-H3 loop B-factor z-score compared with either loop length (left) or
crystal structure resolution (right). There is not an obvious dependence of CDR-H3 loop B-factor
z-score on either.
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Figure 4.A.4: Difference in CDR loop motions upon antigen binding between naïve and mature
antibodies for four catalytic antibodies. Loop RMSDs (in angstroms) were calculated from the
difference in CÎś atom positions after alignment of the corresponding (heavy or light) framework
CÎś atoms. The CDR-H3 loops is highlighted in black. The dashed line indicates 1 Å. A more
negative value here indicates less motion upon binding in the mature antibody. The effects of affinity
maturation on CDR-H3 loop motion in crystal structures are not always significant, with only 2/4
showing motion reduction greater than an angstrom.
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Holo 48G7 Antibody CDR H3 B−Factors
Figure 4.A.5: Caption follows on the next page.
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Figure 4.A.5: (Previous page.) CDR-H3 loop B-factor z-scores for three previously studied antibodies,
with PDB IDs shown above each plot. B-factor z-scores were calculated with respect to the Fv region
and for Cα atoms only. The anti-influenza antibodies have vary in resolution from 2.5 Å for the
naïve and mature to 3.0 Å (4HK3) and 3.6 Å (4HKB) for the intermediates. Additionally, the mature
anti-influenza antibody has antigen bound affecting the CDR-H3 loop B-factors. One can see that




















































































Figure 4.A.6: FIRST-PG analysis of two previously studied antibodies with MD simulations (labelled
MD), RosettaAntibody (labelled RAB), and Rosetta FastRelax (labelled relax) used to generate
structural ensembles. Naïve antibodies are colored blue and mature antibodies are colored red,
while an “intermediate” (4HKB) influenza antibody is shown in green. Subplots, below each main
plot, show the p-value computed by a KS comparison of the naïve and mature DOF distributions
for each hydrogen-bonding energy cutoff, with null hypothesis being that the distributions are the
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Figure 4.A.7: CDR-H3 B-factor z-scores for antigen-bound and free crystal structures of catalytic
antibodies 7G12 and 28B4. The 7G12 antibody has higher z-scores for the mature than the naïve
antibody for both the (A) unbound and (B) bound structures, indicating a gain in flexibility upon
maturation. The 28B4 antibody shows a loss of flexibility upon maturation for the unbound structure




























AZ28 Antibody CDR H3 B-Factors


























Figure 4.A.8: CDR-H3 loop B-factor z-scores for antigen-bound and free crystal structures of the
catalytic antibody AZ-28 reveal no significant difference between the naïve and mature antibodies.
112
References
1. Tonegawa, S. Somatic generation of antibody diversity. Nature 302, 575–581 (1983).
2. Di Noia, J. M. & Neuberger, M. S. Molecular Mechanisms of Antibody Somatic Hyper-
mutation. Annual Review of Biochemistry 76, 1–22 (2007).
3. De los Rios, M., Criscitiello, M. F. & Smider, V. V. Structural and genetic diversity in
antibody repertoires from diverse species 2015.
4. Clark, L. A., Ganesan, S, Papp, S & van Vlijmen, H. W. Trends in antibody sequence
changes during the somatic hypermutation process. J Immunol 177, 333–340 (2006).
5. Burkovitz, A., Sela-Culang, I. & Ofran, Y. Large-scale analysis of somatic hypermu-
tations in antibodies reveals which structural regions, positions and amino acids are
modified to improve affinity. en. FEBS Journal 281, 306–319 (2014).
6. Chothia, C. & Lesk, A. M. Canonical structures for the hypervariable regions of im-
munoglobulins. J Mol Biol 196, 901–917 (1987).
7. Chothia, C. et al. Conformations of immunoglobulin hypervariable regions. Nature 342,
877–883 (1989).
8. Al-Lazikani, B., Lesk, A. M. & Chothia, C. Standard conformations for the canonical
structures of immunoglobulins. J Mol Biol 273, 927–948 (1997).
9. Kuroda, D., Shirai, H., Kobori, M. & Nakamura, H. Systematic classification of CDR-
L3 in antibodies: implications of the light chain subtypes and the VL-VH interface.
Proteins 75, 139–146 (2009).
10. North, B., Lehmann, A. & Dunbrack, R. L. A new clustering of antibody CDR loop
conformations. Journal of Molecular Biology 406, 228–256 (2011).
11. Morea, V., Tramontano, A., Rustici, M., Chothia, C. & Lesk, A. M. Conformations of
the third hypervariable region in the VH domain of immunoglobulins 1 1Edited by I.
A. Wilson. Journal of Molecular Biology 275, 269–294 (1998).
12. Kuroda, D., Shirai, H., Kobori, M. & Nakamura, H. Structural classification of CDR-H3
revisited: A lesson in antibody modeling. Proteins: Structure, Function and Genetics 73,
608–620 (2008).
13. Weitzner, B. D., Dunbrack, R. L. & Gray, J. J. The origin of CDR H3 structural diversity.
Structure 23, 302–11 (2015).
14. Tsuchiya, Y & Mizuguchi, K. The diversity of H3 loops determines the antigen-binding
tendencies of antibody CDR loops. Protein Sci 25, 815–825 (2016).
113
15. Wedemayer, G. J., Patten, P. A., Wang, L. H., Schultz, P. G. & Stevens, R. C. Structural
insights into the evolution of an antibody combining site. Science 276, 1665–1669 (1997).
16. Mundorff, E. C. et al. Conformational effects in biological catalysis: An antibody-
catalyzed oxy-Cope rearrangement. Biochemistry 39, 627–632 (2000).
17. Yin, J. et al. A comparative analysis of the immunological evolution of antibody 28B4.
Biochemistry 40, 10764–10773 (2001).
18. Yin, J., Beuscher, A. E., Andryski, S. E., Stevens, R. C. & Schultz, P. G. Structural
plasticity and the evolution of antibody affinity and specificity. Journal of molecular
biology 330, 651–656 (2003).
19. Li, Y., Li, H., Yang, F., Smith-Gill, S. J. & Mariuzza, R. A. X-ray snapshots of the
maturation of an antibody response to a protein antigen. Nature Structural & Molecular
Biology 10, 482–488 (2003).
20. Manivel, V., Sahoo, N. C., Salunke, D. M. & Rao, K. V. Maturation of an antibody
response is governed by modulations in flexibility of the antigen-combining site.
Immunity 13, 611–620 (2000).
21. Schmidt, A. G. et al. Preconfiguration of the antigen-binding site during affinity matu-
ration of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A 110,
264–9 (2013).
22. Thielges, M. C., Zimmermann, J., Yu, W., Oda, M. & Romesberg, F. E. Exploring the
energy landscape of antibody-antigen complexes: Protein dynamics, flexibility, and
molecular recognition. Biochemistry 47, 7237–7247 (2008).
23. Adhikary, R., Yu, W., Oda, M., Zimmermann, J. & Romesberg, F. E. Protein dynamics
and the diversity of an antibody response. J Biol Chem 287, 27139–27147 (2012).
24. Adhikary, R. et al. Adaptive mutations alter antibody structure and dynamics during
affinity maturation. Biochemistry 54, 2085–2093 (2015).
25. Jimenez, R., Salazar, G., Baldridge, K. K. & Romesberg, F. E. Flexibility and molecular
recognition in the immune system. Proc Natl Acad Sci U S A 100, 92–97 (2003).
26. Jimenez, R., Salazar, G., Yin, J., Joo, T. & Romesberg, F. E. Protein dynamics and the
immunological evolution of molecular recognition. Proc Natl Acad Sci U S A 101, 3803–
3808 (2004).
27. Zimmermann, J. J. et al. Antibody evolution constrains conformational heterogeneity
by tailoring protein dynamics. Proc Natl Acad Sci U S A 103, 13722–13727 (2006).
28. Davenport, T. M. et al. Somatic Hypermutation-Induced Changes in the Structure and
Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure 24, 1346–1357 (2016).
29. Chong, L. T., Duan, Y, Wang, L, Massova, I & Kollman, P. A. Molecular dynamics and
free-energy calculations applied to affinity maturation in antibody 48G7. Proceedings of
the National Academy of Sciences of the United States of America 96, 14330–14335 (1999).
30. Thorpe, I. F., Brooks, C. L. & Brooks 3rd, C. L. Molecular evolution of affinity and
flexibility in the immune system. Proceedings of the National Academy of Sciences of the
United States of America 104, 8821–8826 (2007).
114
31. Wong, S. E., Sellers, B. D. & Jacobson, M. P. Effects of somatic mutations on CDR loop
flexibility during affinity maturation. en. Proteins: Structure, Function and Bioinformatics
79, 821–829 (2011).
32. Li, T. et al. Rigidity Emerges during Antibody Evolution in Three Distinct Antibody
Systems: Evidence from QSFR Analysis of Fab Fragments. PLoS Comput Biol 11 (ed
de Groot, B. L.) e1004327 (2015).
33. Di Palma, F. & Tramontano, A. Dynamics behind affinity maturation of an anti-HCMV
antibody family influencing antigen binding. FEBS Letters 591, 2936–2950 (2017).
34. Babor, M. & Kortemme, T. Multi-constraint computational design suggests that na-
tive sequences of germline antibody H3 loops are nearly optimal for conformational
flexibility. Proteins: Structure, Function, and Bioinformatics 75, 846–858 (2009).
35. Willis, J. R. et al. Human germline antibody gene segments encode polyspecific anti-
bodies. PLoS Comput Biol 9, e1003045 (2013).
36. DeKosky, B. J. et al. Large-scale sequence and structural comparisons of human naive
and antigen-experienced antibody repertoires. Proceedings of the National Academy of
Sciences 113, E2636–E2645 (2016).
37. Weitzner, B. D. et al. Modeling and docking of antibody structures with Rosetta. Nature
Protocols 12, 401–416 (2017).
38. Weitzner, B. D., Kuroda, D., Marze, N., Xu, J. & Gray, J. J. Blind prediction performance
of RosettaAntibody 3.0: Grafting, relaxation, kinematic loop modeling, and full CDR
optimization. Proteins: Structure, Function and Bioinformatics 82, 1611–1623 (2014).
39. Sljoka, A. Algorithms in rigidity theory with applications to protein flexibility and mechanical
linkages PhD thesis (York University, 2012).
40. Sljoka, A. & Wilson, D. Probing protein ensemble rigidity and hydrogen-deuterium
exchange. Physical Biology 10, 056013 (2013).
41. Kim, H. & Ha, T. Single-molecule nanometry for biological physics. Reports on progress
in physics. Physical Society (Great Britain) 76, 016601 (2013).
42. Deng, B. et al. Suppressing allostery in epitope mapping experiments using millisecond
hydrogen / deuterium exchange mass spectrometry. mAbs 9, 1327–1336 (2017).
43. Jacobs, D. J., Rader, A. J., Kuhn, L. A. & Thorpe, M. F. Protein flexibility predictions
using graph theory. Proteins: Structure, Function and Genetics 44, 150–165 (2001).
44. Whiteley, W. Counting out to the flexibility of molecules in Physical Biology 2 (IOP Publish-
ing, 2005), S116–S126.
45. Dunbar, J. et al. SAbDab: The structural antibody database. Nucleic Acids Research 42,
D1140–D1146 (2014).
46. Ehrenmann, F., Kaas, Q. & Lefranc, M. P. IMGT/3dstructure-DB and IMGT/domain-
gapalign: A database and a tool for immunoglobulins or antibodies, T cell receptors,
MHC, IgSF and MHcSF. Nucleic Acids Research 38, D301–D307 (2009).
47. Jeliazkov, J. R. et al. Repertoire Analysis of Antibody CDR-H3 Loops Suggests Affinity
Maturation Does Not Typically Result in Rigidification. Frontiers in Immunology 9
(2018).
115
48. Nivon, L. G., Moretti, R. & Baker, D. A Pareto-Optimal Refinement Method for Protein
Design Scaffolds. PLoS ONE 8 (ed Zhang, Y.) e59004 (2013).
49. Mandell, D. J., Coutsias, E. A. & Kortemme, T. Sub-angstrom accuracy in protein
loop reconstruction by robotics-inspired conformational sampling. Nature methods 6,
551–552 (2009).
50. Alford, R. F. et al. The Rosetta All-Atom Energy Function for Macromolecular Modeling
and Design. Journal of Chemical Theory and Computation 13, 3031–3048 (2017).
51. Chipot, C. et al. Scalable molecular dynamics with NAMD. Journal of Computational
Chemistry 26, 1781–1802 (2005).
52. Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically
disordered proteins. Nature Methods 14, 71–73 (2016).
53. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N·log(N) method for
Ewald sums in large systems. The Journal of Chemical Physics 98, 10089–10092 (1993).
54. Li, T et al. Redistribution of flexibility in stabilizing antibody fragment mutants follows
Le Chatelier’s principle. PLoS One 9, e92870 (2014).
55. Feig, M., Karanicolas, J. & Brooks, C. L. MMTSB Tool Set: Enhanced sampling and
multiscale modeling methods for applications in structural biology in Journal of Molecular
Graphics and Modelling 22 (Elsevier, 2004), 377–395.
56. Michaud-Agrawal, N., Denning, E. J., Woolf, T. B. & Beckstein, O. MDAnalysis: A
toolkit for the analysis of molecular dynamics simulations. Journal of Computational
Chemistry 32, 2319–2327 (2011).
57. Mamonova, T., Hespenheide, B., Straub, R., Thorpe, M. F. & Kurnikova, M. Protein
flexibility using constraints from molecular dynamics simulations. Physical Biology 2,
S137–S147 (2005).
58. Kuroda, D. & Gray, J. J. Pushing the backbone in protein-protein docking. Structure 24,
1821–1829 (2016).
59. Ó Conchúir, S. et al. A Web resource for standardized benchmark datasets, metrics,
and rosetta protocols for macromolecular modeling and design. PLoS ONE 10 (ed
Zhang, Y.) e0130433 (2015).
60. Demirel, M. C. & Lesk, A. M. Molecular forces in antibody maturation. Phys Rev Lett
95, 208106 (2005).
61. Murphy, K., Weaver, C. & Mowat, A. Janeway’s Immunobiology 9th Editio, 1–907 (2017).
62. Boder, E. T., Midelfort, K. S. & Wittrup, K. D. Directed evolution of antibody fragments
with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 97,
10701–10705 (2000).
63. Midelfort, K. S. et al. Substantial Energetic Improvement with Minimal Structural
Perturbation in a High Affinity Mutant Antibody. Journal of Molecular Biology 343,
685–701 (2004).
64. Fukunishi, H, Shimada, J & Shiraishi, K. Antigen-antibody interactions and structural
flexibility of a femtomolar-affinity antibody. Biochemistry 51, 2597–2605 (2012).
116
65. Xu, H. et al. Key mutations stabilize antigen-binding conformation during affinity
maturation of a broadly neutralizing influenza antibody lineage. Proteins 83, 771–780
(2015).
66. Eisen, H. N. & Chakraborty, A. K. Evolving concepts of specificity in immune reactions.
Proceedings of the National Academy of Sciences 107, 22373–22380 (2010).
67. Alzari, P. M. et al. Three-dimensional structure determination of an anti-2-phenyloxazolone
antibody : the role of somatic mutation and heavy / light chain pairing in the matura-
tion of an immune response. The EMBO Journal 9, 3807–3814 (1990).
68. Mizutani, R. et al. Three-dimensional Structures of the Fab Fragment of Murine N1G9
Antibody from the Primary Immune Response and of its Complex with (4-Hydroxy-3-
Nitrophenyl)acetate. Journal of Molecular Biology 254, 208–222 (1995).
69. Yuhasz, S. C., Parry, C., Strand, M. & Amzel, L. M. Structural analysis of affinity
maturation: The three-dimensional structures of complexes of an anti-nitrophenol
antibody. Molecular Immunology 32, 1143–1155 (1995).
70. Mishra, A. K. & Mariuzza, R. A. Insights into the structural basis of antibody affinity
maturation from next-generation sequencing 2018.
71. James, L. C., Roversi, P & Tawfik, D. S. Antibody multispecificity mediated by confor-
mational diversity. Science 299, 1362–1367 (2003).
72. Wang, W et al. Conformational selection and induced fit in specific antibody and
antigen recognition: SPE7 as a case study. J Phys Chem B 117, 4912–4923 (2013).
73. Sterner, E., Peach, M. L., Nicklaus, M. C. & Gildersleeve, J. C. Therapeutic Antibodies





This chapter includes published material, which is free to reuse under the Creative
Commons Attribution license, from Santiago-Frangos A, Jeliazkov JR, Gray JG, and
Woodson SA, “Acidic C-terminal domains autoregulate the RNA chaperone Hfq.”
eLife 6, e27049 (2017), and from Santiago-Frangos A, Frölich KS, Jeliazkov JR,
Małecka EM, Marino G, Gray JG, Luisi BF, Woodson SA, and Hardwick SW,
“Caulobacter crescentus Hfq structure reveals a conserved mechanism of RNA
annealing regulation.” PNAS (2019).
5.1 Overview
The RNA chaperone Hfq is an Sm protein that facilitates base pairing between bacterial small
RNAs (sRNAs) and mRNAs involved in stress response and pathogenesis. Hfq possesses
an intrinsically disordered C-terminal domain (CTD) that may tune the function of the Sm
domain in different organisms. In Escherichia coli, the Hfq CTD increases kinetic competition
between sRNAs and recycles Hfq from the sRNA–mRNA duplex. Here, de novo Rosetta
modeling and competitive binding experiments show that the acidic tip of the E. coli Hfq
CTD transiently binds the basic Sm core residues necessary for RNA annealing. The CTD
tip competes against non-specific RNA binding, facilitates dsRNA release, and prevents
indiscriminate DNA aggregation, suggesting that this acidic peptide mimics nucleic acid to
auto-regulate RNA binding to the Sm ring. The mechanism of CTD auto-inhibition predicts




Over the last twenty years, the traditional paradigm that protein sequence gives rise to
structure and that in turn dictates function has been challenged by the emergence of
intrinsically disorderedi proteins (IDPs) and regions (IDRs) within ordered (structured)
proteins1. More specifically, 8–42% of the residues in the human proteome and 7–30%
of residues in the bacterial proteome are predicted to be disordered, depending on the
prediction method2. Many of these residues partially or entirely constitute proteins with
significant biological function. To give two examples from a plethora of possibilities:
(1) proteins implicated in human neurodegenerative diseases are disordered3 and, (2) in
bacteria, proteins with IDRs regulate transcription and play a central role in stress response4.
The study of IDPs and IDRs is necessary not only to understand and prevent human
disease, but also to delve into fundamental biological processes. However, it is excep-
tionally challenging to study disordered elements at a molecular level. This is because,
unlike well-ordered or structured proteins, IDPs and IDRs do not occupy one low-energy
conformation, instead they exist as a heterogenous and dynamic ensemble of conforma-
tions. The heterogeneity renders X-ray crystallography, which relies on atoms existing in
repeated and regular positions within the crystal lattice, practically useless, unless there
is a single state of interest that can be captured. Furthermore, the dynamic nature of IDP
ensembles might span numerous timescales rendering it challenging to characterize with
a single technique. Sample experimental approaches to studying IDPs and IDRs include
nuclear magnetic resonance (NMR)5, which is low throughput but provides atomic-scale
resolution, single-molecule Förster resonance energy transfer (smFRET)6, and small-angle
X-ray scattering (SAXS)7, both of which can be high throughput but at a lower resolution.
Complimentary to experimental approaches, computational methods can provide
atomic-scale resolution in a high-throughput manner. The most accurate of these ap-
iThe term, intrinsic disorder, implies that it is the protein sequence that gives rise to the lack of protein
structure.
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proaches are all-atom molecular dynamics simulations with explicit solvent8. Accuracy
comes at a steep computational cost: at each time step, atom positions are updated accord-
ing to the potential energy of the system, which is calculated by summing bonded, van der
Waals, and electrostatic over all atom pairs within certain distance cutoffs. Thus, all-atom
simulations for large systems are not possible for long time-scales. Simulations can be
accelerated by using implicit solvent, such that water molecules (which are the plurality of
atoms in a simulation) are not included. Further computational time can be saved by using
Monte Carlo, rather than Newtonian sampling. In a Monte Carlo simulation, motions can
be user-defined (termed move sets), e.g. when modeling a peptide one might only allow
changes in backbone and side-chain dihedral angles, as most bond lengths and angles are
essentially fixed. In scenarios where all-atom simulations are prohibitively expensive in
terms of compute time, Monte Carlo approaches have proven useful in modeling IDPs9,10
and IDRs11.
Within Rosetta, the Monte Carlo approach to modeling IDRs is FloppyTail12. In com-
parison to other approaches, FloppyTail is fast, but simplistic, using only backbone and
side-chain dihedral moves, and has been applied to a limited set of modeling problems,
typically asking whether or not a single IDR can adopt a certain conformation12–14. While
such information is useful, I thought it would be far more informative to extract biophysical
properties (e.g. the average strength of residue–residue interactions between the ordered
and disordered regions of the protein in the ensemble of plausible models). Thus, I sought
to expand the utility of FloppyTail.
To do so, I first identified a well-characterized model system: E. coli protein host factor
for RNA phage Qβ replication (Hfq). E. coli Hfq contains an Sm-like domain (residues 7–65)
that oligomerizes into a homohexameric ring with two sequence-specific RNA-binding
faces. The proximal face of the ring is highly conserved and binds to uridines15,16 at the
3’-ends of bacterial small non-coding RNA (sRNA). The distal face of Hfq binds to AAN
triplet repeats17,18 found in mRNA leaders18,19 and certain sRNAs20,21. In addition to
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these sequence-specific RNA binding sites, arginine-rich basic patches at the rim of the E.
coli Hfq hexamer interact with the sRNA body15,22–24 and facilitate annealing with target
mRNAs25,26. The E. coli Hfq Sm domain is flanked by a short, disordered, N-terminal
domain (NTD; residues 1–6), which protrudes from the proximal face of the hexamer, and
a longer disordered C-terminal domain (CTD; residues 66–102), which extends from the
rim27,28. While I use “domain” here and throughout this Chapter, it is not technically correct.
Traditionally, the word “domain” refers to a folded protein unit, and is inappropriate when
discussing intrinsically disordered segments. Unfortunately, in the Hfq literature CTD and
NTD are established terms29.
Recent work by Dr. Andrew Santiago-Frangos and Professor Sarah Woodson (T.C.
Jenkins Department of Biophysics, Johns Hopkins University) showed that the intrinsically
disordered CTD of Hfq was involved in RNA displacement from the rim and proximal
face of the protein30. Working with Dr. Santiago-Frangos, I applied the updated FloppyTail
algorithm on Hfq, elucidating the molecular mechanism by which the CTD regulates Hfq
activity and improving IDR modeling in Rosetta. In particular, I enabled simultaneous
modeling of multiple disorder regions, I identified a criterion for convergence, defining a
reasonable simulation length, and I developed an ensemble-based analysis method to extract
biophysically relevant properties from models. Simulations of Hfq produced accurate
predictions for the energetic effects of mutations on CTD–rim interactions and molecular
models congruent with experimental data. Confident in the validity of the approach, I
computationally characterized Hfq proteins from other bacterial species, demonstrating a
correlation between certain interactions and the activity of these proteins in vivo. Finally, a
recently-determined crystal structure of the Caulobacter crescentus Hfq protein revealed that




In this study, I modeled six Hfq proteins, starting from crystal structures: E. coli (1HK9),
P. aeruginosa (1U1S), L. monocytogenes (4NL2), B. subtilis (3HSB), S. aureus (1KQ1), and
C. crescentus (6GWK). However, the input to Rosetta FloppyTail is not just the crystal
structure, but also requires the disordered regions to be in extended conformations (ϕ =
−135°, ψ = 135°). As IDRs are not typically resolved in crystal structures, I developed a
PyRosetta31 script (released with Rosetta in the public PyRosetta scripts directory under:
floppy_tail_utility/extend_terminus.py) to append or prepend the missing residues. I
used this script (e.g. extend_terminus.py -c A -o 1hk9.chainA.pdb -p 1hk9.clean.pdb
MAKGQ) to add the N- and C-terminal residues for all of the above Hfq proteins (sequences
can be found in Table 5.1). An additional PyRosetta utility script (convert_to_beta.py)
to extend regions in a beta-strand conformation exists, if the residues are present in the
input crystal structure and do not have to be added. Any mutants were generated using the
PyMOL “mutate” function. Before modeling, the input structures with extended termini
were “relaxed” with constraints using the FastRelax protocol32,33, to eliminate energetically
unfavorable atomic clashes.
Table 5.1: IDR sequences appended to Hfq crystal structures.
Species NTD Sequence CTD Sequence
E. coli MAKGQ SRPVSHHSNNAGGGTSSNYHHGSSAQNTSAQQDSEETE
P. aeruginosa MSKGHS SRPVRLPSGDQPAEPGNA
L. monocytogenes MKQGGQG SPQKNVALNPDAE
B. subtilis MKPIN PQKNVQLELE
S. aureus MIANEN VETEGQASTESEE
C. crescentus MSAEKKQN PAQPVQLYEPSADADD
5.3.2 FloppyTail modeling of IDRs
A modified version of the FloppyTail algorithm was used to model the disordered termini
(see Appendix Figure 5.A.2). The FloppyTail algorithm generates hypothetical, low-energy
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conformations of disordered regions through two stages of modeling: (1) low-resolution
modeling, where side chains are represented as single pseudo-atom centroids, with aggres-
sive sampling of backbone conformational space and gradient-based minimization, and (2)
all-atom modeling, where all side-chain atoms are restored, with fine sampling of backbone
conformational space, side-chain optimization, and minimization. At the end of each stage,
the lowest-energy conformation is recovered. Non-disordered residues have no backbone
motion, but are permitted to sample side-chain conformations.
I adapted the original algorithm to permit simultaneous modeling of multiple disordered
termini. To this end, I expanded the underlying FoldTree. As detailed in Chapter 3, the
FoldTree is a data structure within Rosetta that dfeines the order in which residue positions
are updated. The default approach is to update from the N- to the C-terminus, mimicking
protein folding. This is not optimal for modeling multiple disordered termini. Instead, I
implemented a FoldTree that updates from the center-of-mass out towards the termini, for
each polypeptide chain.
Another improvement I implemented was more extensive and better characterized
sampling of the disordered energy landscape. To achieve this, I tracked the lowest energy
observed at each step the low-resolution stage of an ultra-long E. coli Hfqii simulation,
assessing sampling in terms of energy and identifying an optimal number of low-resolution
steps. The ultra-long simultaion reveal that the energy drops substantially (∼360 Rosetta
Energy Units [REU] for E. coli Hfq) in the first 100,000 steps of the low-resolution stage, but in
the next 900,000 steps the change in energy is minimal (∼60 REU). Following the ultra-long
simulation, I repeated ten shorter low-resolution simulations to assess the stability of my
observation, and the results showed that the ultra-long simulation is indeed representative
(Figure 5.1). Based on this data and considering the computational cost, 50,000–100,000 steps
or approximately 400 backbone moves attempted per disordered residue were identified as
optimal, with the smaller step count used for the non-E. coli Hfq proteins with shorter IDRs.
iiI tested E. coli Hfq as it had the largest IDR, so the number of steps determined here should suffice for any
other Hfq protein in my set.
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Figure 5.1: Semi-log plot of the lowest observed energy for a given number of attempted low-
resolution backbone moves. The mean lowest energy observed for ten simulations is shown in black,
with ± one standard deviation filled in gray. A single simulation run with 1,000,000 attempted moves
is shown in red. The change in energy between 100,000 and 1,000,000 steps is ∼60 Rosetta Energy
Units (REU), which is marginal in comparison to the ∼360 REU change in the first 100,000 attempted
moves. The beneficial energy drop beyond 100,000 steps is outweighed by the computational cost.
Thus, to generate one E. coli Hfq model, approximately 100,000 low-resolution moves should be
sufficient to sample the energy landscape.
I repeated a similar analysis for the high-resolution stage, except there was no need for an
ultra-long simulation as this stage converged within 100 steps (Figure 5.A.1). Ultimately, I
elected to retain 1,000 high-resolution steps, as this was closer to the previously published
3,000 steps12. Based on the previous publication, simulations were used to generate a total
30,000 hypothetical structures for each species’ Hfq protein, but only the 100 lowest-energy
models were analyzed. The full FloppyTail algorithm is detailed in Figure 5.A.2.
5.3.3 Analysis of FloppyTail models
My final contribution to FloppyTail was an ensemble approach to model analysis. To this
end, I used PyRosetta31 to evaluate the energies of pairwise residue–residue interactions.
Pairwise energies were computed with the talaris2014 energy function34, with terms
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capturing van der Waals, solvation, hydrogen bonding and electrostatic interactions. If
a pairwise energy was unfavorable (0 or greater), I did not consider it for further analy-
sis. This script is publicly released with Rosetta in the PyRosetta scripts directory under:
(floppy_tail_utility/identify_interactions.py.
To determine the nature of the CTD interactions, I considered two residue sets, those
in the core (denoted C, for all residues, and B, if basic) and acidic residues in the tail (T )
(see Table 5.2 for the species-specific definitions). I calculated the average number of tail
interactions for a single core residue, x ∈ C, by counting the number of pairwise interactions,
with a lower energy than a pre-determined threshold, between x and every residue in T ,







δ(x, y)/(Nmodels · Nsubunits),
where δ(x, y) is 1 if the residues are interacting (E(x, y) < T) and 0 if the residues are
not interacting (E(x, y) ≥ T), according to a threshold value, T, and the pairwise energiy
E(x, y).
Table 5.2: Core and tail residue selections for energy calculations.
Species Core (C) Basic Core (B) Acidic Tail (T )
E. coli 1–65 3, 16, 17, 19, 47 97, 99, 100, 102
P. aeruginosa 1–65 3, 5, 16, 17, 19, 47 94, 97
L. monocytogenes 1–65 2, 16, 17, 19, 35 100, 102
B. subtilis 1–65 2, 16, 17, 37 71, 73
S. aureus 1–65 10, 16, 41 65, 67, 99, 101, 102
C. crescentus 1–65 5, 6, 18, 19, 21, 49, 50 79, 80, 81
The threshold was determined by analysis of pairwise interactions. Figure 5.A.3 shows
the energy distributions for all basic–acidic residue pairs across all E. coli Hfq simulations.
There are two clear populations: one at 0 REU representative of non-interacting pairs and
one at −2 REU representative of interacting pairs. Thus, the threshold is −1.0 REU for the
talaris2014 energy function. For the newest energy function, REF201535, the threshold is
doubled to −2.0 REU the function weights have changed (data not shown).
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The standard deviation for the average number of tail–core interactions with residue x
was computed by using bootstrap resampling as previously described for protein docking36.
Briefly, I resampled, with replacement, the set of models one thousand times (B = 1, 000)
and calculated resampled counts, N′x, with the equation above for the resampled models.
The standard deviation was computed as: σ2N = ∑B(N
′
x − ⟨N′x⟩)2/B, where ⟨N′x⟩ is the
average count for the resampled set.
Similarly to how the counts were computed, I calculated the average energy for each
interaction meeting the threshold criteria, summed over all residues in the tail set:






δ(x, y)E(x, y)/(Nmodels · Nsubunits).
The standard deviation for the interaction energy was computed without bootstrap re-
sampling; the energy has a distribution within the set of models, whereas the presence of









δ(x, y)E(x, y)− Ex:T
)2
/(Nmodels · Nsubunits).
Finally, I defined an expected energetic contribution (EEC) metric, as the average energy
of a tail–core interaction multiplied by the average number of that tail–core interaction per
model: ∑B⟨Nx⟩⟨Ex:T ⟩. The standard deviation for EEC was computed by assuming that





E⟨Nx⟩2 + σ2N⟨Ex:T ⟩2.
5.3.4 Hfq purification and CTD binding studies
This work was done by Dr. Andrew Santiago-Frangos. Untagged E. coli Hfq102, Hfq-sCTD,
Hfq65, Hfq65-Q35A, Hfq65-K47A, Hfq65-R19D and Hfq65-R16A were over-expressed
in E. coli BL21(DE3)∆hfq::cat-sacB cells grown in 1 L LB-Miller media (10 g/L Tryptone,
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10 g/L NaCl, 5 g/L yeast extract) supplemented with 100 µg/mL ampicillin. Plasmids
for over-expression of mutant Hfq proteins were created by site-directed mutagenesis of
pET21b-Hfq15. The purification method has been previously described30. In brief, resus-
pended cell lysates of Hfq102 and Hfq-sCTD variants were clarified by heat denaturation
and untagged Hfq was purified via Ni2+-affinity. Lysates of Hfq65 variants were further
clarified by ammonium sulfate precipitation after heat treatment, and the protein purified
by hydrophobic interaction chromatography. Finally, all Hfq variants were purified by
cation-exchange chromatography to remove nucleic acids.
To measure binding of CTD-FITC, CTDpos-FITC, or BsCTD-FITC peptides (Table 5.3)
to Hfq65 or Hfq65 mutants, the fluorescence polarization of FITC-labeled peptide was
measured 3 min after the addition of 0–0.3 µM Hfq65. Anisotropy measurements were
normalized to the average anisotropy in the absence of Hfq. Samples were prepared in a 100
µL cuvette containing 100 µL 50 mM TrisHCl pH 7.5, 45 nM CTD-FITC or CTDpos-FITC,
at 30°C. Fluorescence polarization with grating correction factor was measured using a
Horiba Fluorolog-3 (L-format) with single excitation and emission monochromators at 495
nm and 515 nm respectively (5 nm slit widths). Titrations were performed in duplicate and
the curves were fit to a single-site binding isotherm: y = Ka · x/(1 + Ka · x), in which Ka is
the association constant.







5.3.5 RNA binding and annealing
This work was done by Dr. Andrew Santiago-Frangos. The sequences RNA substrates are
listed in Table 5.3. The purification protocols for the molecular beacon25 and Target/Target-
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A1837 have been previously described. Annealing kinetics of molecular beacon (50 nM) to
either Target or Target-A18 RNA (100 nM) by 0–200 nM Hfq hexamer, in 1X TNK (10 mM
TrisHCl pH 7.5, 50 mM NaCl, 50 mM KCl) buffer at 30 °C, were measured by stopped-flow
fluorescence spectroscopy as described previously19,25. Annealing progress curves were fit
to single or double-exponential rate equations.
5.3.6 Hfq alignments and sequence logos
This work was done by Dr. Andrew Santiago-Frangos. All Hfq gene sequences were taken
from Uniprot38. 5359 sequences were aligned using the G-INS-I algorithm on MAFFT
webservers39. This alignment was reduced using CD-HIT40 and Max-Align41. An unrooted,
neighbor-joining tree of the remaining 985 non-redundant, representative, sequences was
made on MAFFT webservers39. Sequence logos of re-aligned sequences from chosen clusters
were generated using WebLogo42.
5.4 Results
5.4.1 C-terminus of Hfq is enriched for acidic residues
To search for conserved features or amino acid motifs amongst the highly heterogeneous
Hfq CTDs, a phylogenetic tree was constructed from the multiple sequence alignment
of nearly 1000 non-redundant sequences. The cluster containing E. coli Hfq contained
many other Hfq variants previously identified as functional in RNA annealing26 or sRNA
regulation43. Therefore, the sequence logo of this cluster of 222 Hfqs was examined in more
detail Figure 5.2A.
The start of the CTD region is delineated by a proline at position 64 of E. coli Hfq that
is strongly conserved across all clades. Additionally, an arginine at the beginning of the
CTD (position 66 in E. coli) that packs against the lateral edge of the Hfq hexamer44 is
strongly conserved. Although the middle linker region of the CTD lacks conserved motifs,
the C-terminus is rich in acidic residues, corresponding to the sequence DSEETE in E. coli.
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Figure 5.2: Caption follows on the next page.
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Figure 5.2: (Previous page.) (A) Sequence logo of the CTD generated from gapped alignment of Hfq
sequences that clustered with E. coli Hfq, numbered according to the E. coli sequence. Regions of
interest are denoted above. The gapped E. coli CTD sequence is shown below. (B) (Top) Average
number of times a given core residue favorably interacts (E < 1.0 REU) with at least one acidic CTD
residue, per low energy model. Acidic CTD residues most frequently interact with basic Hfq core
residues. (Bottom) Mutation of acidic CTD residues 97, 99, 100 and 102 to basic or polar residues
decreases the number of predicted core interactions. Error bars represent ± 1 s.d. as computed by
bootstrap resampling of the computational models. Of 36 core residues not predicted to interact
with the CTD, 14 had accessible surface area < 2.0 A2, computed in PyMOL. (C) (Left) Example
low-energy model of wildtype E. coli Hfq; top-down proximal view. Light grey, NTD; cyan, Hfq core;
pink-purple, CTD; red, CTD tip. (Center) Side view of rim of the same Hfq model. (Inset) Example
hydrogen bonding network at the CTD–core binding interface showing interactions between the
acidic CTD residues (red) and core residues as indicated.
Noting that most Hfq clusters containing a basic patch on the rim also end in acidic residues,
it was hypothesized that the CTD tip binds the rim. Because the basic patch is essential
for sRNA binding and annealing, direct interaction between the CTD tip and the Hfq core
could explain the previously observed auto-inhibition of the CTD30.
5.4.2 De novo modeling of CTD interactions in the Hfq hexamer
To determine whether the acidic tip of the E. coli Hfq CTD could interact with basic residues
in the core, I used Rosetta FloppyTail12, a de novo modeling approach for disordered regions
of proteins. I updated the original FloppyTail algorithm to model multiple disordered
regions simultaneously and to ensure adequate sampling of backbone degrees of freedom.
Then, I generated and analyzed 30,000 models of the full-length E. coli Hfq hexamer. In the
lowest energy (1%) subset of models, the acidic CTD residues (D97, E99, E100, and E102)
frequently interact with basic residues on the rim (R16, R17, R19 and K47) and in the NTD
(K3) (Figure 5.2B, top). By contrast, K31 on the distal face is not predicted to be contacted by
the CTD, although K31 is highly accessible. This bias accords with prior observations that
the CTD does not displace RNA from Hfq’s distal face30. As anticipated for a disordered
domain, no single conformation dominated the ensemble of models (Figure 5.A.4). Rather,
the acidic CTD tip was found to bind to various combinations of residues in the basic patch
(Figure 5.2C).
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To confirm that I was not simply observing the non-specific collapse of the disor-
dered CTD onto the core, or enriching interactions between highly solvent-accessible polar
residues, I repeated these simulations using a mutant Hfq in which the acidic CTD residues
were replaced with polar or basic side chains (D97R-E99N-E100K-E102N). These mutations
drastically decreased the frequency of predicted interactions between the basic core residues
and CTD residues at positions 97, 99, 100 and 102 in our simulations (Figure 5.2B, bottom),
without increasing predicted interactions between this mutant CTD and solvent-accessible
acidic residues on the Hfq core (D9, E18, E37 and D40).
5.4.3 Acidic CTD specifically binds Hfq rim
To determine whether the CTD interacts with the rim as predicted by our models, we used
fluorescence anisotropy to measure the affinity of core Hfq (Hfq65) for a fluorescently-
labeled CTD peptide, CTD-FITC (Figure 5.3A). CTD-FITC lacks residues 65–72 to avoid
contributions to binding from this region, which packs against the Sm domain as one strand
of the β-sheet. Hfq65 bound to CTD-FITC with a Kd of 2.9 µM Hfq monomer in low salt
buffer (cyan in Figure 5.3B). Binding of the CTD-FITC peptide to Hfq65 was weakened by
mutations in the basic rim residues R16A, R19D and K47A (Figure 5.3B), which frequently
interact with the CTD in the computational models (Figure 5.2B). In contrast, mutation of a
surface-accessible polar residue (Q35A) close to the binding interface (Figure 5.2C, inset),
slightly enhanced CTD binding (Figure 5.3B). Intriguingly, A35 is common in Hfq from
γ-proteobacteria. Finally, a CTD peptide containing the mutated C-terminal tip (RSNKTN)
was not able to bind Hfq65, confirming that the acidic residues on the CTD peptide are
necessary for this interaction (grey in Figure 5.3B).
5.4.4 Low-scoring FloppyTail models identify key CTD interactions
To determine how much core residues that bind the CTD contribute to Hfq’s RNA annealing
activity, we compared the effect of rim mutations on the rate of base pairing between an
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Figure 5.3: (A) Scheme for in vitro binding of fluorescent CTD-FITC peptide by Hfq core. The CTD
linker is shown in purple, the acidic tip in red and the N-terminal FITC as a yellow star. Hfq core is
shown in cyan, with basic rim patches in dark blue. (B) Binding of CTD-FITC to variants of Hfq65
core at 30 °C. 45 nM CTD-FITC was titrated with 0–100 µM Hfq monomer in duplicate, and the
average (±s.d.) was fit to a single-site binding isotherm. (C) Reaction scheme for annealing an
RNA molecular beacon to a target RNA (open bar)25. (D) Progress curves for annealing 50 nM
molecular beacon and 100 nM Target by 50 nM Hfq65 hexamer at 30 °C, measured by stopped-flow
fluorescence. (E) Contribution of core residues to CTD binding. Interaction energy (Expected
Energetic Contribution; EEC) in silico for a core residue in the Rosetta models (solid symbols and
solid line; adjusted R2 = 0.77) or the average annealing rates for Target and Target-A18 relative
to Hfq65 (open symbols and dashed line; adjusted R2 = 0.94) versus experimental CTD binding
energy (∆∆G◦) for each Hfq65 variant. The binding energy, ∆∆G◦ = −RT ln(KMUTd /Kd, reflects
the perturbation to CTD binding by a mutation in Hfq65. The interaction energy in silico or EEC
is defined as the average energy of a tail–core interaction multiplied by the average number of
tail–core interactions per model (Figure 1B, top and Equation 3). The relative annealing rate for
Hfq65 variants, krel = kMUTobs /k
WT
obs , is <1 if the mutated residue is important for RNA annealing.
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RNA molecular beacon and a 16 nt Target RNA by stopped-flow fluorescence spectroscopy
(Figure 5.3C). In the absence of competition from the CTD, the rate of annealing in this
assay depends only on interactions between the two RNAs and the Hfq core. As previously
observed30, Hfq65 is highly active in single-turnover annealing assays (Figure 5.A.5A). The
observed annealing rate was most diminished by the loss of basic residues, especially the
conserved R16A, and relatively unaffected by the mutation Q35A (Figure 5.3D). Similar
results were obtained with Target-A18, which anchors to the distal face (Figure 5.A.5B). The
average relative annealing rates of Hfq65 variants correlated well with the importance of
each residue for CTD binding in vitro (Figure 5.3E), suggesting that the CTD peptide and
the RNA interact with the same residues on the rim of Hfq.
The predictive value of our computational approach was validated by a direct correlation
between the experimentally measured contribution (∆∆G◦) of each core residue for CTD
binding with the predicted Expected Energetic Contribution (EEC) of that core residue
to interactions with the acidic CTD in silico (solid symbols and solid line, Figure 5.3E).
EEC is defined as the average energy of a tail–core interaction multiplied by the average
number of tail–core interactions per model. The absolute binding and simulated interaction
energies cannot be directly compared because the peptide binding assay is performed in
trans rather than in cis, and the Rosetta Energy does not account for entropic contributions
to binding. Nevertheless, amino acids that most strongly impacted the free energy of CTD
binding when mutated, also had larger contributions to CTD binding in silico (solid symbols
and solid line, Figure 5.3E; linear regression p-value=0.078), and had stronger effects on
Hfq65 RNA annealing activity in vitro (open symbols and dashed line, Figure 5.3E; linear
regression p-value=0.020).
5.4.5 Key CTD interactions correlate with activity in other species
The results for E. coli Hfq show that the strength and frequency of CTD–core interactions
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Figure 5.4: (Previous page.) (A) Alignment of modeled Hfq sequences in order of decreasing in
vitro RNA annealing activity. Residues are numbered according to the E. coli sequence. Yellow stars,
residues mutated in this study; red hexagon, last residue in Hfq65; grey box, linker removed in
Hfq-sCTD. (B) Average number of favorable interactions per model for each core residue with at
least one acidic CTD residue in the lowest energy models (≤1%). As in Figure 5.2B. Number of
residues with < 2.0A2 accessible surface area: P. aeruginosa, 10; L. monocytogenes, 25; B. subtilis, 19;
S. aureus, 12. (C) Top-down (proximal face) and side (rim) views of example low-energy models
for each Hfq, as in Figure 5.2C. (D) Relative RNA beacon annealing rate for Target-U6 (boxes) and
Target-A18 (circles) in Hfq vs. no Hfq (relative kobs) versus the specificity of predicted CTDâĂŞcore
interactions (∆EEC) for B. subtilis, S. aureus, L. monocytogenes and E. coli Hfq (blue), and P. aeruginosa
Hfq, which is more active in vitro than predicted by its ∆EEC (red). Annealing data are from Zheng
et al.26.
the linker length. Thus, the proposed mechanism for CTD–core interactions can be used to
predict how the degree of CTD autoinhibition may vary among bacterial Hfq’s. I applied
my de novo modeling procedure to estimate the CTD–core interactions in four other bacterial
Hfqs (Figure 5.4A) for which the genetic function and in vitro annealing activity have been
previously characterized26,45–49. I examined low energy models of each Hfq hexamer, and
compared how frequently acidic CTD residues interact with basic rim and NTD residues
(“on-target”) versus other core residues (“off-target”) (Figure 5.4B,C). This comparison was
quantitatively expressed as the difference in the EEC of on-target and off-target interactions
(∆EEC).
For E. coli Hfq, an active chaperone with a basic rim patch and long CTD, the CTD
tip tended to interact with basic residues on the rim and NTD more often and more
strongly than with other residues, resulting in ∆EEC = 1.11 ± 0.20 REU. This was also
true for Listeria monocytogenes Hfq (∆EEC = 1.08 ± 0.22 REU). In contrast, Bacillus subtilis
(∆EEC = 0.51 ± 0.14 REU) and Staphylococcus aureus (∆EEC = 0.19 ± 0.05 REU) Hfq,
which are inactive in our in vitro annealing assay26, did not exhibit specific CTD–core
interactions. Finally, in models of full-length Pseudomonas aeruginosa Hfq, the CTD adopts
an extended β conformation that wraps over the rim of the hexamer and places the C-
terminal acidic residues near the weakly basic NTDs (∆EEC = 0.30 ± 0.04 REU) (Figure
5.4C). In the absence of the NTD, however, the CTDs dock with R16 and K17 on the rim
(∆EEC = 0.50 ± 0.18 REU). Thus, Hfqs that do not anneal RNA in vitro tend to possess
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shorter, less acidic CTDs that form weaker and less frequent interactions with the basic rim
and NTD in silico (Figure 5.4D). There is a similar trend between ∆EEC and the importance
of Hfq for sRNA regulation in each bacterium14,45–47,49–52.
In the above examples, both the CTD and the core co-vary between different species. I
next asked whether the CTD conferred specificity or strength to CTD–core interactions. I
modeled an Hfq chimera consisting of the highly basic E. coli Sm core, fused to the shorter
and slightly less acidic B. subtilis CTD. In our models, the B. subtilis CTD contacted K3 in the
NTD and R17 on the rim more frequently than E. coli CTD (Figure 5.5A), but contacted R16
and R19, which are functionally very important (Figure 5.2 and Figure 5.3), less frequently
than E. coli CTD (Figure 5.5A). This was corroborated with fluorescence anisotropy results
showing that E. coli Hfq65 binds a BsCTD-FITC peptide about three times more weakly
than its own CTD (8.7 µM vs. 2.9 µM; Figure 65.5B). Although it was shown that a foreign
CTD can bind the core of E. coli Hfq, the “specificity” of this interaction may have been lost.
5.4.6 FloppyTail ensembles capture crystallizable states
So far, FloppyTail has demonstrated an ability to model interaction energies in the E. coli Hfq
CTD with good correlations to in vitro mutagenesis assays, and to be potentially predictive
of in vitro annealing activity of four other Hfqs. So, I next sought structural validation,
in collaboration with Dr. Steven Hardwick (Department of Biochemistry, Cambridge
University). Dr. Hardwick had recently acquired a crystal structure of full-length C.
crescentus Hfq, with sufficient electron density to model the CTD (PDB ID 6GWK).
To ensure that the results were not biased, the calculations were performed without prior
knowledge of the crystal structure. The overall basicity of the rim is conserved between
C. crescentus and E. coli Hfqs 5.2. However, the arginines are distributed more towards the
rim-distal face in C. crescentus Hfq. Among the lowest-energy fraction of models generated
in the simulations (1% of all models, sorted by energy), acidic residues at the CTD of C.
crescentus Hfq were found to frequently form energetically favourable contacts with basic
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Figure 5.5: A chimera of E. coli Hfq core (residues 1–64 E. coli numbering) and the B. subtilis CTD
(residues 65–73 E. coli numbering; QKNVQLELE) was modeled with Rosetta FloppyTail as in Figure
5.2. (A) Average number of energetically favorable interactions (E < 1.0 Rosetta Energy Units)
with at least one acidic CTD residue, per low energy model as in Figure 5.2. Error bars (±1 s.d.)
computed by bootstrap resampling. 14 of the core residues not predicted to interact with the CTD
were solvent inaccessible. (B) Binding of BsCTD-FITC peptide to E. coli Hfq65 core at 30 °C. 45 nM
BsCTD-FITC was titrated with 0–100 µM Hfq monomer in duplicate, and the average (± s.d.) was
fit to a single-site binding isotherm with Kd = 8.7µM. Although the binding strength is three times
weaker than for the E. coli CTD peptide, the rank order for interactions with basic core residues no
longer coincides with their relative importance for RNA annealing in vitro (Figure 5.3E). Therefore,
the B. subtilis CTD may not be optimal for auto-regulating the core of E. coli Hfq.
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residues arginine 18, lysine 19 and lysine 21 on the proximal-rim interface (Figure 5.6A),
even when the basic NTDs were excluded from the model. By contrast, few contacts were
observed to arginines 49 and 50, which are solvent exposed but lie toward the distal side of
the rim. Nearly all the lowest-energy fraction of models had at least one CTD in contact
with the rim, and many of the modelled CTD conformations closely resembled (∼2 Å Cα
RMSD) the crystallized CTD-rim interaction (Figure 5.6B and 5.A.6). In silico mutation of
both arginine 18 and lysine 19 to alanine ablated interactions of acidic CTD residues with
these positions on the core (Figure 5.A.6). These results illustrate the predictive power of
Rosetta FloppyTail and suggest that the crystallized CTD–rim interaction is likely to occur
in solution rather than being an artifact of crystal lattice packing.
5.5 Discussion
It was previously found that the flexible CTD of E. coli Hfq sweeps RNAs from the proximal
and rim surfaces of the Hfq ring by an unknown mechanism30. Because the mechanism
was not known, it was not possible to predict whether other bacterial Hfq CTDs, which
are highly variable in sequence composition and length, would perform similar functions.
In this chapter, computational models and experiments showed that the acidic tip of the
CTD interacts with basic patches on the rim of Hfq, potentially competing with RNA in
vivo. The good agreement between the modeled CTD–core contacts and the contributions of
individual residues to the measured CTD binding energies and to RNA annealing validated
the modeling approach, and further suggested that nucleic acids and the acidic tip of the
CTD interact with the same residues in the Hfq core. As expected for a nucleic acid mimic,
CTD–core interactions were dominated by electrostatics (Figure 5.3).
The Rosetta FloppyTail algorithm, enabled by my advances, provided atomic-scale
insight to the accessible conformations of the disordered N- and C- termini of E. coli Hfq
(Figure 5.2C). Furthermore, I developed a metric, EEC, for assessing disordered–order


















































Figure 5.6: (A) Observed frequency of favourable (E < −2.0 REU) residue-to-acidic-CTD interac-
tions in low-energy FloppyTail models. Top panel; full length Cc Hfq. Lower panel; Cc Hfq with
residues of the Nterminal extension deleted (ÎŤNTE). Upon excluding the NTD in silico, only the
basic core residues retain interactions with the CTD. Error bars show ± one standard deviation,
as computed by bootstrap resampling. (B) Side-byside comparison of crystallized and modelled
CTD-core contacts. The acidic tip residues in the CTD of the adjacent monomer (Chain B, light cyan)
contact the basic rim residues of the monomer in the forefront (Chain A, cyan). For clarity, the NTE
and CTD of chain A, and most of chain B except the last betasheet and CTD are omitted. CTDs,
purple; lysines, skyblue; arginines, royal blue. CTD acidic residues are colored in red..
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more accuracy than commonly used distance cutoffs (e.g. defining residues as interacting
if Cα–Cα or Cβ–Cβ < d)12. The ease of modeling Hfq CTDs with FloppyTail enabled
the study of different bacterial Hfqs. This de novo modeling strategy was able to identify
frequent and specific CTD–rim interactions in L. monocytogenes and P. aeruginosa Hfq, which
act in sRNA regulation and annealing, but not for B. subtilis and S. aureus Hfq (Figure
5.4D), in agreement with in vitro experiments. Finally, FloppyTail was found to recapitulate
interactions observed in crystallo for C. crescentus Hfq. Together, these results suggest
that the FloppyTail algorithm could be generally useful for predicting the interactions of
disordered regions with ordered domains.
Many RNA and DNA binding proteins contain disordered or flexible domains that have
been implicated in cooperativity, autoinhibition and liquid phase separation53–55. Hfq is
an example of an emerging paradigm of autoregulation of nucleic acid binding by nucleic
acid mimic peptides. Other examples in which a disordered CTD autoinhibits RNA or
DNA binding include HTLV-1 NC56, E. coli gyrase57, E. coli ssDNA binding protein58 and
mammalian high-mobility group B159. Unlike HTLV-1 NC, which also remodels RNA, the
Hfq CTD gives rise to dynamic cycling of bound RNAs needed to chaperone sRNA–mRNA
interactions. Our modeling procedure could be utilized to screen disordered domains found
in kinases, such as myosin light chain kinases and protein kinase C60, and nucleic acid







1 10 100 1000

















Figure 5.A.1: Semi-log plot of the lowest observed energy for a given number of attempted high-
resolution moves. The mean lowest energy observed for five simulations is shown in black, with
± one standard deviation filled in gray. The initial broad range of high energies is due to clashes
introduced by replacing centroid representations of side chains with all-atom ones. Within 100











1- select random residue (i)
2- sample δ from U(0°,180°)
3a- set Φi ± δ or Ψi ± δ, or
3b- set Φi ± δ and Ψi-1 ∓ δ
High-Resolution
Repeat 1,000x,







1- select random residue (i)
2- sample δ from U(0°, 4°)
3a- set Φi ± δ or Ψi ± δ, or
3b- set Φi ± δ and Ψi-1 ∓ δ
4- independent side-chain packing
Figure 5.A.2: The FloppyTail algorithm operates in two stages: low-resolution (centroid) and high-
resolution. In the centroid stage, 50,000–100,000 moves are attempted. 95% of the moves are either
(3a, 47.5%) Small or (3b, 47.5%) Shear moves whereas the remaining 5% are minimization moves. A
Small move randomly perturbs either ϕ or ϕ by up to 180°. A Shear move randomly perturbs ϕ or ϕ
by up to 180°and then makes an equal and opposite compensatory move in the preceding/following
angle. The lowest-energy conformation is used as input for the high-resolution state. In the high-
resolution stage, all side-chain atoms are restored and only 1,000 moves are attempted. 93.3% of
the moves are Small or Shear, but with a smaller magnitude (4°) followed by RotamerTrials, or
independent sampling of χ angles for each side chain, 3.3% of moves are minimization moves,
and the final 3.3% of moves are PackRotamers moves, or concerted side-chain repacking (where
chi angles of multiple positions are simultaneously optimized). At the end of the simulation, the
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Density of Tail–Rim Interaction Energies
Figure 5.A.3: Energy densities of the pairwise negative-tail to positive-core residue–residue interac-
tions in all models. The vertical line represents the cutoff used to define an “interacting” pair. Each
distribution has two “bumps”: one at 0 REU for non-interacting residues and one at -2 REU for
interacting residues.
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Figure 5.A.4: A gallery of additional low-energy E. coli Hfq models from either a top-down view
through the proximal pore (right) or side-on view of the rim (left), colored as in Figure 5.2.
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Figure 5.A.5: Annealing of 100 nM Target RNA to 50 nM beacon RNA by Hfq65 and Hfq65 variants
was measured by stopped flow fluorescence at 30 °C in 1 ÃŮ TNK buffer. (A) Observed annealing
constants with 0–200 nM Hfq hexamer. Cyan, Hfq65; orange, Hfq65-Q35A; pink, Hfq65-K47A;
green, Hfq65-R19D; steel-blue, Hfq65-R16A. Rate constants are the average of 5 technical replicates
with standard deviations less than 5%. The vertical dashed line indicates the Hfq concentration
for which annealing progress curves are shown in Figure 5.3D and Panel B. The single turnover
annealing rate reaches a maximum at equimolar concentrations of (Hfq)6:beacon. Higher Hfq
concentrations can inhibit annealing due to random-order binding of RNA substrates and the
formation of Hfq12, which is inactive. (B) Target-A18 (distal) annealed by 33 nM Hfq65 hexamer and
variants on Hfq65 background. The change in fluorescence emission intensity was normalized to
the maximum fluorescence within an experiment. The average of five measurements is shown per
progress curve. All progress curves were fitted to single- or double-exponential rate equations to
























C. crescentus Full-Length Model RMSDs
Figure 5.A.6: The alpha carbon coordinates of each subunit from Hfq hexamers modelled with
Rosetta FloppyTail were compared to the coordinates of the subunit with the greatest number of
resolved residues from the crystallographic structure. (A) Low-energy C. crescentus Hfq models
have a significant population of structures with low-RMSD. (B) N-terminal extension residues were
excluded from the simulation to eliminate NTD–CTD interactions. Excluding the NTD during









Cc Hfq ΔNTD, R18A, K19A
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Figure 5.A.7: Observed frequency of favourable (E < −2.0 REU) core residue-to-acidic CTD inter-
actions in low-energy FloppyTail models for Cc Hfq excluding the N-terminus (top panel) and a
variant with two rim residues mutated to alanine (R18A, K19A; bottom panel). Mutating out the
positive rim residues obviates interactions in silico. Error bars show ± one standard deviation, as
computed by bootstrap resampling.
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Re-Design of Protein Crystals
This chapter contains material that is submitted to Acta Crystallographica Section D.
If accepted and published, then this chapter will contain material that is
reproduced with permission of the International Union of Crystallography, as per
the statement of author rights.
6.1 Overview
Substantial advances have been made in the computational design of protein interfaces
over the last 20 years. However, the interfaces targeted by design have typically been stable
and high affinity. Here, I report the development of a generic computational design method
to stabilize the tenuous interactions at crystallographic interfaces. Initially, I analyzed
structures reported in the Protein Data Bank (PDB) to determine whether crystals with
more stable interfaces result in higher resolution structures. I found that, for twenty-two
variants of a single protein, crystallized by a single individual, Rosetta score correlates
with resolution. I then developed and tested a computational design protocol, seeking
to identify point mutations that would improve resolution, on a highly stable variant of
staphylococcal nuclease (SNase ∆+PHS). Only one of eleven initial designs crystallized,
forcing me to re-evaluate my design strategy and base my designs on an ensemble of
protein backbones. Using this approach, four of the seven designs crystallized. Collecting
diffraction data for multiple crystals per design and solving crystal structures, I found
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that designed crystals improved resolution modestly and in unpredictable ways, including
altering crystal space group. Post-hoc, in silico analysis showed that crystal space groups
could have been predicted for four of six variants (including WT), but that resolution did
not correlate with interface stability, as it did in the preliminary results. My results show
that single point mutations can have significant effects on crystal resolution and space
group, and that it is possible to computationally identify such mutations, suggesting a
potential design strategy to generate high-resolution protein crystals from poorly diffracting
ones.
6.2 Introduction
X-ray crystallography is still the primary method for acquiring atomic-scale structural
information about biological macromolecules such as proteins, and it is indispensable
for gaining functional and mechanistic insights across biological and pharmacological
disciplines1. However, because of its highly unpredictable nature, crystallography is viewed
more often as art than as science–a fact reflected by the low rate of success in large-scale
protein crystallization efforts (∼10–20%)2,3. Sometimes, when proteins produce diffraction-
quality crystals, the data may be of low quality or unsolvable. Even when a crystal structure
can be determined, some regions might be missing. For example, approximately 23% of the
crystal structures reported to the PDB diffract to a resolution of ≥2.5 Å4. At a resolution
of 2.5 Å, the backbone, side chains, and small molecules can be fit with a reasonable
degree of precision to the electron density; however, key features such as the placement of
water molecules or alternate side-chain conformations may be less certain. At even lower
resolutions (3–6 Å), ligands or side chains and even the main chain may not be fit reliably5–8.
An inability to resolve ligands, water molecules, small molecules, or side-chain interactions
prevents accurate understanding of catalytic mechanisms, drug-protein interactions, or the
organization of certain macromolecular complexes, and precludes computational design
from using natural proteins as input.
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Historically, rational design has been used to overcome various degrees of protein
recalcitrance to crystallization, from improving existing crystals to generating new ones9.
The variety in strategies has been quite broad. Some strategies can be applied when
only the protein sequence is known, even before crystal trays are laid, e.g. deleting loops
or regions of low sequence complexity10, or by identifying stabilizing mutations from
homologous sequences11, surface entropy reduction (SER)12, or de novo crystal design13.
Other strategies have focused on improving an existing crystal, such as through the rational
engineering of crystal contacts14,15. Of the above strategies, all but SER must be tailored to a
specific target protein. The necessity for protein-specific approaches is somewhat surprising
considering that the underlying physics is universal. For example, Fusco et al. identified
two generic mechanisms underlying crystal formation in their analysis of 182 proteins in
1,536 crystallization conditions16. In principle, a reliable and general method for enhancing
the resolution of poorly-diffracting crystals through rational and computational design
should exist.
Here, I report my attempts to develop resolution-enhancing computational design of
protein–protein interactions at crystallographic interfaces. I began by identifying for the
physical determinants of high-resolution protein crystals. This lead me to identify a positive
correlation between resolution and crystal lattice stability (the Rosetta-determined score
of the asymmetric unit and the unique protein–protein interactions defining the crystal
lattice). A Rosetta protocol was then developed to identify stabilizing (resolution-enhancing)
point mutations. The protocol was benchmarked in silico against rationally-engineered
protein crystals17. I tested my protocol experimentally by designing, cloning, expressing,
purifying, and crystallizing variants of staphylococcal nuclease (SNase). I found that
variants designed on a single, fixed backbone crystallized rarely (1/11), whereas variants
designed on an ensemble of backbones crystallized more readily (4/7). Comparison of
the highest-resolution shells for collected diffraction data (determined by CC1/2) revealed
only minor improvements in resolution (∼0.05 Å) for three of five designs that crystallized.
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Surprisingly, two of the resolution-enhancing designs altered the crystal space group. An
analysis of my efforts shows that space group changes could have been predicted for three
of the five designs, but that crystal lattice stability does not correlate with resolution for my
test protein.
6.3 Methods








6.3.1 Curation of crystal datasets
Three protein structure datasets were constructed on October 10th, 2016, from the Protein
Data Bank4 (PDB), termed the: “PDB representative”, “SNase”, and “Mizutani” sets.
To generate the PDB representative set, I first generated three lists of PDB IDs and then
took the intersection of the lists. The first list ensured that I only analyzed non-redundant,
reasonable-quality protein structures. Using the PISCES server18, I generated a list of
non-Cα-only X-ray structures in the PDB adhering to the following criteria (culling by
chain):
• 25% maximum sequence identity,
• resolution better than 3.0 Å,
• R-value < 0.3, and
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• proteins comprising more than 40, but less than 10,000 residues.
This list, pisces.txt, contained 10,886 PDB IDs. Next, I generated a second list to limit
my analysis to solely crystallographic protein–protein interactions. Using the advanced
search option on the PDB website, I generated a list of PDB structures with monomeric
stoichiometry and only a single chain in both the biological and asymmetric units. This
list, pdb.txt, contained 36,899 PDB IDs. Finally, I generated a third list to exclude struc-
tures containing many ligands or non-protein atoms. Starting with the PDB IDs from the
pisces.txt list, I used a Python script (1-parse-pdb-remarks.py) to filter PDB IDs, select-
ing for the absence of REMARK 465/470/475/480 records, which indicate missing atoms, and
a fraction of non-HOH HETATM records greater than 0.1. This list, missing_or_nonhet.txt,
contained 873 PDB IDs. I took the intersection of my three lists of PDB IDs as my “PDB
representative” set; this was performed in R using the merge-three-lists.R script. The
final list contained 379 PDB IDs.
Separately, to generate the SNase set, I used a new PDB advanced search to select for
X-ray structures with UniProt Accession ID: P00644, in addition to the above criteria for
stoichiometry, biological unit, and asymmetric unit, but not culling for sequence identity,
R-value less than 0.3, absence of atoms or presence of ligands. The SNase set contained 256
PDB IDs, which were not present in the PDB representative set.
Finally, the Mizutani set was simply composed of the 21 structures of diphtine synthase
deposited by Mizutani et al. in their study of rational crystal contact engineering17. These
structures were not present in either the PDB representative or SNase set.
6.3.2 Modeling of crystals
In this study, I sought to computationally quantify crystallographic protein–protein inter-
actions. To that end, proteins were modeled in three states: (1) as a crystal, including all
symmetry mates within 12 Å, (2) as a collection of pairwise interfaces, and (3) as a monomer.
These states were constructed for each dataset. Furthermore, pairwise interfaces were
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analyzed with the Evolutionary Protein–Protein Interface Classifier19 (EPPIC) to verify that
the interactions I was assessing were crystallographic and not biological.
PDB Representative: Monomers were downloaded from the PDB and energy mini-
mized using Rosetta, weekly version: v2018.24. To ensure accurate energy calculation and
because Rosetta cannot model all ligands/co-factors/etc., HETATM records were omitted.
Energy minimization was performed by the FastRelax protocol20,21 with the following
command line:
relax.linuxgccrelease -l list.txt -relax:ramp_constraints -relax:
constrain_relax_to_start_coords -ex1 -ex2 -use_input_sc -flip_NHQ -
no_optH false -nstruct 10 -out:pdb_gz
where list.txt contained the PDBs. Individual crystallographic interfaces were generated
and analyzed using the pre-compiled EPPIC command-line interface (version 3.0.5):
epicc -i 1ABC.pdb -l -p -s
where 1ABC.pdb is any PDB. Any PDB ID with an interface predicted by EPPIC to be
biological and not crystallographic was excluded from further analysis if the corresponding
PDB entry or supporting literature indicated that the biologically relevant state was not
monomeric (as I only wished to study crystallographic interactions). Crystals were modeled
using the same protocol, except this time the -symmetry:symmetry_definition CRYST1
flag was included to enable modeling of the asymmetric unit and all symmetry mates
within 12 Å as previously described22. The energy of crystallization was computationally
determined, using the weekly PyRosetta23 release, v2018.24, and the November 2016 version
of the Rosetta scoring function24,25. The script score_crystal_interfaces_parallel.py
evaluated the energy of each crystallographic interface, which was later combined with
the energy of the monomer to yield the crystal energy (see Results). After excluding
four structures that could not be modeled with my approach and twelve structures that
accidentally included biological interactions in the crystal, 364 PDBs were analyzed from
the PDB. These PDBs are listed in: pdb-representative-rosetta.txt.
SNase: As above, SNase monomers were downloaded from the PDB and energy min-
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imized using Rosetta v2018.24. Unlike above, HETATM records were retained, because the
nucleotide analog thymidine-3’,5’-diphosphate (THP) bound by the enzyme makes im-
portant crystal contacts. The ligand geometry was fixed in simulations and read from the
PDB Chemical Components Dictionary. Energy minimization was performed as described
above. Individual crystallographic interfaces were not generated and analyzed using EPPIC
because SNase is known to be a monomer. Crystals were modeled and crystal energies
were computed as described above.
Mizutani: Modeling of the 21 diphtine synthase structures from Mizutani et al. was per-
formed similarly to modeling of the PDB and SNase crystal structures, as described above.
The only exception being that diphtine synthase is naturally a dimer, so during energy
evaluation the two dimeric chains were treated as a monomer and only crystallographic,
not biological, interfaces were considered. As with SNase, because the biological state is
known, EPPIC was not used to generate or analyze crystallographic interfaces. Crystals
were modeled and crystal energies were computed as described above.
6.3.3 Forward design of dipthine synthase
To determine the computational design approach most likely to be experimentally success-
ful, I tested several strategies on diphthine synthase. Since the resolution is reported for
twenty variants, I asked if a particular design strategy can predict resolution-improving
variants. This approach is known as forward design. The energy-minimized structure
of wild-type diphthine synthase (PDB ID: 1WNG) was used as input for design. At each
position mutated by Mizutani et al. (26, 49, 54, 65, 69, 79, 140, 142, 146, 171, 173, 187, and
261), each amino acid except cysteine or proline was tested. I attempted to accommodate
the mutation by permitting varying degrees of freedom in the wild-type crystal form (simu-
lated by Rosetta Symmetry). These different design strategies ranged from only permitting
neighboring side chains to repack to re-docking in the crystal lattice (see Results). All energy
calculations were performed in the crystal form and averaged over ten repeats.
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6.3.4 Computational design of SNase
Design for SNase variants initially followed my most successful diphthine synthase ap-
proach: introducing a point mutation at a position followed by repacking of side-chains
followed by energy minimization of side-chain and backbone dihedral angles. An energy-
minimized structure of ∆+PHS SNase (PDB ID: 3BDC) was used as input. The geometry
of the THP ligand was held fixed during the simulation and defined by a Rosetta params
file derived from the PDB coordinates. Later, I introduced an ensemble of 200 perturbed
backbones generated by Rosetta Backrub26 as it has been shown that interface ∆∆G pre-
diction is more accurate when using an ensemble of backbones rather than just a single
input27. The following steps were repeated for each member of the backbone ensemble and
for every designable surface position, defined as residues having a Cα–Cα distance under 8
Å across any crystallographic interface. First, the position was mutated to one of eighteen
amino acids (cysteine and proline were excluded). Then, the crystal form was generated
using Rosetta Symmetry in the wild-type space group and unit cell dimensions. Finally,
side-chains were repacked to accommodate the mutation in the crystal form. The error in
this modeling was calculated across the ensemble of 200 backbones, instead of by repeating
the simulation ten times.
6.3.5 Cloning, expression, and purification of proteins
Point mutations were introduced by Quikchange mutagenesis28 into the highly stable
∆+PHS variant29, expressed in E. coli BL21/DE3 cells transformed with the pET-24a+, and
purified as previously described30.
6.3.6 Protein Crystallization
Crystals of ∆+PHS and its variants were grown by the hanging drop vapor-diffusion
method at 277 K. The reservoir solution varied, ranging in pH from 6–9, with 20–40% (v/v)
2-methyl-2,4-pentanediol (MPD), either 3 or 2 molar equivalents of THP, either 2 or 1 molar
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equivalents CaCl2, and 25 mM potassium phosphate. The protein concentration varied
across variants, but was always mixed in a 1:1 ratio with the reservoir solution to make
the drop. Conditions are detailed for each crystal in Supplemental Table 6.A.1. Crystals
typically appeared after one week, were harvested with Hampton Research CryoLoops™
on CrystalCap™ Copper HT magnetic sample mounts, and were immediately flash-cooled
in liquid nitrogen. Crystals were stored at 77 K until data collection.
6.3.7 Data collection and structure determination
X-ray diffraction data were collected for single crystals at 77 K using a Rigaku FR-E Super-
Bright rotating anode X-ray generator and a Rigaku DECTRIS PILATUS 200K pixel array
detector. Diffraction data were indexed, integrated, and scaled using the XDS program
package31. Phasing, modeling building and model refining was performed using PHENIX32.
Phasing was performed by molecular replacement in PHASER33 using the search model
3BDC, with solvent-exposed or mutated side chains truncated to the Cα position to avoid
biasing side-chain placement at crystal contact sites. Side chains were rebuilt using COOT34:
initial placement was performed using the Mutate and Autofit function and followed by
manual refinement. Whole-structure refinement and water placement was performed using
phenix.refine35 and phenix.rosetta_refine36. Data collection and refinement statistics
are shown in Supplemental Table 6.A.2. Crystal structures deposited to the PDB include
models 6OK8 (K127L), 6OK9 (K133M), and 6OKA (Q123D).
6.4 Results
The primary goal in this effort was to develop a broadly applicable, Rosetta-based computa-
tional method for crystal contact design, with the goal of systematically predicting single
point mutations that could enhance resolution. To this end, I first asked whether or not









































































Figure 6.1: Caption follows on the next page.
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Figure 6.1: (Continued from previous page.) Rosetta score correlates with resolution when com-
paring crystals of the same protein varying only by point mutations. The per-monomer crystal
scores (i.e. the score of the monomer plus all crystallographic interactions, which is the minimal
interacting unit required to generate the crystal) and crystal resolutions are compared for three sets
of protein structures. The PDB-representative set (A) samples 364 monomers with distinct sequences
and shows no relationship between score and resolution. The SNase set (B, excluding an outlier
at 2.5 Å) compares only crystals of Staphylococcal aureus nuclease variants, attempting to rule out
the protein as a variable, but still there is no trend. Finally, the dipthine synthase set (C) compares
crystals that vary only by a point mutation, ruling out most extrinsic variables, and score correlates
with resolution.
6.4.1 Rosetta score correlates with resolution, when other variables are con-
trolled
With over 129,000 crystal structures of biological macromolecules4, the PDB provides a
trove of data that can be used to determine whether or not Rosetta score correlates with
the resolution of protein crystals. To ensure a fair comparison, structures must be first
energy-minimized in the Rosetta scoring function using the Rosetta FastRelax protocol20,21.
As FastRelax runtime scales with protein size, testing every structure in the PDB is not
feasible. Furthermore, some structures are overrepresented in the PDB, which might bias
analyses. Instead of analyzing all structures, I selected a diverse and representative subset
of the PDB containing 364 structures, which had a maximum sequence identity of 25%,
a resolution better than 3 Å, R-values less than 0.3, and featured only crystallographic
interactions (fully described in Methods). For every structure in the set, I generated all
symmetry-mates within 12 Å using Rosetta Symmetry22 and energy minimized this “crystal”
form ten separate times using the default FastRelax protocol, which features four cycles of
minimization each with progressively weaker harmonic constraints to prevent substantial
deviation from the starting coordinates. Separately, I energy minimized the monomeric
form of the protein, which was also the asymmetric unit and the biologically-relevant unit. I
approximated the energy of the crystal as EC = ⟨Em⟩+ 12 ∑i⟨Ei⟩, where ⟨Em⟩ is the average
Rosetta score of ten energy-minimized monomers and ∑i⟨Ei⟩ is the average Rosetta score
of interface i in the crystal form, summed over all interfaces within 12 Å of the asymmetric
unit. Hence, EC represents that energy of the minimal unit required to generate the crystal.
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The relationship between resolution and score is shown in Figure 6.1.
I initially found a slight anti-correlation between resolution and score for the represen-
tative PDB set: low-resolution structures had lower scores than high-resolution ones. I
hypothesized that this unexpected result was caused by my inability to control for the many
variables that affect resolution that are not captured by Rosetta score (e.g., how the highest
resolution-shell cutoff was decided, user handling, the content of the reservoir solution,
etc.). To test this hypothesis, I analyzed two additional sets of crystal structures in the same
manner as the PDB representative set. The first additional set I analyzed controlled for the
protein as a variable. I searched for a small, globular protein, with many structures in the
PDB that differed only slightly from each other, but that spanned at least 1 Å in resolution.
Of the multiple proteins fulfilling these criteria, I selected SNase, which had 256 crystal
structures. I used Rosetta Symmetry and FastRelax to generate ten energy-minimized
monomers and crystals, and computed the energy of the crystal as described above. The
SNase set did not show a strong correlation between resolution and score (Figure 1B).
To further control extrinsic variables, I analyzed twenty-two variants of a single protein
(diphthine synthase) that had been previously cloned, expressed, purified, crystallized and
the crystal structures solved by one scientist in a crystal engineering study by Mizutani et
al.17. Despite the variants only differing by a point mutation or two, the crystal structures
spanned a range of resolutions from 1.5 Å to 2.3 Å. The structures were energy minimized
and the crystal energies calculated in a similar fashion as for the previous two sets. The
Mizutani set showed a strong correlation (R2 = 0.8) between Rosetta score and resolution
(Figure 6.1).
6.4.2 Rosetta can identify resolution-enhancing mutations
Since low score corresponded to high resolution for the Mizutani set, I next sought a fast
computational design strategy that could identify resolution-enhancing mutations from the
wildtype (WT) crystal structure. I tested six strategies on the Mizutani set in an approach
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known as forward design. Using the energy-minimized crystal form of the wild-type protein
as input, I introduced point mutations one-by-one at the positions engineered by Mizutani et
al. I then optimized side-chain dihedral angles while keeping the backbone fixed (side-chain
repacking)37. Following repacking, I tested six design strategies with varying degrees of
freedom: (1) I did nothing else before evaluating the score, (2) I applied gradient-based
energy minimization on side-chain dihedral angles, (3) I applied gradient-based energy
minimization on side-chain and backbone dihedral angles, (4) I applied gradient-based
energy minimization on side-chain dihedral angles and the relative position/orientation of
the protein and its symmetry mates, (5) I applied gradient-based energy minimization on
side-chain and backbone dihedral angles and the relative the relative position/orientation
of the protein and its symmetry mates, and (6) I sampled the relative position/orientation
of the protein and its symmetry mates, translating in steps of 0.05 Å and rotating in steps
of 0.1 degrees, followed by energy minimization as in Strategy 5 over four Monte Carlo
cycles. All gradient-based minimization was run until convergence was achieved, defined
as a change in Rosetta score of less than 0.00001 following an iteration of minimization, or
for 200 iterations. Each strategy was tested ten times to assess error. The forward design
results for all strategies are shown in Supplemental Figure 6.A.1.
I found Strategy 3 (minimizing on side-chain and backbone torsion angles after repack-
ing) to be the most successful. Figure 6.2 compares the predicted change in score between
each variant and WT diphthine synthase for Strategy 3. This approach successfully predicts
6 of 17 (35.3%) resolution-enhancing mutations identified in the paper. In addition to these
six, this approach predicts 46 other mutations to have lower energy than WT and thus could
be potentially resolution-enhancing; however, these were not experimentally characterized
by Mizutani et al., so it is unclear if these predictions are correct. Assuming a worst-case
scenario where these uncharacterized point mutations do not enhance resolution-enhancing
mutations, this design approach would predict 6 resolution-enhancing mutations out of




































Repacking with Rotamer and Backbone Minimization
Figure 6.2: Forward design on dipthine synthase suggests that Rosetta can successfully identify
mutations that improve or worsen resolution. The figure plots the difference in score (in the crystal
form) between WT and various designs versus the experimentally determined resolution17, with the
dashed lines indicating the WT values. The black points are mutations whose score correctly predicts
the sign of the resolution change (i.e. better than WT score results in better than WT resolution
and vice versa) whereas the hollow points are mutations whose score incorrectly predicts resolution
change. Standard deviations in score are calculated from 10 repeats of the design simulation.
historical protein interface design success rates, which are typically under 10%38.
6.4.3 Rosetta-designed crystals slightly improve resolution
To determine whether my design approach was applicable to other proteins, I tested
it on a model system: ∆+PHS, a user-friendly, highly stable variant of staphylococcal
nuclease (SNase)29. I identified candidate designable residues at crystallographic interfaces
as those with a Cα–Cα distance under 8 Å to neighboring symmetry mates. At each
position, I introduced a point mutation followed by side-chain repacking and energy
minimization of side-chain and backbone dihedral angles. I selected eleven designs for
experimental characterization. However, of the eleven, only a single variant crystallized
in conditions where the WT protein normally crystallizes. Since I wanted my approach to
yield crystals without having to reoptimize crystal growth conditions, I sought to improve
the crystallization rate of my designs. To this end, I introduced a step to generate backbone
diversity before design. I drew inspiration from recent work showing that interfacial ∆∆G
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calculations are more accurate when the change in energy is computed across an ensemble
of models27. Since backbone diversity was introduced beforehand, I was more conservative
in my approach and I followed the introduction of point mutations with only side-chain
repacking (Strategy 1). From the second round of design, I identified seven possible variants,
but since two overlapped with those found in the first round, only the five new variants
were experimentally characterized. With this design approach, four of the seven variants
yielded crystals in WT-like conditions; thus, designing on an ensemble of structures had
improved my crystallization rate from 9% to 57%.
Next, I determined the resolution of the diffraction data collected for my variants and
compared it to that of the WT protein. To control for differences across crystals, I collected
full diffraction data sets for at least three crystals of each variant (up to a maximum of
fifteen), depending on the propensity of each variant to form diffraction-quality crystals. The
K127L variant, in particular, affected crystal growth and nucleation significantly, yielding
larger crystals across more conditions than the other variants. I then indexed, integrated,
and scaled the data sets using XDS. The most likely space group was determined by
POINTLESS39. For all variants except K64R and K127L, this was the WT space group (P21).
I found that K64R crystallized in P212121 and K127L crystallized in P41, the third and second
most common space groups for SNase crystals, respectively. In total, I were able to process
the data for 37 of the 43 crystal diffraction patterns collected, with the remaining six datasets
failing to index due to issues such as ice rings or poor spot profiles. I report a summary of
the collected and processed diffraction data in Supplemental Table 6.A.1.
Following processing with XDS, I identified the highest resolution shell as the shell
with the highest resolution still having a significant CC1/2 (t < 0.01). I used CC1/2, or the
correlation between intensities when the data is split in half, to select the highest resolution
shell because it provides a rigorous statistical cutoff40. To compute significance I calculated
a t-value, t = r
√
n−2
1−r2 , where r is the CC1/2 value and n is the number of reflection pairs















































Highest Resolution by CC1/2
Figure 6.3: Distributions of the highest resolution shell show that some designs improve on WT
resolution. Data were collected from multiple X-ray diffraction experiments and determined by
significant CC1/2 according to Student’s t-test. Boxplots show the median resolution ± one quartile.
Open circles indicate the average resolution. The dashed line is the average WT resolution. Designs
K127L, K64R, and Q123D have higher average resolution than WT.
of freedom41. I found that, on average, three of the five designs (60%: Q123D, K64R, and
K127L) achieved a higher resolution than WT (Figure 6.3). However, the improvement was
minimal (<0.05 Å). In general, variant resolutions fell within a very narrow range: 1.67–1.85
Å, the width of which was only slightly greater than the range typically spanned by the
resolutions of multiple crystals from the same variant (∼0.1 Å).
6.4.4 Rosetta-designed crystals do not behave as predicted
Intrigued by the unexpectedly small variation in resolution between designed variants, I
solved the crystal structures of several candidates to ask whether there was an underlying
structural basis for the changes in resolution. I discuss the variants below, grouped by their
observed effects on SNase crystallization, and provide a general summary of observations
across all variants.
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Figure 6.4: Q123D design (green) predicts the correct interaction type, but the incorrect interaction
residue. In the design, residue D123 is predicted to form an electrostatic interaction with residue K71’
(’ indicates symmetry mate), improving on the WT Q–K interaction (pale yellow). However, this
interaction is missing in the density and crystal structure of the variant (both orange; the 2mFo-DFc
map contoured at 1.5σ for the Q123D variant crystal structure is carved within 2 Å of residues
71, 84, and 123). In place of the Q123–K71 interaction, D123 hydrogen bonds to K84, which also
non-covalently interacts with the nucleotide analog (thymidine-3’,5’-diphosphate, THP) bound in
the SNase active site. In this figure, each residue belongs to either the asymmetric unit or a different
symmetry mate. Key interactions with atom-pair distances under 3.5 Å are shown as dashed lines.
6.4.4.1 Q123D and Q123E
In silico, the Q123D design strengthened the crystallographic interface by introducing an
electrostatic interaction between D123 in the asymmetric unit and K71 in a neighboring
symmetry mate. Upon solving the crystal structure, I found minor changes (less than 0.5
Å RMSD) in the backbone conformation (Supplemental Figure 6.A.2). Analysis of the site
around the Q123D mutation revealed that residue D123 interacted with residue K84 of a
neighboring symmetry mate (with a 3.1 Å distance between the lysine nitrogen and aspartic
acid oxygen), instead of K71 (Figure 6.4). This result is in contrast to the WT structure,
where residue K71 interacts with Q123 (3 Å distance between the corresponding oxygen and
nitrogen atoms) and K84 solely interacts with the phosphate oxygen of THP (Supplemental
Figure 6.A.3).
Although I was unable to solve the crystal structure for the Q123E variant due to
twinning and the presence of ice, I expect a similar interaction to be occurring. This
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Figure 6.5: Superposition of the designed (green) and crystallized (orange) K133M structure. The
2mFo-DFc map is contoured at 1.5σ and carved within 2 Å of residues 8 and 133. The designed
packing interaction does not occur in crystal, instead the side chains occupy alternative rotamers.
supposition is supported by the observed average resolutions, which are quite similar to
the WT protein: Q123D slightly improves (by 0.01 Å) resolution whereas Q123E slightly
worsens resolution (by 0.02 Å).
6.4.4.2 K133M
Like Q123E and Q123D, the K133M variant did not significantly alter resolution with
respect to the WT protein and resulted in minimal backbone movements (0.17 Å backbone
RMSD, Supplemental Figure 6.A.2). The design was favored in silico because it replaced an
unfavorable electrostatic interaction between K133 and H8 with a van der Waals contact
between M133 and H8, while also slightly reducing the entropic cost of forming that crystal
contact (Figure 6.5). However, the K133M crystal structure revealed that, although the
interface had compacted slightly, the side chains were too distant to interact. Compared to
the design, the minimum distance between M133 and H8 in the crystal grew from 3.6 Å to
5.3 Å. This lack of interacting side chains likely explains the minimal effect of this mutation
on crystal resolution.
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6.4.4.3 K64R and K127L
The variant K127L produced the highest-resolution crystals in my study, though it did so
in a manner not predicted by design: it altered the crystal space group. The WT protein
crystallizes in the space group P21, and, in this crystal form, K127 forms a salt bridge
with the THP molecule bound in the neighboring SNase active site. When this lysine is
mutated to leucine, the salt-bridge interaction cannot form, destabilizing the P21 crystal
form. Instead, the designed protein crystallizes in P41, a higher symmetry space group,
where L127 packs against a neighboring loop by forming backbone interactions with K28
and G29. In this space group, K71 replaces K127 as the interacting partner of the THP in
the crystal form, suggesting that the interaction of the substrate phosphate groups with a
positively-charged side chain might be useful for SNase crystallization (Figure 6.6).
In addition to the space group change, the K127L variant had the largest backbone
motions of all variants. These motions are in the loop region (residues 114–118) that
precedes the α-helix containing L127. They occur when residue K116 shifts from contacting
the neighboring molecule in the crystal to make contacts to the bound nucleotide analog
instead.
The other variant that improved resolution in my study, albeit with a sample size of
one, was K64R. Although I was unable to solve a crystal structure due to problems with
twinning and the presence of ice, I was able to determine from the diffraction data that K64R
(like K127L) resulted in a change in space group, going from P21 to the higher symmetry
space group P212121. To gain structural insight as to why this variant and space group
might lead to higher resolution, I aligned my K64R model to a different SNase structure
crystallized in the same space group (PDB ID: 5KEE) and applied the symmetry operations
necessary to generate the neighboring symmetry mates, using unit cell dimensions from
the diffraction data. I then used Rosetta’s FastRelax protocol to alleviate any clashes that
might have been introduced. I observed two possible hydrogen bonding interactions for
171
Figure 6.6: The variant, K127L, which yields the highest-resolution crystals, crystallizes in a higher
symmetry space group (P41) than WT (P21) because it breaks an electrostatic contact central to a
crystallographic interface in P21. (A) In the K127L crystal, the previous K127–THP salt bridge was
retained, albeit with a different lysine residue (71). The 2mFo-DFc map is contoured at 1.5σ and
carved within 2 Å of residues 71 and the THP molecule. (B) The new crystallographic interface
containing L127 is well-resolved in density, and features non-specific side-chain–backbone contacts.
The 2mFo-DFc map is contoured at 1.5σ and carved within 2 Å of residues 28, 29 and 127.
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R64 that might account for this change in space group: one with the carboxylic acid of E135
of a neighboring symmetry mate and another with the backbone carbonyl of the oxygen of
the same residue (Figure 6.7).
6.4.5 Retrospectively: Rosetta score recovers space group changes, but not res-
olution
Since I did not include the possibility of space group changes in my design protocol, yet I
observed changes for two variants, I retrospectively asked whether Rosetta could recover
the correct space group (Figure 6.8) by modeling and scoring each variant and the WT in
each of the three most popular SNase space groups. For four out of six crystals (including
WT), I found that Rosetta could correctly predict the space groups. Rosetta failed to predict
the correct space group changes for the K127L variant, yielding P212121 as the lowest
scoring space group (when the actual space group was P41), and for the K64R substitution,
yielding P21 as the lowest scoring space group (the actual space group was P212121).
Finally, I asked whether the Rosetta score of the solved crystal structures correlated with
the resolution, as I found to be the case for the engineered variants studied by Mizutani et
al.17. I analyzed the crystal structures of my designs as previously described. Surprisingly, I
found an anti-correlation between score and resolution (Figure 6.9), although it should be
noted that this resolution range only spans ∼0.1 Å, whereas ∼0.8 Å was spanned by the
crystal structures from Mizutani et al. (Figure 6.1).
6.5 Discussion
I attempted to develop and validate a generic computational method for protein crystal
contact design to engineer crystals that yield high-resolution structural information. Probing
the PDB, I found that Rosetta score correlated with crystal resolution when accounting
for common external variables relevant to crystallization. Using data from an existing
study in crystal engineering17, I developed a design approach that recapitulated resolution-
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Figure 6.7: Models (orange) of the possible K64R interactions in the P212121 space group show two
new possible electrostatic interactions, with either the side-chain or backbone atoms of glutamic acid
135 in the neighboring symmetry mate (indicated by the ’). Residue K64 was not strongly interacting
in WT, showing multiple possible rotameric states in electron density and missing density for some
atoms (Supplemental Figure 6.A.4). Thus, the introduced R64–K78’ interaction in the design (green)
was intended to be stabilizing.
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Q123E, Δ=6.5WT, Δ=6.2
































































































Figure 6.8: Scores of designs in the three most popular space groups for SNase. The lowest scoring
space group is the experimentally observed space group in four out of six cases. For each design,
average scores are shown ± one standard deviation, computed over ten energy-minimized structures
in P21, P212121, and P41. The experimentally observed space group is indicated by an open circle.
The designs are ordered by the score difference, ∆, between the lowest scoring and second lowest
scoring space group. The ∆ value was greater on average for the designs crystallizing in P21 (6.3
REU vs. 3.6 REU). For, the two designs (K127L and K64R) that did not crystallize in P21, the correct



























Figure 6.9: Ex post facto analysis shows an unexpected anti-correlation between resolution and score
when the score is derived from the solved crystal structures of the designs. Error bars show the
standard deviation in resolution (from collecting and analyzing multiple diffraction patterns) and
score (from ten repeated energy-minimizations).
enhancing mutations at a rate of at least 11.5% (and at best 35.3%). I tested my design
approach on a model SNase system, ∆+PHS, and found that my initial approach only
resulted in one crystallizable variant out of ten, so I improved my approach by designing
on an ensemble of backbones to increase this ratio to four in five. Finally, I solved the crystal
structures of several of my designs but unfortunately observed little to no improvement in
resolution. Post-facto analysis revealed that (1) improvements in resolution came primarily
from changes in space group and (2) Rosetta score of designs was not predictive of crystal
resolution.
6.5.1 Point mutations affected side-chain interactions and space groups
In general, when all variants were compared to both the WT and predicted design structures,
the changes in the fold of SNase were undetectable, but there were detectable changes in
side-chain interactions at the crystallographic interfaces. First, there were minimal changes
in backbone structure, as anticipated for variants that differ by only point mutations
at surface residues. The maximum observed root-mean-squared deviation (RMSD) for
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backbone atoms (N, C, CA, O) between the designed model (or WT, since the backbone
was fixed during design) and variant crystal structure was 0.53 Å for the variant K127L,
with all other variants having lower backbone RMSD to their respective designed model
(or WT, Supplemental Figure 6.A.2). Second, all mutations had some unpredicted effects on
the interactions at the targeted crystallographic interface. These effects ranged from slight
differences in side-chain rotameric states to entirely new interfaces. The smallest number
of differences was observed in the K133M variant, where only a few side-chain dihedral
angles differed from the designed structure and the interface was not greatly perturbed in
general (Figure 6.5).
The greatest difference I observed was that two variants crystallized in higher symmetry
space groups than WT (P21): K64R crystallized in the space group P212121 and K127L
crystallized in the space group P41. Several observed improvements in resolution were
seen for this additional symmetry, such as a consistently higher I/σ value (a measure of
the information content) over all resolution shells (Supplemental Figure 6.A.5). The space
group change for K127L was driven by breaking the WT lysine–THP contact across one
crystallographic interface (Figure 6.6), whereas the driver for the space group change of
K64R was not definitively determined. The K64R substitution was desired because, in the
WT space group (Figure 6.7), it introduced a putative electrostatic interaction between a
terminal amino group of R64 and the carbonyl oxygen of K78 of a symmetry mate. The
substitution did not disrupt any contacts, as K64 was not resolved in the electron density of
the WT crystal structure (Supplemental Figure 6.A.4); however, this alteration still resulted
in a change in space group. Since I was unable to solve a crystal structure for this variant, I
resorted to modeling K64R in the new space group. My models hinted that this space group
might be preferred over the WT because R64 can potentially form a hydrogen bond with
E135 via both side-chain–side-chain and side-chain–backbone interactions (Figure 6.7).
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6.5.2 The relationship between score and resolution is unclear
My initial hypothesis was that crystal interface stability, as captured by Rosetta score,
would correlate with crystal resolution. I had two reasons that led me to this hypothesis.
First, crystal growth occurs when the rate of protein incorporation into a crystal lattice
(attachment) is greater than the rate of protein detachment from the crystal. The rate of
attachment depends on the flux of molecules to the growing crystal step, the possible
interaction area of the step, and the probability of attachment. The rate of detachment
depends on the frequency of detachment events and the detachment probability. Point
mutations can affect both the detachment and attachment probabilities. The detachment
probability in particular is related to interface stability by the Boltzmann factor42: Pd = e
−Ei
kT .
All other factors being equal, more stable native crystal interfaces will result in lower
probabilities of detachment and thus may improve crystal morphology. Second, as interface
stability is conferred by favorable molecular interactions and tighter side-chain packing, I
reasoned that more stable interfaces would be less dynamic and less mobile, improving the
homogeneity of protein positioning within the crystal. Hence, I anticipated that more stable
interfaces would result in larger crystals with less mosaicity, which in turn would improve
crystal resolution.
An initial analysis comparing Rosetta scoring and crystal resolution for a subset of the
PDB revealed no relationship between the two. I reasoned that the analysis was obfuscated
by many factors that affected resolution, but could not be captured by score alone (e.g. the
protein, X-ray source intensity, detector resolution, user handling, etc.). First, I controlled for
just the protein by analyzing only structures of SNase in the PDB. I found that controlling
for the protein alone was insufficient – there was no trend between resolution and score for
this set. However, when I controlled for more factors by analyzing the crystal structures
of twenty-two variants of a single protein, with all data gathered by the same individual,
using the same process, and with the same equipment, I found, as hypothesized, that lower
Rosetta scores correlated with higher resolution (Figure 6.1). Yet, when I repeated the same
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analysis for crystals of my model protein (again with all experiments conducted identically
by one individual), I found an anti-correlation.
Why is there an inconsistent behavior between score and resolution? From the PDB, it is
apparent that higher resolution crystal structures tend to have better protein geometry, i.e.
fewer improbable side-chain rotamers, fewer outliers for bond lengths, fewer outliers for
bond angles, or fewer atomic/steric clashes43. It is possible that because Rosetta represents
proteins in internal coordinate space (Φ/Ψ), with fixed bond lengths and angles, it cannot
rescue inherently poor geometry and thus better geometry contributes to a lower Rosetta
score, even after energy minimization. Then, it is possible that the correlation observed
between Rosetta score and resolution for the Mizutani set was a manifestation of the protein
geometry improvements that come with higher resolution data, while some external factor,
unaccounted for by Rosetta score, affected resolution. If resolution does indeed drive
score, then for crystals in a narrow range of resolutions, we would not expect to observe a
correlation between Rosetta score and resolution, as was the case for the ∆+PHS variants.
In fact, MolProbity44, a structure validation software, only compares structures within 0.25
Å bins to account for the improvements in protein geometry offered by higher resolution
data.
6.5.3 Backrub improves design
Over the course of this study, I attempted both fixed-backbone design on the WT backbone
and fixed-backbone design on a perturbed ensemble of 200 models generated from the WT
backbone. To generate the perturbed ensemble, I used an approach known as Backrub26
that slightly alters the direction of the Cα–Cβ vector to expose the side chain to a new
environment while minimally altering the backbone. I found that variants designed using
an ensemble of backbones crystallized at a higher rate (4/7) than variants design using
the single WT backbone (1/11). I reason that this is because Backrub-generated ensembles
capture local backbone fluctuations, whereas fixed-backbone models do not, resulting in
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a better estimate of point mutation effects, including to interface energy27. In general, it
is well known that proteins are dynamic and are readily capable of incorporating point
mutations, especially at protein surface positions45, so a fixed-backbone approximation is
not sufficient. Hence, I observed an increase in crystallization (success) rate when I designed
on an ensemble of backbones and selected designs scoring well across multiple backbones
for experimental characterization.
6.5.4 Rosetta could not predict changes in rotamers and space groups
Of the five designed proteins, only K133M resulted in a crystal structure similar to the
design. The designs Q123D and Q123E resulted in the introduction of E/D–K electrostatic
interactions, but with a neighboring symmetry mate instead of the one targeted by the
design. For these designs, it is not clear how to improve the design algorithm.
For the K127L and K64R designs, I observed unpredictable changes in space group. In
retrospect, the K127L design should not have scored well in Rosetta, as the K127 amino
group clearly makes electrostatic contacts with the phosphate groups of the THP molecule
bound by the neighboring symmetry mate. Despite breaking the lysine–THP interaction,
the Rosetta score was lower for the variant than the WT protein (in the WT space group),
indicating that Rosetta does not correctly weigh the strength of this electrostatic interaction.
One possible solution to overcome this issue in the future would be to bias the Rosetta score
by the WT electron density, such that eliminating a clearly present interaction is strongly
penalized whereas designing residues that are not well-resolved is favored.
One possible reason for the failure to improve resolution is that Rosetta is not yet finely
tuned for the types of atomic interactions we tried to create. Rosetta was first developed to
study protein folding in the context of small, globular domains, before being applied to the
inverse challenge, design46. Over the years Rosetta has performed best when redesigning
protein cores and tightly-packed interfaces47–50. Our objective here is one of the first
attempts to design a loosely-packed interface with a significant amount of water involved.
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Future work to improve design of solvated interfaces might include explicitly analyzing
water interactions the interface either by flooding, as was recently successfully used to dock
interfacial waters51, or the recently developed HBNet method in Rosetta, which has been
used to design hydrogen bonding networks de novo52. Multi-state design53 might also be
necessary to prevent undesired changes in space group.
6.5.5 The model protein was likely optimal for crystallization
Initial analyses showed that diffraction patterns collected for the WT control in this study
had an average high-resolution limit of 1.77 Å (Figure 3), which agrees with the resolution
(1.8 Å) of the PDB-deposited crystal structure of ∆+PHS (3BDC). This value falls firmly in
the middle of the distribution of all SNase crystal resolutions (Figure 2), with 1.35 Å and 2.5
Å being the highest and lowest observed resolutions, respectively. Separately, Mizutani et
al. observed changes from +0.2 to −0.6 Å in their study of the effects of point mutations
on diphthine synthase crystals17. Based on these prior observations, I expected to observe
changes in resolution of ±0.5 Å; however, I instead found that designs spanned a narrow
range of 1.67–1.85 Å or ∼1.77±0.1 Å. Nonetheless, the variance in resolution within crystals
of the same variant compared favorably between my study and that by Mizutani et al. I
observed ranges of ∼0.1 Å, while Mizutani et al. reported a 95% confidence interval estimate
of ±0.05 Å for WT diphthine synthase, analyzing the diffraction data from 13 crystals17.
One possible explanation for my designs’ minimal improvement in resolution is that my
choice in model protein, ∆+PHS, was already optimized for forming high-quality crystals. I
selected ∆+PHS as a model system for its high stability (11.8 kcal/mol)29, high yield (over
60 mg protein per 1 L of cell culture), and crystallizability (over 300 crystal structures have
been deposited in the PDB). I selected for these features so my model protein would readily
incorporate point mutations and so the corresponding designs would likely express in high
quantities and readily crystallize. However, these features also likely pre-selected for a
protein that is optimal for crystallization, one for which a majority point mutations might
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not be able to yield significant improvements in resolution. Future work might then focus
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Figure 6.A.1: The ability for Rosetta to correctly forward design resolution-enhancing mutations
on diphthine synthase depends on the degrees of freedom sampled during the simulation. Each
plot here shows the same data as Figure 6.2 for a particular design strategy. The x-axis indicates
the variant resolution and the y-axis shows the difference in energy with respect to the WT (hence
the dashed lines represent the WT values for both). Standard deviations are calculated across 10
repeated design simulations. Point color indicates either a correct (i.e. a lower score than WT and
corresponding higher resolution, blue) or incorrect prediction (red). The strategies are fully detailed
in the Results section. Neither the strategy with the most (Crystal Docking, #6 in Results) nor the
fewest (Repack, #1) degrees of freedom sampled was particularly successful. In fact, minimizing on
side-chain (Repack and SC Min, #2) or rigid-body degrees (Repack and SC, Jump Min, #4) of freedom
was not sufficient. Rather, successful strategies featured backbone minimization after the point
mutation was introduced (Repack and SC, BB Min, #3, or Repack and SC, BB, Jump Min, #5).
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Figure 6.A.2: Alignments between designs (orange) and crystal structures (yellow) show minor





Figure 6.A.3: WT interactions between THP and K84, and Q123 and K71. Coordinates for the WT
come from PDB ID 3BDC. The 2mFo-DFc map was downloaded from the Uppsala Electron Density
Server. The map is contoured at 1.5σ and carved within 2 Å of residues 71, 84, 123, and the THP.
Distances below 3.5 Å are highlighted by green dashed lines.
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Figure 6.A.4: WT density of K64 is missing for some atoms and shows multiple rotameric states.
Coordinates for the WT come from PDB ID 3BDC. The 2mFo-DFc map was downloaded from the














Figure 6.A.5: Average I/σ values ± one standard deviation for each resolution shell for each variant.




Table 6.A.1: Exact crystallization conditions for each crystal from which diffraction data were
collected, including initial values for I/σ and completeness in the last resolution shell
Variant % MPD pH Ca2+ pdTp Space Resolution I/σ Completeness (%)
Ratio Ratio Group
∆+PHS K127L 40 9 3 2 P 41 1.67 3.36 9.0
∆+PHS K127L 40 9 3 2 P 41 1.77 4.74 48.8
∆+PHS K127L 40 8 3 2 P 41 1.69 2.37 9.5
∆+PHS K127L 42 9 3 2 P 41 1.77 2.23 46.3
∆+PHS K127L 42 9 3 2 P 41 1.69 5.10 9.0
∆+PHS K127L 42 9 3 2 P 41 1.68 3.59 7.7
∆+PHS K127L 42 8 3 2 P 41 1.73 4.78 25.0
∆+PHS K127L 44 9 3 2 P 41 1.83 2.72 79.6
∆+PHS K127L 44 8 3 2 P 41 1.73 4.57 23.2
∆+PHS K127L 44 8 3 2 P 41 1.78 2.48 44.0
∆+PHS K127L 46 9 3 2 P 41 1.68 2.98 7.7
∆+PHS K127L 46 9 3 2 P 41 1.73 6.77 26.4
∆+PHS K127L 46 8 3 2 P 41 1.68 2.29 8.7
∆+PHS K127L 46 8 3 2 P 41 1.83 3.05 69.5
∆+PHS K127L 46 8 3 2 P 41 1.78 2.34 46.4
∆+PHS WT 21 6 3 2 P 1 21 1 1.73 3.35 11.4
∆+PHS WT 18 6 3 2 P 1 21 1 1.77 3.33 33.0
∆+PHS WT 18 6 3 2 P 1 21 1 1.78 2.74 25.9
∆+PHS WT 18 6 3 2 P 1 21 1 1.74 3.60 12.1
∆+PHS WT 18 6 3 2 P 1 21 1 1.83 2.08 45.4
∆+PHS Q123E 18 6 2 1 P 1 21 1 1.89 2.79 68.8
∆+PHS Q123E 20 6 2 1 P 1 21 1 1.94 2.62 66.2
∆+PHS Q123E 20 6 2 1 P 1 21 1 1.89 3.61 56.5
∆+PHS Q123E 20 6 2 1 P 1 21 1 1.84 2.37 24.6
∆+PHS Q123E 18 6 2 1 P 1 21 1 1.89 5.14 60.2
∆+PHS Q123E 18 6 2 1 P 1 21 1 1.88 2.64 67
∆+PHS Q123E 18 6 2 1 P 1 21 1 1.96 2.37 87.1
∆+PHS K133M 20 6 2 1 P 1 21 1 1.84 2.16 43.7
∆+PHS K133M 18 6 2 1 P 1 21 1 1.89 2.48 67.4
∆+PHS K133M 18 6 2 1 P 1 21 1 1.90 3.98 81.6
∆+PHS K133M 18 6 2 1 P 1 21 1 1.79 2.62 26.6
∆+PHS K133M 22 6 2 1 P 1 21 1 1.89 3.58 74.3
∆+PHS Q123D 20 6 2 1 P 1 21 1 1.95 2.39 87.9
∆+PHS Q123D 20 6 2 1 P 1 21 1 1.78 2.61 25.9
∆+PHS K64R 18 6 3 2 P 21 21 21 1.73 2.13 22.2
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Table 6.A.2: Crystallographic data collection and refinement statistics. Values for the highest
resolution shell are in parenthesis. PDB IDs to be added after submission.
K127L (6OK8) K133M (6OK9) Q123D (6OKA)
Wavelength (Å) 1.54 1.54 1.54
Resolution Range (Å) 38.26–1.80 (1.87–1.80) 32.21–1.90 (1.97–1.90) 32.3–1.86 (1.93–1.86)
Space Group P41 P21 P21
Unit Cell Dimensions
a, b, c (Å) 48.097 48.097 63.122 30.927 60.473 38.105 30.853 60.715 38.119
α, β, γ (°) 90 90 90 90 93.017 90 90 92.648 90
Total Reflections 72360 (1421) 33219 (1633) 34560 (1407)
Unique Reflections 12307 (715) 10702 (874) 11133 (680)
Multiplicity 5.9 (2.0) 3.1 (1.9) 3.1 (2.1)
Completeness (%) 91.93 (53.32) 96.32 (79.71) 93.59 (56.06)
Mean I/σ(I) 35.73 (5.59) 25.62 (3.92) 18.37 (5.10)
Wilson B-factor 22.28 29.02 28.23
R-merge 0.02957 (0.1052) 0.02397 (0.1765) 0.03833 (0.1442)
R-meas 0.03219 (0.1381) 0.02873 (0.2304) 0.04588 (0.1879)
R-pim 0.01254 (0.08851) 0.01565 (0.146) 0.02494 (0.119)
CC1/2 1 (0.984) 0.999 (0.983) 0.998 (0.978)
CC* 1 (0.996) 1 (0.996) 1 (0.994)
Reflections used
in refinement 12308 (715) 10706 (868) 11125 (680)
Reflection used
for R-free 619 (38) 538 (44) 562 (38)
R-work 0.1950 (0.2892) 0.2199 (0.3940) 0.1986 (0.3391)
R-free 0.2331 (0.4364) 0.2635 (0.4842) 0.2532 (0.4043)
CC(work) 0.961 (0.826) 0.956 (0.785) 0.935 (0.475)
CC(free) 0.947 (0.871) 0.953 (0.818) 0.941 (0.205)
# non-H Atoms:
Total 1147 1058 1102
Macromolecules 1032 993 999
Ligands 26 26 26
Solvent 89 39 77
Protein Residues 129 129 129
RMS(bonds) Å 0.022 0.025 0.022
RMS(angles) ° 2.03 1.63 1.73
Ramachandran
favored (%) 92.91 94.49 93.70
allowed (%) 4.72 4.72 5.51
outliers (%) 2.36 0.79 0.79
Rotamer outliers (%) 3.74 3.09 1.04
Clashscore 1.41 2.52 3.01
Average B-factor:
Total 25.95 38.52 31.71
Macromolecules 25.29 38.54 31.51
Ligands 34.24 39.44 28.08
Solvent 31.23 37.34 35.60
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Chapter 7
Conclusion and Future Directions
Proteins are the machinery of life, involved in most, if not all, cellular function. Structural
studies of proteins provide snapshot images of these machines at work and are necessary
to build a bottom-up understanding of biology. For example, acquiring atomic-resolution
structural information about proteins involved in disease, such as antibodies, can lead to
the development of new therapeutics and vaccines. In most cases, X-ray crystallography
is the standard approach to structure determination, but it is not always feasible. X-ray
crystallography may not be the most optimal approach when there are numerous protein
targets because of its significant labor and reagent cost or when the target proteins are
flexible and do not possess a single, static structure because of the requirement for structural
homogeneity underlying the technique. Computational approaches that provide atomistic
models can complement X-ray crystallography in these cases, as computational methods
methods are inexpensive and often output a range of plausible models. In this dissertation,
I have advanced computational modeling approaches for antibodies and antibody–antigen
complexes, applied modeling to gain scientific insight to systems which would otherwise
have been unattainable through experiment, and attempted to combine computation and
experiment to improve the resolution of crystal structures.
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7.1 My Contributions
I began my research in computational protein modeling through participation in the CAPRI
competition1. CAPRI’s numerous blind protein complex prediction challenges highlighted
shortcomings in Rosetta’s modeling and docking of camelid (heavy-chain only) antibodies.
To address these shortcomings, I developed a more robust antibody modeling framework
free from previous assumptions that were based on the traditional antibody structure of a
paired heavy and light chain. Simultaneously, a growth in the need for antibody modeling
exposed a lack of breadth in the template database and an unsustainability in our template
grafting script. I addressed the former issue by developing an automatically updating
database and implementing a scientific benchmark to evaluate grafting accuracy. The latter
issue was addressed by refactoring the grafting protocol to be object-oriented, providing a
framework for future development, by a team of developers, myself included2.
My development of RosettaAntibody was inspired in part by recent improvements in
the accuracy and decreases in the cost of high-throughput B cell3 sequencing. As the recent
growth in antibody sequences has not been matched by a growth in antibody structures,
there was an opportunity to test whether modeling could be used to gain structural insights
from a large set of antibodies. Experimentally-derived antibody sequences can be catego-
rized as naïve or antigen experienced (based on cell-surface receptors). This distinction
permitted me to ask whether the process of affinity maturation (antigen exposure) drives
CDR-H3 loop rigidification, a structural property that had previously only been studied
on the scale of tens of antibodies4–6. Coupling Rosetta modeling with a graph theoretical
approach for quantifying flexibility7 from a static structure, I determined the flexibility of
the CDR-H3 loop for thousands of models of the human peripheral blood cell antibody
repertoire. I found no clear delineation in the flexibility of naïve and antigen-experienced
antibodies, contrary to prior observations. I further investigated this surprising result by
using additional measures of flexibility and studying the hundreds of crystal structures
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available in the PDB. Again, I did not observe a drastic decrease in flexibility upon affinity
maturation. Further analysis still incorporated molecular dynamics and showed that there
was a spectrum of changes in flexibility that depended on the specific antibody in question.
My results suggested that rigidification may be just one of many biophysical mechanisms
for increasing affinity, and were recently validated by another research group8.
Another, similari, system I computationally modeled was the bacterial protein Hfq,
which is present in most sequenced bacteria. With strong sequence conservation only in
its core domain, the role of Hfq’s termini is unclear. To investigate, I modeled E. coli Hfq
and identified key interactions between its disordered C-terminal domains (CTDs) and its
ordered core domains (Hfq is a homohexamer). In the process, I improved the disordered
region modeling protocol in Rosetta, FloppyTail, by enabling the simultaneous modeling of
multiple disordered regions, examining the extent of sampling in ultra-long simulations,
and developing a novel, ensemble-based analysis for low-scoring models. For E. coli Hfq, I
identified multiple key CTD–core interactions, which were validated experimentally. In
conjunction with competitive binding experiments, the models showed that the acidic
CTD transiently bound the basic core residues at the Hfq rim, which are involved in RNA
annealing. To test whether this result was generalizable, I modeled the Hfq proteins found
in five other bacterial species and showed that the presence of CTD–rim interactions was
correlated with RNA annealing activity in four of the five species. Separately, my Hfq
models for one of the species, C. crescentus, were validated by a recently determined crystal
structure9.
The final thrust of my PhD research focused on applying computational design to im-
prove the resolution of protein crystal structures. I demonstrated that the resolution of a
subset of crystal structures in the PDB correlated with the Rosetta score of the crystallo-
graphic interactions. In a “forward design” study, I investigated multiple computational
design approaches on this subset of crystal structures to identify the one with the greatest
iIn the sense that many variants of a single protein exist that would be tedious to study experimentally, but
can be feasibly modeled.
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success rate. I then applied this approach to design the crystallographic interactions of
a model protein (SNase). Only five of my sixteen designs formed crystals, and of the
crystal-forming designs only two slightly improved resolution. Surprisingly, after solving
the designs’ crystal structures, I found that two had altered space groups, which could not
be predicted by Rosetta score, and that, over the narrow resolution range of the designs,
score no longer correlated with resolution. My results show that point mutations can have
significant effects on protein crystallization, but may have been hampered by my efforts to
design a protein that already optimal for crystallization.
7.2 Future Directions
I will present future directions in reverse order from how the thesis is structured, starting
with crystal design. I believe there is much potential for computational design to stabilize
weak crystallographic interfaces. Chapter 6 showed that point mutations can have signifi-
cant effects. However, design attempts only resulted in minimal improvements (∼0.1 Å) to
resolution as the model protein crystallized quite readily, forming crystals that diffracted
to a high resolution (∼1.8 Å). Going forward, I propose the computational redesign of
ribonuclease H, a protein that is easy to purify in high quantities, but that does not form
crystals diffracting beyond 2.8 Å10. Optimizing a protein crystal with an initial resolution of
2.8 Å may leave more room for improvement than a protein crystal starting at 1.8 Å. Future
designs should consider making use of a large ensemble of backbones, as I demonstrated
that using a Backrub-generated11 ensemble improved design success rate. Another advance
to be made beyond my original approach is to design the entire interface, which can take
the form of fixed backbone design or include the addition of contact-forming loops, rather
than targeting single point mutations.
Modeling disordered regions continues to be challenging, although I have shown in
Chapter 5 that models can be predictive and, when combined with experiments, can eluci-





Figure 7.1: Schematic example of the effects of minimization on moves from state i, in energy
landscape E. Minimization inevitable leads to state j, if a move is made to any intermediate state
(gray, unlabelled).
which prevents the calculation of true thermodynamic properties from simulations. De-
tailed balance requires equal-probability sampling of states and is defined as Piπij = Pjπji12,
where Pi is the probability of observing state i and πij is the probability of transitioning
to state j from state i, which can also be written as πij = αijaij, where αij is probability of
performing the move from state i to state j and aij is the probability of accepting them move.
FloppyTail, and most Rosetta protocols, break this by minimizing before evaluating the
Metropolis criterion so πij and πji are skewedii. See for example, Figure 7.1, where if a
Rosetta move from state i goes to any state near the local energy minima j, minimization will
move towards j, and this probability of sampling j is much greater than it would be under
a sampling approach without minimization. Working to eliminate such bias in FloppyTail,
a future developer would begin by creating a move set without minimization. Additionally,
they would need to demonstrate fair sampling of conformational space by their move set
as Smith and Kortemme have for the Backrub protocol13. A thermodynamically rigorous
FloppyTail would permit more direct comparison to experiment and could be used to make
stronger predictions (e.g. the occupancy of low-energy states would be known rather than
just knowing that the states are low energy).
Further advances could be made in the physical rigor of the low-resolution energy
potential of FloppyTail (and Rosetta in general). In Rosetta, the cen_std low-resolution
iiThat’s not to say this is the only way to break detail balance. Biasing sampling, for example, would also
suffice as it effectively increases the probability transitioning to or occupying certain states.
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energy potential contains only four terms: env, pair, cbeta, vdw14. The three first terms are
purely statistical and capture all residue–residue interactions. The latter term is physical,
but only contains the repulsive component of the Lennard-Jones potential. It is somewhat
surprising that an energy potential with no explicit consideration of electrostatics has been
successful in modeling disordered interactions, which are heavily dependent on electrostat-
ics15. A step forward might be to incorporate additional physical terms in the low-resolution
potential, while validating against experimental observations. An approach in this spirit
has been made by John Ferrie (Department of Chemistry, University of Pennsylvania),
who constrained disordered regions during simulation using a potential derived from the
Gaussian chain probability distribution16.
In Chapter 4 I showed how antibody modeling could be combined with antibody se-
quencing to garner useful structural information, despite the fact that modeling is not 100%
accurate. The need for fast and accurate antibody modeling will rise over the coming years
due to the development of high-throughput B-cell sequencing technologies3,17. Most anti-
body regions are already modeled at close to 90% accuracy and with reasonable speed18,19.
The only exception is the CDR-H3 loop.
Modeling the CDR-H3 loop is slow because models must be generated de novo and
refined. Most of the time in a loop closure simulation is not spent identifying plausible
loop backbone conformations, but rather placing the residue side chains in a low-energy
conformation for their environment and ruling out backbone conformations that result
in side-chain clashes. The difference is an order of magnitude, with a 12-residue loop
requiring approximately 200 seconds for de novo closure and 4,000 seconds for refinement.
Thus to decrease the computational time cost of CDR-H3 loop modeling, one must expedite
the high-resolution refinement stage of Rosetta’s loop modeling protocol, or incorporate
a different, fast loop modeling approach such as DiSGro20,21, which is efficient because it
samples only relevant protein conformations by building loops sequentially where each
residues placement is based on observed distance distributions from the PDB.
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In addition to improving the speed of CDR-H3 loop modeling, we must also strive to
improve the accuracy, which is a significant challenge requiring two sources of error to
be addressed. First, during antibody modeling, multiple templates are grafted into one
structure and this introduces model error; the local environment for the loop does approxi-
mate the native environment well. Second, even when in a close-to-native environment, we
struggle to model CDR-H3 loops, because these loops are inherently structurally diverse22.
Overcoming the first source of error amounts to improving the template prediction. This can
be done by testing template selection strategies that are more sensitive to minor sequence
changes than BLAST (e.g. decision trees19 or position-specific scoring matrices [PSSMs]23).
Implementing and benchmarking new grafting strategies should be straightforward in
the current RosettaAntibody framework thanks to the advances I outlined in Chapter 3.
Overcoming errors in CDR-H3 loop modeling will be a more difficult proposition. Perhaps
a rigorous characterization of particularly challenging loops might yield some insight as
to why these cases are so difficult and could lead to an improved modeling strategy. For
example a long molecular dynamics simulation might reveal that the crystallographic loop
conformation is but one of many accessible low-energy states, so modeling the loop as an
ensemble would be an improved approach, particularly if one seeks to use the models for
downstream applications such as docking.
Antibody–antigen docking itself could be improved. One exciting advance is being
pursued, in Prof. Jeff Gray’s lab, by Dr. Jing Zhou. She is currently developing a Snug-
Dock variant that takes advantage of hydrogen–deuterium exchange mass spectrometry
(HDX-MS) data to more accurately model camelid antibodies (cAb) and cAb–antigen com-
plexes. It would be a substantial advance if combining SnugDock and HDX-MS could yield
atomic accuracy models, because HDX-MS data is easier and faster to collect for a given
CAb–antigen complex than it is to solve the crystal structure. Preliminary results show
that experimentally-guided SnugDock simulations sample more low-scoring, native-like
states, albeit with a corresponding increase in non-native low-scoring states. More work is
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necessary to distinguish the two sets of states in a blind scenario. However, the concept
of combining experimental data with simulation to improve accuracy is a powerful one,
and more efforts should be made to standardize this incorporation as high-throughput
experiments are steadily becoming the norm and data will be plentiful.
7.3 Parting Thoughts
To unite multiple, disparate research topics in a single dissertation speaks volumes on the
current state of computation and science in general. Rosetta’s versatility has grown expo-
nentially since its inception twenty-two years ago24 as a protein folding tool. Nowadays,
it is possible to model not just soluble, globular proteins, but also non-canonical amino
acids25, RNA26, membrane proteins27, and carbohydrates28. These advances have been
enabled by the conversion of Rosetta from a set of Fortran subroutines to an easy-to-use
and well-organized object-oriented C++ framework29 and by the development of a more
rigorous energy function30. The versatility of Rosetta will only continue to grow as Python31
and XML32 scripting interfaces expose the underlying code to regular users. The universal
accessibility of modeling tools will be key as scientific research is becoming ever more
interdisciplinary. If one thing has been demonstrated in this dissertation it is that by com-
bining computational and experimental approaches, we are able to solve more diverse set
of problems than when using either approach in isolation.
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